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ABSTRACT 
Patients with trisomy of chromosome 21, known as Down’s syndrome (DS), have a 
lower incidence of solid tumours than unaffected age-matched individuals. However, 
the cellular and molecular basis for this observation is not well understood. We 
hypothesised that a direct link between Down’s syndrome and angiogenesis exists, 
whereby the overexpression of human chromosome 21 (Hsa21) genes causes the 
repression of angiogenesis (gene dosage effects) resulting in the inhibition of solid 
tumour growth.  
 
In this project we investigated the angiogenic phenotype of an animal model of 
Down’s syndrome, the Tc1 mouse, which contains a large freely segregating fragment 
of Hsa21 containing over 200 human genes. We found that the growth of both B16F0 
melanoma and Lewis Lung Carcinoma cells was impaired in Tc1 mice. Tumour 
vascularity also was reduced. This is supportive of the epidemiological data from the 
human DS population and supports the hypothesis that Hsa21 contains anti-angiogenic 
genes. 
 
Candidate genes were selected due to their endothelial specificity or likelihood to 
function in angiogenesis based on functional data or similarity to other proteins. Ex 
vivo RNAi assays were used to examine their roles in angiogenesis. We have found 
that reducing the expression of human Adamts1, Erg, Jamb or Pttg1ip in Tc1 tissue 
can restore its angiogenic potential, suggesting that the dosage of these genes (i.e. 3 
copies instead of 2) can inhibit angiogenesis. 
 
Following from this study we also examined the role of selected adhesion related 
genes found on chromosome 21 in angiogenesis. Cldn14 encodes the tight junction 
9 
 
molecule Claudin14 but its role in angiogenesis was unknown. We found that partial, 
but not complete, depletion of Cldn14 can increase the proportion of non-lumenated 
tumour blood vessels; decrease supporting cell association with tumour vessels; and 
increase endothelial cell proliferation in vivo, ex vivo and in vitro. 
 
Taken together this series of experiments has identified novel regulators of 
angiogenesis and has demonstrated the gene dosage effects of a subset of Hsa21 genes 
on angiogenic processes. 
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CHAPTER 1 INTRODUCTION 
 
1.1 Cancer 
Cancer is a leading cause of mortality worldwide and the second most common cause 
of death in England and Wales. It is set to become even more significant as 
populations age; while medical care in general continues to improve, the proportion of 
the population suffering from diseases of old age increases, placing more burden on 
these areas of care and treatment. It is predicted that by 2050, 21% of the world’s 
population will be over 60 years of age, with the figure nearing 35% in more 
developed regions (Ferlay et al. 2010). In order to develop more effective cancer 
treatments, we must improve our understanding of cancer biology and progression. 
 
1.1.1 Cancer growth and angiogenesis 
Several conditions are now known to be necessary for malignancy to take hold; for 
cells to grow and become cancerous, they must evade all control mechanisms that 
normally maintain the cells of multicellular organisms. In solid tumours, these 
conditions could be simplified as: the induction of angiogenesis (growth of blood 
vessels); resisting programmed cell death; evasion of growth suppression; sustaining 
cell division signalling and replicative capabilities; and the activation of cell invasion 
into surrounding tissue and eventual metastasis. Emerging hallmarks of some (and 
perhaps all) tumours include the avoidance of immune cell detection and destruction 
and establishing tumour-promoting inflammation (Figure 1.1). Further conditions are 
being described and the detailed mechanisms behind those already established are still 
being studied further (Hanahan and Weinberg 2011). It has become apparent that it is 
not only tumour cells themselves that drive and maintain cancer, but also the cells and 
components surrounding them; termed the tumour microenvironment or stroma 
(defined as cells and connective tissue providing a framework for an organ or tissue). 
11 
 
Tumour blood vessels and the cells that comprise them are part of the stroma and now 
recognised as integral players in tumour development and growth (Tlsty and Coussens 
2006). Also in the stroma are inflammatory components (immune cells such as 
macrophages), the extracellular matrix (ECM), fibroblasts and lymphatic vessels. In 
this thesis, “stroma” will refer to all “non-tumour cell” components, which includes the 
blood vessels. The role of the stroma in cancer development is discussed in detail by 
Tlsty and Coussens, 2006. 
 
The induction of angiogenesis is the main area of investigation in this thesis and will 
therefore be discussed in the greatest detail. Solid tumours, like any organ in the body, 
need a vasculature in order to survive. Tumour blood vessels deliver the oxygen and 
nutrients required to maintain growth and also dispose of the waste products of 
metabolism and respiration to prevent toxicity (Nishida et al. 2006, O'Reilly 2007, 
Sund et al. 2005, Weinberg 2007). Without vasculature, tumours cannot grow beyond 
2-4 mm3 due to the limited distance over which oxygen can diffuse from blood vessels 
to tumour cells; approximately 145 µm (Bertout et al. 2008). Hypoxia (less than 0.2% 
O2, where tissues are normally 2-9% O2 (Bertout et al. 2008)) is a major driving force 
behind the growth of new blood vessels into the tumour environment (explored further 
in 1.4) (Adams and Alitalo 2007, Bertout et al. 2008, Weinberg 2007). Since tumour 
growth is unregulated (in contrast to normal developmental processes), tumours must 
adapt and acquire the ability to attract blood vessels (Nishida et al. 2006). Vessel 
density within tumours has been found to correlate with tumour progression, since the 
greater the angiogenic potential of the tumour, the faster its growth (Hanahan and 
Weinberg 2000, Weinberg 2007). Dissecting the cellular and molecular basis of 
tumour angiogenesis not only enables us to understand these processes better but may 
also offer opportunities to control cancer growth and spread. 
12 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1 The evolving hallmarks of solid cancers 
The six “original” hallmarks of cancer as described by Hanahan and Weinberg in 2000 are shown in the 
inner circle: the induction of angiogenesis (growth of blood vessels); resistance against programmed cell 
death; evasion of growth suppression; sustaining cell division signalling and replicative capabilities; the 
activation of cell invasion into surrounding tissue and eventual metastasis. Emerging hallmarks of some 
(and perhaps all) tumours include the avoidance of immune cell detection and destruction and 
establishing tumour-promoting inflammation. Characteristics that allow cancerous cells to achieve these 
states and further promote tumorigenesis include the deregulation of cellular energetics (including 
metabolism and respiration) and underlying genome instability and mutation. It is expected that further 
categories will be added in time (Adapted from Hanahan and Weinberg 2011). 
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1.2 Blood vessel morphology 
The mature vascular network consists of three main vessel types: arteries, veins and 
capillaries. Thick, elasticated arteries carry oxygenated blood from the heart at 
relatively high pressure; the capillary network delivers oxygen and nutrients to the 
body’s tissues; and veins, with a series of valves to control blood flow at low pressure, 
return deoxygenated blood to the heart which is circulated to and from the lungs for 
oxygenation via the pulmonary circulation. Further vessel type subdivisions include 
arterioles and venules, which carry blood into and out of capillary networks 
respectively. (Jain 2003, Risau 1997, Thurston et al. 2000). The majority of cells in the 
body are located within 50-100 µm of a capillary in order to remain oxygenated 
(Alberts et al. 2002). 
 
All blood vessels are lined with endothelial cells (ECs) (Adams and Alitalo 2007, 
Alberts et al. 2002, Ling et al. 2004, Robinson et al. 2004). Capillaries – both the most 
abundant and smallest blood vessels, which link arteries and veins – consist of a 
monolayer of ECs, which line the lumen of the vessel and are attached to a basement 
membrane (BM). ECs recruit supporting cells (pericytes), whose association stabilises 
newly formed blood vessels (Adams and Alitalo 2007, Alberts et al. 2002, Jain 2003) 
(Figure 1.2). The normal, mature vasculature is an organised and efficient network 
from which tissues receive an adequate blood supply. Tumour vasculature, in contrast, 
is disorganised and leaky (roughly ten times more permeable than normal) due to its 
rapid and poorly regulated formation (explored further in 1.5.1.2) (Dudley 2012). This 
results in hypoxic and necrotic areas within solid tumours, depending on the 
sufficiency of the blood supply and, therefore, oxygen availability (Thomlinson 1977). 
14 
 
 
 
 
 
 
 
Figure 1.2 Capillary morphology 
A simplified depiction of a capillary type blood vessel. The endothelial cell monolayer lining the 
capillary lumen is associated with sparse supporting cells (pericytes). These cells are in contact with 
their basement membranes (BM) and in turn surrounded by the extracellular matrix (ECM). 
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1.2.1 Cellular components 
There are two main blood vessel cell types that are of particular interest in this study: 
endothelial cells, which line blood vessels, and their supporting cells, typically referred 
to as pericytes. 
1.2.1.1  Endothelial cells 
The endothelial cell (EC) is the specialised cell type that lines all blood vessels. As the 
intermediary between the blood and surrounding tissues, the endothelial layer controls 
the movement of molecules and cells between the two compartments. They are 
sensitive to blood flow and interstitial pressure, responding to and regulating vessel 
morphology accordingly. In vessels in vivo they are polarised cells with an apical side 
(facing the vessel lumen) and a basal side (attached to a basement membrane and 
supporting cells) (Carmeliet and Jain 2000, Jain 2003). The BM in which blood vessel 
endothelial and supporting cells are embedded is a specialised, dense form of ECM 
that is mainly comprised of laminins, nidogens, collagen IV and perlecan. The BM 
contributes to blood vessel function through organising ECs and providing mechanical 
support (Eming and Hubbell 2011, LeBleu et al. 2007). Indeed, deletion of some BM 
components has been found to cause blood vessel leakage (Abraham et al. 2008, 
Eming and Hubbell 2011). 
 
The precise characteristics of ECs, including their arrangement in the vessel wall, cell-
cell adhesive properties and degree of polarisation can vary depending on the vessel 
type, tissue location and quality of blood flow; for example in the brain, endothelial 
cells forming the blood-brain-barrier (BBB), which must be highly selective in terms 
of the volume and type of substances allowed to pass through from the blood to the 
brain tissues, are adhered strongly together and regularly arranged, creating an 
extremely low-permeability barrier almost epithelial in nature (Nitta et al. 2003, Rubin 
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et al. 1991). Endothelial cells in the BBB are highly specialised for their function, as 
are ECs in other situations, such as the postcapillary venules and collecting venules 
(connecting capillaries to veins) with looser EC connections, which allow for immune 
cell interaction and leak blood plasma during inflammation (Thurston et al. 2000). ECs 
change their morphology and migratory properties in vitro depending on their 
confluence. While ECs in sparse cultures have a more motile fibroblast-like phenotype, 
in confluent cultures they have a characteristic cobblestone appearance (Lampugnani 
et al. 2002). 
 
1.2.1.2  Pericytes  
ECs recruit pericytes, also known as vascular mural cells, to maturing blood vessels in 
order to stabilise the vessel structure (Hall 2006). Pericytes are found to cover 
capillaries sparsely, in postcapillary venules more densely and are formed in multiple 
layers around larger arterial vessels, where they are referred to instead as vascular 
smooth muscle cells (vSMCs) (Bergers and Song 2005, Jain 2003, Thurston et al. 
2000). They are characterised by an extended morphology with finger-like protrusions 
that contact multiple endothelial cells through gaps in the basement membrane (Hall 
2006), communicating with ECs both directly by cell-cell contact (discussed further in 
1.7.1 and 1.8) and indirectly via extracellular signalling, although the details of these 
interactions are not yet well-described. They are also bound to the basement 
membrane, which is rich in fibronectin and synthesised by pericytes and ECs together 
(Armulik et al. 2005, Mandarino et al. 1993, Gerhardt and Bersholtz 2003). 
 
The exact cellular progenitors of these cells are not known for certain and it depends 
on the tissue as to which cells may differentiate into pericytes. Like ECs, pericytes 
have specialised functions in different contexts. A specific marker of differentiation for 
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all pericytes has not yet been found, though commonly used markers include α-smooth 
muscle actin (α-SMA), NG2 (a chondroitin sulphate proteoglycan marker expressed 
by arteriolar and capillary-associated pericytes, but not venular pericytes), and the 
platelet-derived growth factor receptor beta (PDGFRβ) as detailed further in 1.5.3 
(Hall 2006, Murfee et al. 2005). 
 
1.3  The process of angiogenesis 
Angiogenesis is the growth of new blood vessels from the pre-existing vasculature 
(Adams and Alitalo 2007, Carmeliet 2003, Hanahan 1997, Jain 2003). It is normal and 
vital in physiological process such as wound healing and the menstrual cycle where the 
onset and cessation of blood vessel growth is tightly regulated (Carmeliet and Jain 
2000). Many factors control angiogenesis and its molecular mechanisms are still being 
elucidated. In contrast, pathological angiogenesis is deregulated, especially in the case 
of solid tumours. 
 
In vivo, the balance of pro-angiogenic and anti-angiogenic factors regulates 
angiogenesis. Normally, the influences of anti-angiogenic factors keep vessels in a 
quiescent state except in some cases, such as wound healing, when pro-angiogenic 
factors temporarily become the dominant force (Carmeliet and Jain 2000, Jain 2003). 
Cancer growth depends on the ability to shift the equilibrium to favour angiogenesis; 
they must activate the “Angiogenic Switch”  (Figure 1.3) (Bergers and Benjamin 
2003, Sund et al. 2005).  
 
Although sprouting angiogenesis is highly complex, involving the interplay of many 
factors and processes, it can be simplified as a series of events, as depicted in Figure 
1.4. This sequence includes: 1) Vessel dilation. Existing vessels dilate and become 
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leaky in response to vascular endothelial growth factor (VEGF) (Keck et al. 1989, 
Thurston et al. 2000). 
  
2) Basement membrane dissolution. Vessel plasticity and basement membrane 
dissolution are regulated by angiopoietin-2 (Ang2), an inhibitor of signalling from the 
EC-specific receptor Tie-2, which promotes the detachment of supporting cells and 
loosening of the underlying matrix (Armulik et al. 2005, Felcht et al. 2012, Gale and 
Yancopoulos 1999, Jones et al. 2001, Maisonpierre et al. 1997). In addition, matrix 
metalloproteinases (MMPs) degrade the ECM and release growth factors bound to and 
sequestered within it, such as VEGF and basic fibroblast growth factor (bFGF) 
(Nelson et al. 2000, Rundhaug 2003). VEGF also stimulates the secretion of other 
proteases such as collagenase, urokinase-type plasminogen activator (uPA) and tissue-
type plasminogen activator (tPA), which also contribute to the de-anchoring of ECs 
from the ECM. Also, the cell-cell junctions that bind endothelial cells together in the 
monolayer become destabilised (Lamalice et al. 2007). 
 
3) Endothelial proliferation and migration. Once endothelial cells are no longer tightly 
bound to the BM or to each other, they are free to proliferate and migrate through the 
ECM in response to stimulation by numerous pro-angiogenic factors, including VEGF, 
Ang1 and bFGF (Carmeliet and Jain 2000, Suri et al. 1998, Veikkola et al. 2000). At 
this point, cell adhesion molecules (including integrins, as described further in 1.5.4) 
mediate endothelial cell migration into the formation of new vessel tubes from non-
lumenated endothelial cords (Eliceiri and Cheresh 1999, Lamalice et al. 2007, 
Lauffenburger and Horwitz 1996). 
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4) Tube formation and elongation. Endothelial sprouts comprise three main cell 
populations: specialised “tip cells” at the sprout leading edge; the proliferating stalk 
cells; and quiescent phalanx cells around the base of the sprout. It is thought that the 
guidance of angiogenic sprouting, at least in the retina and perhaps in other angiogenic 
contexts as well, involves the co-ordination of tip cell migration and stalk cell 
proliferation in response to VEGF (Gerhardt et al. 2003).  
 
5) Vessel maturation. Lastly, vessel maturation commences with the deposition of a 
new BM, strengthening of cell-cell contacts, formation of the vascular lumen and 
recruitment of supporting cells.  Platelet derived growth factor B (PDGFB) recruits 
pericytes (Armulik et al. 2005, Lindahl et al. 1998). Other signalling pathways 
reported to play a role in pericyte recruitment include those of S1P (sphingosine-1-
phosphate)/EDG-1 (endothelial differentiation gene-1) receptor and EGF (epidermal 
growth factor)/EGFR, which stimulate migration and proliferation of pericytes; TGFβ1 
(transforming growth factor β1) and TGFβR-II are involved in ECM deposition and 
pericyte differentiation; and Ang1/Tie2 signalling stabilises the EC/pericyte 
connection, but its mechanism is not yet fully understood (Armulik et al. 2005, Gale 
and Yancopoulos 1999, Lindahl et al. 1998, Suri et al. 1998, Chantrain et al.  2006). 
 
Importantly, this pattern of normal vessel development is severely disrupted within 
tumours (explained further in 1.5.5.1). Vessel formation in tumour environments is 
erratic and highly dynamic, with vessel functionality changing continuously, and 
largely unproductive. Steps 4) and 5) in which endothelial cords sprout, grow, mature 
and create a functional lumen are often disrupted, leaving non-lumenated vessels 
without blood flow (Gerhardt 2008, Jain 2005). 
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Figure 1.3 The balance between pro- and anti-angiogenic factors: the “angiogenic switch” 
The relative abundance of pro- and anti-angiogenic factors, including those listed above, determines 
whether blood vessel growth is stimulated or repressed. In most normal tissues, angiogenesis is 
“switched off” except at certain times when it is required, such as during wound healing. However, in 
the tumour microenvironment, the balance is tipped in favour of angiogenesis as tumour cells secrete 
pro-angiogenic factors and sequestered factors are released from the extracellular matrix, together 
resulting in angiogenesis being “switched on” (Adapted from Weinberg 2007). 
21 
 
 
 
 
Figure 1.4 Stages of sprouting angiogenesis 
The formation of an angiogenic sprout from a pre-existing capillary. 1) Endothelial cells are initially 
activated by a pro-angiogenic stimulus, shown here as binding of VEGF to ECs. 2) The pro-angiogenic 
stimulus causes the secretion of matrix metalloproteinases (MMPs) e.g. MMP9, which degrade the 
surrounding basement membrane components to which ECs are adhered. Endothelial cell-cell junctions 
also destabilise. 3) ECs proliferate in response to downstream signals caused by the angiogenic stimulus 
and begin to migrate towards the source of the signal. 4) EC migration is led by specialised tip cells, 
characterised by multiple filopodia (membrane protrusions). Stalk cells behind the tip cell proliferate to 
extend the vascular tubule, which connects to the original vessel at its base via phalanx cells. Cells re-
form junctional complexes between one another. 5) Vessel maturation involves BM deposition, 
strengthening of endothelial cell-cell junctions and pericyte recruitment via PDGFB signalling. 
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1.4 Hypoxia and angiogenesis 
Tumours are heterogeneous, rapidly expanding cellular masses with high demands on 
oxygen and nutrient supplies. Many areas within tumours experience localised 
hypoxia, which can drive the development of new blood vessels into the tumour mass 
(Thomlinson 1977). However, these vessels are poorly formed, far more leaky and 
inefficient than the normal vasculature, and therefore further contribute to the poor 
oxygenation of tumours (Konerding et al. 1999). Hypoxia is also a significant element 
of tumour biology because of its propensity both to protect tumour cells from 
radiotherapy, chemotherapy and the immune system (Bertout et al. 2008, Chouaib et 
al. 2012, Thomlinson 1977), and, as more recently described, to stimulate tumour 
metastasis (Branco-Price et al. 2012). 
 
The action of Hypoxia-Inducible Factor-1α (HIF-1α) is a major cellular “oxygen-
sensing” mechanism (Bertout et al. 2008, Nishida et al. 2006, Yoo et al. 2006). The 
HIFs play a variety of roles in different cell types, including epithetlial to 
mesenchymal transition (EMT), thought to be important in carcinogenesis Shiren et al. 
2009, Yang et al. 2008). Continuing with particular focus on the stimulation of pro-
angiogenic signalling by hypoxia, under normoxic conditions, proline hydroxylase 
enzymes containing prolyl hydroxylase domains (PHDs) add oxygen to proline 
residues within HIF-1α. The hydroxyprolines allow recognition and polyubiquitination 
of HIF-1α by the tumour suppressor E3 ubiquitin ligase VHL (von Hippel-Lindau). 
This marks HIF-1α for degradation by the 26S proteasome, preventing it from 
dimerising with its partner HIF-1β and transcribing pro-angiogenic target genes 
(Bertout et al. 2008).  
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However, under hypoxic conditions, HIF-1α does not display hydroxyprolines and 
VHL does not ubiquitinate it, leaving it free to dimerise with HIF-1β and bind to HRE 
(hypoxia response element) sequences in the promoters of pro-angiogenic genes such 
as VEGF and PDGFB, activating their transcription (Figure 1.5) (Bertout et al. 2008). 
The resulting pro-angiogenic factors expressed then induce the proliferation and 
migration of ECs, allowing increased vascularisation of the hypoxic tissue; a positive 
angiogenic process following such events as ischaemic trauma and stroke, but also 
supporting pathological conditions such as solid tumour growth. 
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Figure 1.5 Regulation of HIF-1α activity according to oxygen availability.  
Under hypoxic conditions the half-life and therefore abundance of HIF-1α is increased and it is free to 
dimerise with HIF-1β in the nucleus to form an active heterodimeric transcription factor. The HIF 
complex activates pro-angiogenic genes (including vascular endothelial growth factor; VEGF) via 
binding to promoter hypoxia response elements (HREs). In normoxic conditions, however, the 
hydroxylation of HIF-1α proline residues by proline hydroxylase domain enzymes (PHD proteins) leads 
to its ubiquitination (attachment of ubiquitin, Ubi) by the pVHL (von Hippel-Lindau protein) complex 
and degradation by the 26S proteasome (Adapted from Weinberg 2007). 
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1.5 Growth factors and their receptors 
Angiogenesis is regulated by a variety of molecules including growth factors, their 
receptors and adhesion molecules. A major route by which tumours stimulate 
angiogenesis is through production of the potent pro-angiogenic factor VEGF, by both 
tumour and stromal cells including macrophages, fibroblasts and endothelial cells 
(Neufeld et al. 1999, Kiriakidis et al. 2002, Ito et al. 2007, da Silva et al. 2010). Other 
notable pro-angiogenic factors with surface receptors on vascular cells include: the 
angiopoietins, angiogenin, basic fibroblast growth factor (bFGF), platelet-derived 
growth factor (PDGF), and transforming growth factor β (TGFβ) (Adams and Alitalo 
2007, Carlson et al. 2001, Karsan et al. 1997, ten Dijke and Arthur 2007). 
 
1.5.1 VEGF 
The VEGF protein family consists of 7 members: VEGFs A-E and PlGF (placenta 
growth factor). VEGF isoforms -A, -B, -C and -E act on blood vessels via VEGFR-1 
(Flt1) and/or VEGFR-2, whereas VEGF-C and VEGF-D influence lymphangiogenesis 
through VEGF receptor 3 (VEGFR-3), which is also expressed in the tumour 
vasculature (Robinson and Stringer 2001, Roy et al. 2006). VEGF-A, located on 
human chromosome 6q21.3 (mouse chromosome 17C), was originally designated 
vascular permeability factor (VPF) for its ability to increase vessel permeability 
markedly (Keck et al. 1989). It is produced by several cell types including 
macrophages, keratinocytes, pancreatic cells, hepatocytes, vSMCs, embryonic 
fibroblasts and tumour cells, and promotes endothelial proliferation, migration, 
survival, differentiation, vessel tube formation, permeability and maintenance 
(Carmeliet 2005, Ferrara et al. 2003, Yancopoulos et al. 2000). Henceforth, given its 
pivotal role in angiogenesis and tumour growth and being a focus of this study, 
“VEGF” will refer specifically to VEGF-A. 
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VEGF mRNA is alternatively spliced to give at least 6 variants in humans, named for 
their translated amino acid length: 121, 145, 165, 183, 189 and 206, of which VEGF165 
is the most studied and known as VEGF164 in mice, since all the murine isoforms are 
one amino acid shorter than their human orthologs (Robinson and Stringer 2001). 
VEGF165 could also be considered the vital VEGF isoform, since it is only the 
exclusively VEGF164-expressing transgenic mouse, and no other single variant-
expression model, that develops normally (Eming and Hubbell 2011, Neufeld et al. 
1999, Robinson and Stringer 2001). Demonstrating the vital function of VEGF, 
deletion of only one allele results in embryonic lethality at E11-12 due to aberrant 
vascular development (Ferrara et al. 1996), while total deletion causes earlier (E9) 
lethality due to more severe defects (Carmeliet et al. 1999). VEGF is regulated in 
several ways: at the transcriptional (including via HIF-1α as described in 1.4), post-
transcriptional, translational and post-translational levels. 
 
Post-transcriptionally, the half-life of VEGF mRNA is only around one hour due to the 
presence of AU-rich elements (AREs) in its 3’ UTR, which mark it for degradation. 
However, under hypoxic conditions, an RNA-binding protein called HuR (human 
protein R) binds to the AREs, stabilising the mRNA to extend its half-life, causing an 
increase in VEGF levels (Nabors et al. 2001, Kurosu et al. 2011). In addition to 
hypoxia, VEGF expression is also regulated by other growth factors, cytokines 
secreted by immune cells, hormonal signalling and cellular stresses (Eming and 
Hubbell 2011). It has been shown that the overexpression of HuR allows enhanced 
tumour growth and that HuR deletion results in decreased growth, assumed to be due 
to VEGF mRNA stabilisation (Yoo et al. 2006). At the translational level, Myc binds 
to Vegf mRNA and upregulates translation initiation by approximately ten-fold (Yoo et 
27 
 
al. 2006). Since Myc activating mutations are common in tumours, this may be a 
common route by which tumours overproduce VEGF and indeed, expression of VEGF 
family members was observed immunohistochemically in approximately 50 % of 
human cancers investigated in 1998 (Nishida et al. 2006). 
 
Post-translationally, the bioavailability of VEGF is limited by its binding to the ECM. 
The isoforms VEGF165 and VEGF189 bind heparin in the ECM, whereas VEGF121 
diffuses freely (Robinson and Stringer 2001). VEGF165 is also cleaved by MMPs, 
which are secreted both by ECs and tumour-associated macrophages (TAMs). This 
generates two bioactive N-terminal fragments, VEGF11-110 and 111-165, of which the C-
terminal fragment has been found to be critical for binding to the ECM and to cognate 
receptors, and for mediating EC adhesion and survival. It has been shown that MMP 
inhibitors can attenuate pathological angiogenesis, showing that release of GFs from 
the ECM is a key part of angiogenic sprouting (Eming and Hubbell 2011, Kowanetz 
and Ferrara 2006, Tlsty and Coussens 2006). 
 
1.5.1.1 VEGF receptor 2 
The VEGF family members bind to their cognate receptors, VEGF receptors (VEGFR) 
1, 2, and 3 to exert their biological effects. These receptors are transmembrane tyrosine 
kinases for which the binding of their ligands to their extracellular domain induces 
dimerisation and autophosphorylation of their intracellular domain and subsequent 
activation of downstream signalling cascades (reviewed by Olsson et al. 2006, and 
Shibuya 2006). Although VEGF-A interacts with both VEGFR1 and VEGFR2, its pro-
angiogenic effects are mediated mainly by binding to VEGFR2 (in mice: foetal liver 
kinase 1 [Flk-1], also kinase-insert domain containing receptor [KDR] in humans), a 
tyrosine kinase receptor (RTK) found almost exclusively on ECs (Ferrara et al. 2003, 
28 
 
Robinson and Stringer 2001, Roy et al. 2006, Shibuya 2006, Waltenberger et al. 
1994). 
 
Downstream pathways include proliferative and anti-apoptotic signalling via 
phospholipase C-γ (PLCγ), increasing the concentration of intracellular Ca2+, and 
stimulation of protein kinase C (PKC). Activation of the mitogen-activated protein 
kinase/extracellular signal-regulated kinase (MAPK/ERK) cascade follows, which 
continues after clathrin-dependent receptor internalisation (Ewan et al. 2006, 
Takahashi et al. 2001). VEGFR2 is also recycled to the cell surface, or can continue in 
the endocytosis pathway to degradation in the lysosome (Ewan et al. 2006). Thus, 
VEGFR2 trafficking and its subcellular localisation is thought to be an integral part of 
the regulation of VEGF signalling (as reviewed by Horowitz and Seerapu 2012) 
(Figure 1.6). Survival signals are mediated via the kinase Akt, as well as the 
stimulation of migration via phosphatidylinositol-3-kinase (PI3K) and the small 
GTPases Rho and Rac (Matsumoto and Mugishima 2006). 
 
The importance of VEGFR2 is demonstrated by the Flk-1 knockout mouse, which 
shows an embryonic lethal phenotype between E8.5 and E9.5 due to vasculogenic 
defects and severely impaired development of endothelial and haematopoietic cells 
(Shalaby et al. 1995). VEGFR2 also acts with the co-receptor Neuropilin-1 (NP-1), 
which appears to be necessary for VEGFR2 internalisation (Horowitz and Seerapu 
2012). Indeed, the NP-1-null genotype is also embryonic lethal, illustrating its 
requirement in blood vessel development (Neufeld et al. 2002, Robinson and Stringer 
2001). VEGFR2 over-expression in colorectal cancer is also considered an 
independent prognostic factor, further demonstrating the relevance of angiogenic 
signalling in solid tumour progression (Eppenberger et al. 2010). 
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Figure 1.6 Signalling from VEGFR2 
Basic representations of key signalling pathways originating with VEGFR2 in endothelial cells. Upon 
binding of the VEGF ligand, the receptor dimerises and is autophosphorylated. VEGFR2 is internalised 
into endosomes, from which it can continue to signal within the cell. It is then either recycled to the cell 
surface or degraded in the lysosome. Via the binding of adapter proteins (omitted for clarity), 
downstream effects such as migration are mediated via phosphatidylinositol-3-kinase (PI3K) signalling 
through small GTPases Rho and Rac, remodelling of the actin cytoskeleton and turnover of cell surface 
adhesion complexes. Phospholipase C-γ (PLCγ) also heads a proliferative signalling cascade from the 
active receptor, via protein kinase C (PKC) and a MAPK/ERK cascade.   
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1.5.2 Fibroblast growth factor 
FGFs are pleiotropic factors that exert their effects upon several different cell types, 
including endothelial cells. FGFs contribute to embryonic development, wound 
healing and tissue homeostasis in the adult, and angiogenic processes (Böttcher and 
Niehrs 2005, Dailey et al. 2005, Ornitz and Itoh 2001). There are 22 known human 
FGFs, of which FGF-1 (or acid FGF) and FGF-2 (or basic FGF, bFGF) have been 
particularly well studied and are expressed almost ubiquitously in both humans and 
mice (Dailey et al. 2005). However, the FGFs could be considered non-essential 
players in angiogenic processes (compared to VEGFs), since the FGF-1/2 double 
knockout mouse exhibits a relatively mild phenotype, with only minor neuronal and 
haematopoietic changes, compared to the lethal phenotypes of VEGF and VEGFR 
knockouts (Miller DL et al. 2000). 
 
FGF ligands bind to the FGF receptors (FGFR1-4 and their derived isoforms, which 
can each bind different FGFs), with the complex in turn binding heparin or heparan 
sulphate proteoglycan (HSPG), abundant extracellular molecules, via one of the three 
extracellular Ig-like loop domains of the receptor. This interaction is required for 
signal transduction (Ornitz and Itoh 2001). Downstream signalling can influence 
proliferation, migration, survival and differentiation in a number of cell types (Dailey 
et al. 2005). bFGF can also elicit the same sequence of angiogenic responses in ECs as 
VEGF, but it is far less specific (Ornitz and Itoh 2001). VEGF also elicits a stronger 
anti-apoptotic signal in microvascular endothelial cells than bFGF (Gupta et al. 1999). 
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1.5.3 Platelet derived growth factor 
There are several PDGF isoforms: PDGFA, -AB, -C, -D and PDGFB, and three 
cognate receptor isoforms to which they bind: PDGFRα, -αβ and PDGFRβ. 
PDGFB/PDGFRβ-stimulated pericyte recruitement is of particular interest in this 
study, in relation to sprouting angiogenesis. PDGFB is released from ECs (of arterioles 
and capillaries, but not venules - mainly by endothelial tip cells in healthy tissue, but 
more heterogeneously by tumour microvessels (Gerhardt and Bertsholtz 2003) and can 
bind to proteoglycans in the ECM until released by MMPs, similar to VEGF (Kurup et 
al. 2006). Free PDGFB facilitates the recruitment of pericytes to stabilise new vessels 
via binding to its receptor PDGFRβ on pericytes, stimulates the mesenchymal cells to 
migrate towards local endothelial cells and form cell-cell contacts (Adams and Alitalo 
2007, Hall 2006, Homsi and Daud 2007, Thurston et al. 2000, Gerhardt and Bertsholtz 
2003), as described in 1.2.1.2.  
 
Both PDGFB-null and PDGFRβ-null mice have embryonic lethal phenotypes 
involving severe pericyte deficit, demonstrating the requirement both for the 
supporting cells themselves and the major signalling pathway that recruits them to 
maturing blood vessels (Lindahl et al. 1997, Soriano 1994). The vital role of PDGFRβ 
is also demonstrated by the injection of PDGFRβ blocking antibodies in neonatal mice, 
which completely prevented pericyte recruitment to retinal vessels and severely 
impaired development of the network (Uemura et al. 2002). 
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1.5.4 Integrins 
Endothelial cells adhere to the surrounding ECM via cell surface molecules including, 
in particular, the integrins. Integrins are transmembrane heterodimeric receptors 
composed of one α and one β subunit, of which β is smaller. The combinations of 
subunits dictate the ECM component binding specificity of the cell surface complex 
(Table 1.1). Integrins are not restricted to endothelial cells, though some are cell type-
specific, for example, integrin β2 is found only on leukocytes. Endothelial integrin 
dimers include α1β1, α2β1, α3β1, α4β1, α5β1, α6β1, αvβ3 and αvβ5, with α7β1 and 
α8β1 found on pericytes, and several β1 dimers expressed by both cell types 
(Abraham et al. 2008, Silva et al. 2008, Stupack and Cheresh 2002). 
ECM component Binding integrin heterodimers 
Laminin 
α3β1, α6β1. 
α6β4 
Collagen α1β1, α2β1 
RGD peptide motif 
(FG, FN, vWF, VN) 
α5β1, αvβ3, 
αvβ5 
 
Table 1.1 Binding specificity of endothelial integrin heterodimers 
The ECM component and the integrins found on the surface of endothelial cells that bind to that 
molecular family. FG = fibrinogen, FN = fibronectin, vWF = von Willebrand factor, VN = vitronectin 
(Compiled using Eming and Hubbell 2011). 
 
Integrins, as well as mediating adhesion to the ECM, are also signal transduction 
molecules. They not only convey contact information from the ECM to the cell interior 
by linking it to the cytoskeleton, but also cross-talk with growth factor signalling 
pathways (outside-in signalling) and their own ECM binding properties are regulated 
from inside the cell (inside-out signalling) (Giancotti and Ruoslahti 1999, Ginsberg et 
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al. 2005, Coppolino et al. 2000, Ginsberg et al. 1992). The clustering of ECM-bound 
integrins and their cytoplasmic binding partners at the membrane and recruitment of 
the key downstream signalling protein focal adhesion kinase (FAK) is termed 
formation of a focal contact. Focal contacts connect actin cytoskeleton stress fibres 
within the cell to the ECM in focal adhesion complexes (Geiger and Bershadsky 2001, 
Yamada 1997). 
 
The full range of integrin functions, however, is not yet fully understood, as evidenced 
by apparently conflicting results from blocking antibody and knockout mouse model 
studies. It was thought that a simple relationship between integrins and pro-
angiogenesis would exist and this idea is supported by some integrin-inhibition studies. 
For example, a small molecule dual inhibitor of αvβ3 and αvβ5 (LM609) decreased 
tumour growth in vivo and angiogenesis in the chick chorioallantoic membrane assay 
(Kumar et al. 2001). Additionally, administration of an anti-αvβ3 antibody, Vitaxin, to 
a small cohort of late-stage cancer patients in the clinic gave positive results (Gutheil 
et al. 2000). However, the assumption that integrins are only pro-angiogenic does not 
hold true. For example, in mice lacking β3 or both β3 and β5 integrins, tumour growth 
and vascularisation were in fact enhanced, which was found to be mediated by 
increased VEGFR2 expression (Reynolds et al. 2004, Reynolds et al. 2002). 
Subsequently, VEGF-induced blood vessel permeability was enhanced in β3-null 
mice, and use of the anti-VEGFR2 antibody DC101 abrogated this phenotype 
(Reynolds et al. 2002, Robinson et al. 2009). Similarly, endothelial cell-specific 
deletion of α6 integrin using a Tie-1 Cre recombinase model also increased tumour 
growth and vascularisation, and VEGF-stimulated angiogenesis, concurrent with 
VEGFR2 upregulation (Germain et al. 2009). Recently, α2β1 integrin was also found 
to promote EC quiescence (Cailleteau et al. 2010). 
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Most strikingly, when the dosage of RGD ligand-mimetic αvβ3 and αvβ5 inhibitor 
drugs in clinical trials was examined in detail, it was found that low doses could 
actually stimulate tumour growth and angiogenesis (Reynolds et al. 2009). Together 
these apparently conflicting results show that our knowledge of integrin modes of 
action in ECs and angiogenesis, especially in pathological contexts, is still lacking. 
Further examination of the molecular interactions between blood vessel cells and their 
environment, and with each other, is required to inform the development of more 
effective therapies. 
 
1.5.5 Anti-angiogenic therapy 
The rationale behind anti-angiogenic therapy is that severing the tumour’s blood 
supply by removing angiogenic stimuli and promoting tumour EC death should starve 
the tumour and perhaps reduce metastasis by removing the conduit for tumour cells to 
enter the blood stream and travel to new niches (Cheresh 1998, Fidler and Ellis 1994). 
Initially, “first generation” therapies focused on VEGF signalling, being a dominant 
pro-angiogenic force in tumour growth (as discussed in 1.5.1) and some of these 
strategies are depicted in Figure 1.7. For example, the humanised monoclonal anti-
VEGF antibody bevacizumab (or Avastin®, produced by Genentech) was the first 
drug of its kind to be approved by the US Food and Drug Administration (FDA) and is 
now administered as monotherapy to non-responding glioblastoma patients (Shih and 
Lindley 2006). However, in most cases bevacizumab is not beneficial when 
administered alone and serious side effects have also been noted, due to off-target 
damage to healthy tissue (Chen and Cleck 2009, Loges et al. 2010).  
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“Second generation” broad-spectrum receptor tyrosine kinase inhibitors (RTKIs) 
targeting VEGFR2 and other RTKs such as FGFR, EGFR and PDGFR have also been 
developed. These include sunitinib and sorafenib, which are also approved in some 
advanced cases of renal cell, gastro-intestinal and hepatocellular cancers as 
monotherapy, presumed to be more effective than first generation strategies due to 
their multi-target mechanisms (Gotink and Verheul 2010, Homsi and Daud 2007). 
However, in most cases such therapies have been limited to extending survival only for 
several months (Loges et al. 2010, O'Reilly 2007).  
 
The original assumptions behind anti-angiogenic therapy have been challenged by pre-
clinical and clinical results, so it is now acknowledged that targeting only one factor is 
not enough; the use of anti-angiogenic agents alone has proved insufficiently 
efficacious. It has been reported that improved blood flow and normalisation of 
interstitial pressure can lead to deeper, more efficient drug delivery and indeed, 
bevacizumab is approved for administration to metastatic colorectal, selected non-
small cell lung and metastatic renal cell cancer patients, in combination with cytotoxic 
or cytokine therapy (Carmeliet and Jain 2011). Combination therapies are being tested 
and approved more frequently but require extensive evaluation for safety.  
 
Most recently, “third generation” strategies are emerging, involving other concepts in 
tumour biology: targeting myeloid cells (e.g. TAMs) in the immune compartment; 
promoting non-productive angiogenesis; blocking neuropilin (Nrp) receptors both to 
synergistically enhance anti-VEGF targeting and as an anti-lymphatic treatment; and 
finally, through vessel normalisation, which is explained further in 1.5.5.1 below and 
demonstrated in Figure 1.8 (Loges et al. 2010). 
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Figure 1.7 Types of anti-angiogenic therapies targeting VEGF 
Five of the main therapeutic strategies developed to date are depicted: 1) anti-VEGF antibodies, which 
bind directly to soluble VEGF, such as bevacizumab (Avastin®, Genentech), which binds to all VEGFA 
isoforms, and ranibizumab. 2) Specific anti-VEGFR antibodies designed to target and block the function 
of VEGF receptors. 3) Soluble VEGFR fragments designed to competitively bind VEGF to prevent it 
from binding to functional receptors, such as VEGF-Trap, a hybrid VEGFR1/VEGFR2/antibody protein 
that inhibits all VEGFA isoforms and PlGF. 4) VEGF aptamers such as pegaptanib, which bind to and 
block the function of VEGFs. 5) Broad-spectrum small molecule tyrosine kinase receptor inhibitors 
(RTKIs), which interact with and block downstream signalling from VEGFRs as well as other receptors. 
For example Sunitinib (SU11248 or Sutent®, Pfizer) binds PDGFR, VEGFR, c-KIT and FLT-3, and is 
FDA approved for kidney cancer and neuroendocrine tumour patients. Sorafenib (BAY439006 or 
Nexavar®, Bayer and Onyx) binds c-Raf, B-Raf, PDGFR and VEGF, and is FDA approved for 
hepatocellular carcinoma and kidney cancer. Vatalanib (PTK787) binds VEGFRs, PDGFRβ and c-KIT 
but particularly VEGFR2. 
37 
 
1.5.5.1 Vascular normalisation 
Since endothelial cells are non-neoplastic cells they were thought to be less likely than 
tumour cells to develop resistance to therapy, but the development of resistance has in 
fact been observed, whereby angiogenesis is stimulated via alternative pathways 
including PlGF, Ang-1 and FGF signalling (Loges et al. 2010). In addition, the 
promotion of metastasis as a result of such treatments has been observed but this effect 
is still in debate due to conflicting data (Carmeliet and Jain 2011, Pàez-Ribes et al. 
2009, Singh et al. 2012). Despite these findings, anti-angiogenic therapy is still an 
attractive anti-cancer strategy, in part due to a phenomenon first described in the 70s 
termed “vessel normalisation” (Figure 1.8), which serves to decrease hypoxia and 
metastasis and could improve drug delivery and efficacy (Carmeliet and Jain 2011, 
Serve and Hellmann 1972). 
 
Importantly, while tumour ECs are non-neoplastic, the tumour vasculature is 
nevertheless unlike the normal vasculature. Tumour vessels themselves are more leaky 
than normal vessels, chaotic and tortuous in their organisation, and extremely 
heterogeneous (Dudley 2012, Tlsty and Coussens 2006). Tumour ECs often display 
little to no polarity, are poorly differentiated and loosely associated with the BM and 
with each other, and form multi-layers with gaps between cells. Tumour vessels are 
also often “mosaic”, with EC-mimicking tumour cells and other cell type progenitors 
incorporating into the vessel wall (Wang et al. 2010). In some cases, ECs are absent 
from sections of vessels, with BM-only “string vessels” remaining (Carmeliet and Jain 
2011, Dudley 2012, Yuan et al. 2012). Other vessel wall abnormalities include 
variable (but often poor) de-differentiated pericyte coverage, and the generation of an 
unstable thicker BM as well as, due to high turnover rates, “naked” EC channels 
completely devoid of BM (Carmeliet and Jain 2011).  
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Figure 1.8 Tumour vasculature abnormalities and the phenomenon of vascular normalisaiton 
A: Represensations of vascular strutures in Normal tissues (far left) and tumours (right). It is now 
thought that antiangiogenic therapy at first improves structure and function of tumour blood vessels 
(‘Abnormal’), making them resemble the Normal vasculature more closely (or to become ‘Normalised’). 
However, sustained or particularly potent treatments may cause excessive vessel pruning, creating an 
‘Inadequate’ vasculature (far right). B: Vascular normalisation as induced by treatment of murine colon 
carcinoma with anti-VEGFR2 antibody, as compared to normal skeletal muscle (far left). C: 
diagrammatic representation of changes to basement membrane (purple) and pericyte coverage (green) 
around vessels (red). D: Hypothesised changes to pro- and anti-angiogenic factor (green and red, 
respectively) balance in the tissue during antiangiogenic therapy. (Adapted from Jain 2005.) 
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Together the abnormalities of tumour vessels contribute to the inefficient function of 
the tumour vasculature, including heterogeneous blood flow, poor tumour perfusion 
and restricted immune access, which in turn promotes hypoxia, further non-productive 
angiogenesis and vascular remodelling in a positive but futile feedback loop. 
Consequently, metastasis can become more likely as tumour cells have a low-
resistance barrier to intravasation. 
 
Attempts to restore the angiogenic “balance” (a more anti-angiogenic state, as shown 
in Figure 1.3) in preclinical models, for example by decreasing VEGF availability or 
manipulating the HIF-1α pathway, have shown that a transient vessel normalisation 
window presents itself in which tumour perfusion, oxygenation and drug delivery are 
increased. The promotion of vessel maturation (improving vessel quality and function 
rather than vessel pruning and blockade) is another aspect of normalisation. This can 
involve the stimulation of pericyte coverage and tightening EC contacts via blocking 
the pro-angiogenic factor Ang-2. In addition, blocking PlGF appears to promote the 
M1 phenotype of tumour-associated macrophages or TAMs (where the M2 phenotype 
is pro-angiogenic) and create a more uniform tumour vasculature (Bouzin and Feron 
2007, Carmeliet and Jain 2011). 
 
Clinically, collection and analysis of data can prove difficult, since imaging 
technology is limited and monitoring during treatment is typically infrequent. 
However, some normalisation has been observed in small patient trials and human 
tumour samples. It is hypothesised and supported by some data that increased tumour 
cell proliferation around normalised vessels can sensitise them to cytotoxic 
chemotherapy, and that decreased hypoxia due to improved blood flow and oxygen 
delivery can increase the efficacy of radiotherapy (Bertout et al. 2008, Carmeliet and 
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Jain 2011). Normalisation also improves immune cell infiltration into tumours, 
assisting immunotherapy strategies. 
 
Anti-angiogenic strategies have not only focused on VEGF (and other pro-angiogenic 
growth factors) and vascular normalisation, but also on cell adhesion molecules such 
as integrins; the examples of Cilengitide (Merck), which binds to and inhibits αv 
integrins (Reynolds et al. 2009), and Vitaxin, which is a blocking antibody for αvβ3 
integrins, were introduced in 1.5.4. In addition, histone deacetylase (HDAC) inhibitors 
have been targeted in an attempt to modulate HIF-1α activity and downstream 
angiogenic responses, as described in 1.4, and have been successful in preclinical 
models and early clinical trials (Ellis et al. 2009). MMPs have also been targeted with 
limited success but may be more effective as combination therapy (Zucker et al. 2000). 
It is likely that many viable anti-angiogenic therapeutic strategies are yet to be 
discovered and improving our understanding of the molecular players in tumour 
angiogenesis will surely reveal new targets. 
 
1.6 Endothelial cell-cell adhesion 
The endothelial cell-cell junctions include both tight junctions (TJs) and adherens 
junctions (AJs), which are depicted in Figure 1.9 with their associated cell surface 
molecules and cytoplasmic binding partners. For multicellular organisms to function, 
individual cells must adhere to each other as well as their environment in order to form 
functioning tissues and barriers between bodily compartments and the outside world. 
The endothelial barriers of blood vessels are semi-permeable to allow the controlled 
release of fluids, solutes, proteins and immune cells. Transcellular permeability 
describes the movement of solutes through cells via vesicular transport, whereas 
paracellular permeability involves the control of the spaces between cells. The 
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integrity of the endothelial cell barriers in different parts of the vascular system is 
determined by how robustly ECs are adhered to one other via cell-cell junctions and 
their temporary breakdown is required for endothelial cell division, migration and 
formation of new blood vessels during angiogenesis, with cell contacts re-established 
during maturation (Lampugnani et al. 2002). The rapid formation and constant 
remodelling of tumour vessels leads to abnormalities in vessel permeability, lumen 
formation, supporting cell association, and overall functionality, as described in 
1.5.1.2, with endothelial cells poorly adhered to one another. 
 
AJs are ubiquitous in the vascular system, while TJs are thought to be more restricted 
to certain endothelial layers such as the blood-brain barrier (BBB) where TJs are 
especially abundant, with fewer well-developed TJs in other vessels such as 
microcapillaries (Willis et al. 2007). The space between adjacent cell membranes at an 
AJ is 3 nm on average, compared to the 1 nm TJ average where membrane proximity 
is very high (Yuan and Rigor 2010). Together these cell-cell junctions regulate 
endothelial paracellular permeability (Bazzoni and Dejana 2004). While comprising 
different components, AJs and TJs both contain specialised transmembrane proteins, 
which bind cytoplasmic adapter proteins. Together they mediate contact inhibition of 
cellular proliferation, with downstream signalling altering gene transcription, and also 
maintain cellular polarity (Bazzoni and Dejana 2004). The characteristic 
transmembrane elements of AJs are cadherins, specifically vascular endothelial 
cadherin (VECAD) in endothelial cells. Cadherins bind catenin proteins in the 
cytoplasm, which contact and connect AJs to the cytoskeleton. AJs prompt the 
formation of TJs, but are not necessary for their maintenance (Hartsock and Nelson 
2008). Occludin and claudins form the TJ “backbone”, also known as strands, and they 
in turn associate with other transmembrane proteins such as the junctional adhesion 
42 
 
molecules (JAMs), together regulating paracellular permeability. In the cytoplasm, 
claudins and occludin bind to adapter proteins including the zonula occludens (ZO) 
family, as well as nuclear shuttling proteins.  
 
Outside of AJs and TJs is another notable adhesion molecule, PECAM (platelet 
endothelial cell adhesion molecule), a transmembrane immunoglobulin commonly 
referred to as CD31, which is commonly used as an EC marker. PECAM is a widely 
expressed surface receptor with many functions, also interacting with integrins and 
immune cells (as reviewed by Jackson 2003). It is not an endothelial-specific cell 
adhesion molecule but is highly expressed on endothelial cells. PECAM interacts 
homophilically at the surface of neighbouring ECs to regulate endothelial barrier 
function together with the cell junction complexes (Bazzoni and Dejana 2004). 
 
The majority of junctional studies have been performed in epithelial cells, since 
epithelial layers are also polarised and tightly adhered together and arguably epithelial 
tissues are more accessible for study due to both their higher abundance and ease of 
cell culture in vitro, compared to endothelial cells. However, much of what has been 
found so far in endothelial cells appears to reflect epithelial adhesion. Here I will 
concentrate on endothelial junction structure, function, protein components and 
downstream effects. 
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Figure 1.9 Endothelial cell-cell junctions 
Cartoon of two contacting endothelial cells and one pericyte with major junctional molecules indicated. 
Tight junctions include: claudins and occludin, JAMs (junctional adhesion molecules), and ESAM 
(endothelial cell selective adhesion molecule). Downstream zonula occludens (ZO) adapter proteins are 
shown linking TJs to the cytoskeleton. Adherens junctions include: VECAD (vascular endothelial 
cadherin), shown bound to catenins p120, γ-catenin and β-catenin, linked to the cytoskeleton. PECAM 
(platelet endothelial cell adhesion molecules) also adheres endothelial cells to one another via 
homophilic interaction and is commonly used as an endothelial cell marker. NCAD (neuronal cadherin) 
is thought to be involved in endothelial-pericyte interactions in the form of NCAD/β-Catenin adherens 
junctions (Gerhardt and Bersholtz 2003). The polarity of the cells is indicated, with the cell apices 
facing inwards towards the lumen and basal sides contacting the basement membrane (BM). (Adapted 
from Dejana 2004). 
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1.7 Adherens junctions 
The patterning of adherens junctions (AJs) on endothelial cells varies between tissues 
and this correlates with the level of vascular permeability in that tissue. For example, 
AJs in the BBB are typically located at basolateral surfaces of ECs, where they 
maintain a tight barrier structure. In contrast, AJs in microcapillaries are more 
diffusely distributed around the cell and this correlates with a more permeable barrier 
type (Bazzoni and Dejana 2004). 
 
1.7.1 Vascular endothelial cadherin (VECAD) 
VECAD is the major transmembrane protein found in endothelial AJs. The 
extracellular domain, containing five extracellular cadherin (EC) domains, interacts 
homotypically with VECAD proteins on the surface of adjacent cells. The interaction 
of VECAD cytoplasmic tails with catenin binding partners and their associated 
proteins is collectively referred to as the cytoplasmic cell adhesion complex (CCC). 
The CCC as a whole is required for stable AJ formation and maintenance, and for the 
regulation of endothelial morphology and paracellular permeability (Corada et al. 
2002). 
 
Members of the “classical” or Type I subset of the cadherin family of proteins were 
named for the cell type in which they were found: epithelial cadherin (ECAD or E-
Cadherin) neural cadherin (NCAD or N-Cadherin) and placental cadherin (PCAD or P-
Cadherin). VE-cadherin is a Type II cadherin, distinguished by the lack of an HAV 
cadherin binding motif present in the Type I cadherins (Vestweber 2008). Both 
VECAD and NCAD are expressed by endothelial cells, with NCAD thought to 
mediate pericyte-endothelial interaction at sites of contact via NCAD/β-Catenin AJs 
(Gerhardt and Bersholtz 2003). All cadherins have a single pass transmembrane 
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structure with cadherin repeats in the extracellular domain, which require calcium ions 
(Ca2+) for cell adhesion complex function (Braga et al. 1999, Gumbiner 2005, 
Wheelock and Johnson 2003). Ion-bound VECAD monomers interact laterally 
together at the cell surface and homotypically via the extracellular domain to contact 
neighbouring ECs. Multiple functions have been described for VECAD, not limited to 
its cell-cell adhesion role, but extending to the regulation of VEGFR2 signalling and 
directing the transcription of other endothelial proteins (Bazzoni and Dejana 2004, 
Carmeliet et al. 1999, Christofori 2003, Lampugnani et al. 2006). VECAD controls 
vascular permeability dynamically via three main mechanisms: 1) phosphorylation (as 
well as that of its catenin binding partners), 2) internalisation and 3) cleavage (Dejana 
2004). 
 
VECAD is phosphorylated at five known tyrosine sites and one serine site (reviewed 
in Dejana et al. 2008). The extent of tyrosine phosphorylation was found to correlate 
inversely with cell density in culture, although the significance of VECAD 
phosphorylation in vivo is not yet fully understood (Dejana et al. 2008, Lampugnani 
and Dejana 1997). In addition, tyrosine phosphorylation was also found to inhibit p120 
and β-catenin binding, maintaining ECs in a mesenchymal migratory state (Potter et al. 
2005). Rac-mediated serine phosphorylation of VECAD also leads to its clathrin-
dependent internalisation and subsequent degradation, which increases permeability 
(Horowitz and Seerapu 2012). This cascade was found to be triggered by VEGF-
mediated activation of Src, which phosphorylates a Rac-activating protein, VAV2. 
This VECAD internalisation was also found to be inhibited by p120 binding (Xiao et 
al. 2005). Cell morphology and motility is also controlled via p120 catenin, which 
interacts with the small Rho GTPase proteins Rho, Rac (as indicated downstream of 
VEGFR2 in Figure 1.6) and cdc42 that together regulate the different structures that 
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compose the cytoskeleton (Braga 2002, Lampugnani et al. 2002, Perez-Moreno and 
Fuchs 2006). Finally, VECAD cleavage occurs upon exposure to certain MMPs, also 
leading to increased permeability (Dejana et al. 2008). 
 
At the cell surface, VECAD can also interact with activated VEGFR2 and forms a 
complex with β-Catenin and phosphatidyl inositol-3 kinase (PI3K), which then 
transduces cell survival signals via Akt and the anti-apoptotic protein Bcl2 (Carmeliet 
et al. 1999, Dejana et al. 2000). Although this interaction has not been fully 
characterised, in confluent cells it appears to be an important aspect of contact 
inhibition; the growth-inhibiting property of normal, non-cancerous cells that restricts 
proliferation when cells are contacting one another. VECAD reduces VEGFR2 
internalisation, thereby limiting its endosomal signalling potential upon VEGF 
stimulation, as well as reducing VEGFR2 phosphorylation via the dephosphorylating 
action of density-enhanced phosphatase-1 (DEP1), thus inhibiting downstream 
proliferative signalling (Dejana et al. 2008) (Figure 1.10). 
 
VECAD deficiency results in an embryonic lethal phenotype at E9.5 due to severe 
vascular remodelling and maturation defects, a phenotype also observed in a truncation 
mutant unable to bind β-Catenin (Carmeliet et al. 1999, Gory-Faure et al. 1999, Vittet 
et al. 1997). BV13, a monoclonal antibody (mAb) against VECAD, inhibited VECAD-
mediated adhesion and signalling in vitro and was found to inhibit angiogenesis in a 
number of mouse models, including tumour growth, concurrently increasing lung and 
heart vascular permeability (Liao et al. 2000). In contrast, mAb BV14 did not impact 
upon paracellular permeability in vitro or vascular permeability in any organs in vivo. 
It did, however, inhibit tumour angiogenesis similarly to BV13 (Corada et al. 2002). 
Since the antibodies bound different regions of the VECAD extracellular domain, they 
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showed that these regions have different roles in quiescent and actively growing 
vessels. 
 
Considering these interactions together, the molecular complexity of EC permeability 
becomes apparent. These activities of VECAD have been shown to be crucial in the 
regulation of permeability, but they do not perform this function alone. 
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Figure 1.10 VE-cadherin and VEGFR2 
Association of activated VEGFR2 with VECAD, p120 and β-catenin at the endothelial cell surface 
activates cell survival pathways via phosphatidylinositol-3-kinase (PI3K), Akt and Bcl-2. This 
association also blocks VEGFR2 internalisation into the endosomal compartment and decreases receptor 
phosphorylation via the phosphatase activity of density-enhanced phosphatase-1 (DEP1) (Dejana et al. 
2008, Lampugnani et al. 2006). Thus, the AJ protein VECAD attenuates VEGF proliferative signalling 
from VEGFR2, PLCγ and MAP kinases, as shown in Figure 1.6. 
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1.7.2 Catenins 
VECAD effects on endothelial cell behaviour are also mediated by its binding to 
catenin proteins in the cytoplasm, which itself is modulated by catenin 
phosphorylation. The membrane-proximal regions of the VECAD cytoplasmic tail also 
interact with p120-catenin and thus lateral clustering of cadherins in the membrane 
occurs as the contact matures (Perez-Moreno and Fuchs 2006).  
 
The distal portion of the VECAD cytoplasmic tail binds β-catenin or γ-catenin (also 
known as plakoglobin), which in turn contact α-catenin, thought to link the junctional 
complex with the actin cytoskeleton (Bienz 2005, Carmeliet et al. 1999, Dejana et al. 
2008, Gumbiner 2005). Catenin proteins, β-catenin in particular, are known for their 
ability to translocate to the nucleus and modulate transcription of genes involved in 
proliferation via interaction with transcription factors such as the TCF/lef family 
(Bienz 2005, Perez-Moreno and Fuchs 2006). Sequestration of catenins at the cell 
membrane allows the regulation of gene transcription by cell-cell contacts. 
Traditionally α-catenin has been described as the link between the actin cytoskeleton 
and β-catenin-VECAD. However, it may act instead in a “switch” manner, existing 
either as monomers or homodimers, the former binding β-catenin and the latter binding 
actin filaments (Drees et al. 2005). Phosphorylation and subcellular localisation of the 
α-catenin pool are also proposed as regulatory mechanisms in the linkage of AJs to the 
actin cytoskeleton (Burks and Agazie 2006). 
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1.8 Tight junctions 
Tight junctions (TJs) are close protein complex interactions that completely close the 
intercellular space at “kissing points” between adjacent cell membranes, which are 
visible as “strands” under freeze-fracture electron microscopy (Tsukita et al. 2001). 
Like AJs, the degree of TJ formation and maintenance differs between endothelial 
tissues. For example, in the BBB, TJs are dense and regimented in their structure to 
create a minimally permeable and highly selective barrier, but even within this tissue 
different areas exhibit varied junctional composition and structure (Willis et al. 2007). 
In contrast, TJs are less frequent and more loosely structured in microcapillaries to 
allow greater permeability (Bazzoni and Dejana 2004, Risau Werner 1998, Thurston et 
al. 2000). Tight junctions have also been reported to play a role in pericyte-EC 
contacts (depicted in Figure 1.9), along with NCAD-based AJs and gap junctions 
(pore-like connections between adjacent cell membranes), although the characteristics 
of these EC-pericyte tight junctions are not well described (Gerhardt and Bersholtz 
2003). 
 
TJs are composed of transmembrane proteins: claudins, occludin and junctional 
adhesion molecules (JAMs), and other proteins interacting both laterally in the 
membrane and as ‘plaque’ complexes in the cytoplasm (González-Mariscal et al. 2003, 
Nitta et al. 2003, Saitou et al. 2000, Sasaki et al. 2003, Tsukita et al. 2001). The TJ 
protein families, including occludin, JAMs and claudins, have some endothelial cell-
specific members such as vascular endothelial junctional adhesion molecule (VE-JAM, 
also known as JAM-B or JAM2), and endothelial cell-enriched molecules like 
Claudin5 (Aurrand-Lions Michel et al. 2001, Morita et al. 1999). Tight junction 
functions, component proteins, and some downstream signalling effects are depicted in 
Figure 1.11. 
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TJ “barrier” and signalling functions regulate paracellular vascular permeability to 
small molecules and cells as well as membrane trafficking, cell motility, quiescence, 
apoptosis and proliferation (Balda and Matter 2009, Gonzalez-Mariscal et al. 2008, 
González-Mariscal et al. 2007, Köhler and Zahraoui 2005, Matter and Balda 2003, 
Tsukita et al. 2001, Zahraoui et al. 2000). TJs have been found to crosstalk with AJs 
(Taddei et al. 2008) but in addition to their role in vascular permeability (the barrier 
function), TJs also perform a “fence” function that prevents free movement of solutes, 
proteins and lipids around the cell membrane between apical and basal plasma 
membrane domains, helping to determine and maintain cell polarity (Dörfel and Huber 
2012) (Figure 1.11 A and B). 
 
Most studies of downstream pathways originating at the TJ have been performed in 
epithelial cells in vitro, so not all signalling described so far can be definitely said to 
function in the same manner in endothelial cells. Some TJ signalling is summarised 
here with the assumption that highly similar pathways operate in endothelial cells. TJs 
communicate contact information from the environment to the cell interior, regulating 
cell morphology, motility, gene expression and signalling cross talk (Balda and Matter 
2009, Bazzoni and Dejana 2004, Escudero-Esparza et al. 2012, Gonzalez-Mariscal et 
al. 2008). They are themselves regulated by cell confluence, phosphorylation, 
endocytosis and other signalling pathways (Köhler and Zahraoui 2005, Marchiando et 
al. 2010). Little information has been uncovered to date regarding the dynamics and 
regulation of tight junctions in vivo. 
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Figure 1.11 Tight junction functions and downstream signalling 
A: The TJ “barrier” or “gate” function. Perspective showing TJ “kissing point” protein complexes that 
regulate paracellular flow of solutes (red arrows). Adapted from M. Ruiz with permission. B: The 
“fence” function of TJs: preventing the free movement of apical (blue)/basolateral (purple) proteins and 
lipids around the cell membrane, to maintain cell polarity. C: Integral membrane proteins within and 
associated with TJ strands as well as cytoplasmic binding partners: occludin and claudins together make 
up the TJ strands; JAMs, which associate laterally with TJs and can interact with integrins (not shown). 
The ZO-1 adapter protein binds both claudins, occludin and JAM-B and many other partners including 
ZO-2 and -3 (via PDZ domains); ZONAB can shuttle to the nucleus where it interacts with Cdk4 and 
modulates cell cycle progression; MUPP1 whose function has not been elucidated; MAGI scaffold 
proteins, actin cytoskeleton-binding proteins such as cingulin (omitted) and small GTPases (omitted). 
JAM-C is known to bind the PAR3/6 complex, which regulates cell polarity. 
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1.8.1 Occludin 
Occludin is a tetraspanin (a protein containing four transmembrane domains) with a 
long C-terminal cytoplasmic domain and was the first component of TJs to be 
discovered in 1993 (Furuse et al. 1993). In the TJ strands, occludin interacts with 
claudins and JAMs via its second extracellular loop (EL). Occludin is expressed by 
both epithelial and endothelial cells and some results have suggested that occludin 
membrane distribution and expression levels, which are high in the brain but 
undetectable in some other tissues, facilitate its modulation of TJ-mediated 
permeability (Hirase et al. 1997). Occludin has been placed in a small family of 
proteins, the TAMPs (tight junction-associated MARVEL [MAL and related proteins 
for vesicle trafficking and membrane link] proteins) together with tricellulin (or 
MarvelD2) and MarvelD3. TAMPs share the two ELs plus one intracellular loop-
structure and appear to have similar functions, indicating some possible redundancy as 
well as some unique functions that cannot be compensated for (Dörfel and Huber 
2012, Raleigh et al. 2010). Occludin knockout mice, however, are viable and gut 
junctions were found to assemble normally, although other organs displayed 
histological abnormalities, male mice are infertile and pups do not grow normally after 
birth (Saitou et al. 2000). This variety of phenotypes suggests a complex function and 
requirement for occludin, which is not yet fully characterised. 
 
Recently, phosphorylation has been investigated as a regulatory mechanism of 
occludin functions (as reviewed by Dörfel and Huber 2012). Hypoxia-induced tyrosine 
phosphorylation of occludin by Src was shown to prevent interaction with the ZO-1 
adapter protein at junction sites (Elias et al. 2009). VEGF-induced phosphorylation of 
occludin at Ser-490 was also shown to be vital for its ubiquitination and subsequent 
internalisation, also resulting in increased vascular permeability (Horowitz and 
55 
 
Seerapu 2012, Murakami et al. 2009). Conversely, protein kinase C-ζ (PKCζ)-
mediated threonine phosphorylation of occludin is required for its localisation to 
epithelial TJs (Jain S et al. 2011). 
 
1.8.2 JAMs 
JAMs are associated laterally with TJ strand proteins, though not constituents of the 
strands themselves, and appear to be important in TJ formation as well as the adhesion 
and transendothelial migration (diapedesis) of leukocyte immune cells (Bazzoni 
Gianfranco 2003). As members of the immunoglobulin (Ig) protein superfamily, JAMs 
are single-pass transmembrane proteins with extracellular Ig domains. The 
nomenclature of the three family members is often unclear: JAM-A was the first 
member described, originally termed JAM and sometimes referred to as JAM-1; JAM-
B is also known as VE-JAM, and JAM-2 in humans, but JAM-3 in mice; and JAM-C 
is known as JAM-3 in humans but also as JAM-2 both in humans and mice (Bazzoni 
Gianfranco 2003). 
 
JAM-A is not an endothelial-specific molecule as it is found in platelets, epithelial and 
immune cells as well as ECs (Aurrand-Lions Michel et al. 2001, Bazzoni Gianfranco 
2003). JAM-B, the least studied of the group, is specific to vascular endothelial cells, 
hence its VE-JAM alternative nomenclature (Aurrand-Lions M. et al. 2002, Bazzoni 
Gianfranco 2003). JAM-C is expressed in both lymphatic and venule endothelial cells 
and was found to localise to junctions via the ZO-1 adapter protein (Aurrand-Lions 
Michel et al. 2001). It was shown to mediate the transendothelial migration of 
leukocytes via interaction with the leukocyte receptor integrin αΜβ2, together with 
JAM-B (Johnson-Léger et al. 2002, Lamagna et al. 2005b). JAM-C/JAM-B also 
contacts PAR3 directly, which, in concert with AJ downstream signalling, regulates 
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cell polarity (Ebnet et al. 2003). Interaction of the integrin αvβ3 with JAM-C was 
recently shown to regulate permeability in a GTPase-dependent manner (Li et al. 
2009).  
 
JAM-A deficient mice are viable but display abnormal leukocyte transmigration 
(Woodfin et al. 2007). JAM-B knockout mice are also viable and show defective 
haematopoietic stem cell maintenance in the bone marrow, with the authors concluding 
that this may be due to altered interactions with the bone marrow stroma (Arcangeli et 
al. 2011). JAM-B was also found to be essential for muscle fibre formation in a study 
using JAM-B-/- zebrafish (Powell and Wright 2011). JAM-C knockout mice exhibit 
defective motor function due to abnormal myelin sheath coverage (Scheiermann et al. 
2007). Knockdown of JAM-C in ECs decreased permeability and was concurrent with 
increased VECAD adhesion (Orlova et al. 2006). Finally, knockout of the JAM-like 
molecule ESAM also increased VEGF-stimulated vascular permeability (Wegmann et 
al. 2006), though ESAM was not found to interact with PAR3 in the control of polarity 
(Ebnet et al. 2003). 
 
As with VECAD, the JAMs have presented as promising targets for vascular-
modulating therapy. In mice, anti-JAM-C antibody therapy was found to inhibit the 
growth of tumours in vivo (with no effect on normal kidney). This encouraging result 
was accompanied by a decrease in tumour-associated macrophage (TAM) numbers, 
inhibited retinal neovascularisation following hypoxia and completely ablated 
microvessel sprouting from explanted aortic rings ex vivo (Lamagna et al. 2005a). 
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1.8.3 TJ plaque proteins 
The integral membrane proteins of TJs interact via PDZ domains with plaque proteins 
in the cytoplasm, linking them to the JAMs and further binding partners. The zonula 
occludens (ZO) proteins ZO-1, ZO-2 and ZO-3 are scaffolding/adapter molecules that 
interact directly with occludin and claudins at TJs as well as with AJs and the 
cytoskeleton. They are of the membrane associated guanylate kinase homologue 
(MAGUK) family, containing PDZ and SH3 protein-protein interaction domains as 
well as a guanylate kinase (GK) module (González-Mariscal et al. 2000). ZO proteins 
also appear to contain both nuclear localisation and nuclear export signals (NLS/NES) 
though their potential roles in EC transcriptional modulation are unclear (Gonzalez-
Mariscal et al. 2008, González-Mariscal et al. 2003). ZO-1 and ZO-3 also directly bind 
F-actin, thus linking TJs to the cytoskeleton (González-Mariscal et al. 2000). ZO-1 
expression is regulated by cell density, as demonstrated by the finding that ZO-1 levels 
are elevated proportionally in MDCK cells with increasing confluence (Balda and 
Matter 2000). It has also been reported that VEGF can regulate ZO-1 expression, 
though the effect depends on the particular endothelial cell type (Ghassemifar et al. 
2006). Demonstrating its pivotal role in TJs and vessel wall integrity, the ZO-1 
knockout phenotype is embryonic lethal, partly due to yolk sac angiogenic defects 
(Katsuno et al. 2008). 
 
The Y-box transcription factor ZONAB (ZO-1-associated nucleic acid binding protein) 
binds the ZO-1 SH3 domain and can shuttle to the nucleus, interacting with Cdk4 to 
induce cell cycle progression from G1 to S phase via transcriptional upregulation of 
Cyclin D1 and PCNA in sparsely-cultured cells, as depicted in Figure 1.11 C (Balda 
and Matter 2009, Dejana 2004, González-Mariscal et al. 2007, Sourisseau et al. 2006, 
Tsapara et al. 2006). In a similar manner to VECAD and β-catenin, the sequestration 
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of ZONAB at the TJ membrane complex by ZO-1 thus allows TJs to regulate cellular 
proliferation. In low density, proliferating cells, ZO-1 levels are low and ZONAB is 
largely localised to the nucleus. Conversely, in confluent cells, ZO-1 expression is 
high, with ZONAB bound at TJs, limiting the nuclear ZONAB pool available for the 
promotion of transcription (González-Mariscal et al. 2007, Tsapara et al. 2006). 
 
Other TJ-associated MAGUK proteins include the scaffolding MAGI proteins 
(MAGUK with inverted orientation), PAR-3 and -6 (partitioning defective), and 
MUPP1 (multi-PDZ-domain protein). PAR proteins are known to mediate cell 
polarity, particularly during embryonic development, and MUPP1 appears to interact 
directly with claudin-1 and JAMs via its PDZ domains; perhaps acting as a scaffold in 
a similar manner to ZO-1, though its precise function is not known (González-Mariscal 
et al. 2003, Hamazaki et al. 2002). Little has been confirmed regarding the 
downstream actions of TJ plaque constituents in ECs specifically. 
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1.8.4 Claudins 
At TJs where cell membranes come into close contact, claudins are a major component 
of the cell-cell contact strands and are known to be vital for TJ formation and 
maintenance. The claudin strands perform the fence function of TJs, as shown in 
Figure 1.11 B (Hartsock and Nelson 2008, Tsukita et al. 2001). Claudins recruit 
occludin to the junctional complex and bind the plaque proteins via their PDZ 
domains. There are 24 known claudin (Cldn) proteins in the mammalian family, with 
humans possessing 23 (lacking Cldn13) and mice coding for all 24 (Hewitt et al. 2006, 
Lal-Nag and Morin 2009). They are tetraspan membrane proteins, with intracellular N- 
and C-termini (Figure 1.13). The intracellular loops undergo post-translational 
modifications such as phosphorylation and palmitoylation, which is required for their 
localisation at the membrane, and they can also be regulated by endocytic 
internalisation (Lal-Nag and Morin 2009, Morin 2005, Van Itallie et al. 2005). While 
structured similarly to the TAMPs, except for shorter N- and C-termini, they are not 
similar in sequence and therefore not of the same protein family (Dörfel and Huber 
2012).  
 
The expression patterns and functions of many claudin family members remain poorly 
characterised but claudin expression is known to be tissue-specific. However, most 
tissues express multiple members of the family, suggesting some functional 
redundancy and a capacity for tissue-specific functional consequences of 
heteropolymerisation, since variable amino acid composition of the extracellular loops 
(ELs) allows combinations of claudins to create paracellular selectivity for differently 
charged ions (González-Mariscal et al. 2007, Tsukita et al. 2001). 
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Knockout mouse models have demonstrated the significant and diverse roles of 
claudins in vivo. For example, Cldn1-/- mice do not survive long after birth due to 
dehydration, with the lack of Cldn1 severely destabilising the epidermal barrier leading 
to severe water loss (Furuse et al. 2002). Cldn11-/- male mice are sterile and both 
Cldn11-/- and Cldn14-/- mice exhibit deafness, though due to different cellular 
malfunctions in the ear (Ben-Yosef et al. 2003, Gow et al. 2004). Loss of Cldn11 
abolishes TJs normally found in the basal cells of the stria vascularis in the cochlear 
duct of the inner ear, while Cldn14 loss causes the rapid degeneration of outer hair 
cells in the cochlea as well as slower degeneration of inner hair cells, both leading to 
hearing loss. However, while TJs were lost in the Cldn11 knockout, strands were still 
visible in the Cldn14-/- animals, showing that the effects of its loss were functional and 
not structural. Finally, the Cldn19-/- mouse exhibited behavioural defects due to 
impaired nervous impulse conduction, which showed that TJs are vital to Schwann cell 
insulation of nerve fibres (Miyamoto et al. 2005). 
 
Considering that claudins are a large protein family, expressed in a range of cell types 
with apparently pleiotropic actions as further discussed below, it has now become clear 
that their function is not limited to the traditional barrier/fence role of TJs. The 
diversity of claudins compared to other junctional proteins suggests that they are likely 
responsible for the striking range of EC barrier types in different tissues, and other 
claudin functions may exist that are yet to be defined. 
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Figure 1.12 Claudin protein structure, function and posttranslational modifications 
Representation of a claudin protein family member in the cell plasma membrane. The four 
transmembrane domains (TM1-4) are shown together with intracellular and extracellular loops (EL1 and 
2 and intracellular Loop), plus the intracellular amino (NH2) and carboxy (COOH) termini. The 
Hepatitis C Virus (HCV) binding region in claudins 1, 6 and 9 and the Clostridium perfringens 
enterotoxin (CPE) binding site in claudins 3 and 4 are indicated. CPE binding causes cytolysis and this 
characteristic has been considered for therapeutic exploitation (Morin 2005, Saeki et al. 2010, Sawada et 
al. 2003). EL1 is required for paracellular ion selectivity and EL2 for Cldn oligomerisation at junction 
sites. PAL * = palmitoylation, required for Cldn14 localisation at TJs (Van Itallie et al. 2005). (Adapted 
from Lal-Nag and Morin 2009 and Morin 2005). 
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1.8.4.1 Claudins in human disease 
Several claudins have been implicated in diseases affecting humans. These include 
mutations in the claudin genes themselves, changes in expression, and interaction of 
normally functioning proteins with pathogens. 
 
Mutations in Cldn19 have been found to cause ocular diseases including myopia (Lal-
Nag and Morin 2009). Cldn16 mutation can result in a rare autosomal recessive 
calcium/magnesium wasting disorder, FHHNC, with Cldn19 mutations also causing 
similar symptoms in some cases (Hampson et al. 2008, Lal-Nag and Morin 2009). 
Cldn14 is essential for correct functioning of the organ of Corti in the inner ear and 
mutation at the DFNB29 locus causes autosomal recessive non-syndromic hearing loss 
(Wilcox et al. 2001). A Cldn1 mutation has also been found to cause atopic dermatitis 
and an extremely rare ichthyosis syndrome, NISCH, with fewer than ten patients 
recorded to date (De Benedetto et al. 2011, Feldmeyer et al. 2006). In terms of changes 
to expression levels, elevated expression of Cldn1 and -5 was noted in the peripheral 
blood leukocytes of multiple sclerosis (MS) patients, as well as overexpression of 
Cldn1 in Type 1 diabetes samples (Mandel et al. 2011). Also, in the inflammatory 
bowel condition Crohn’s disease, Cldn5 and -8 were downregulated whereas Cldn2 
expression was greatly increased (Zeissig et al. 2007). 
 
Claudin extracellular loops are known to participate in pathogenic bacterial behaviour, 
including binding of the Clostridium perfringens enterotoxin (CPE) to Cldn3 and 
Cldn4 first extracellular loops (EL1), as noted in Figure 1.12 (Lal-Nag and Morin 
2009, Sawada et al. 2003). Some viruses also interact with claudin proteins, including 
hepatitis C (HCV), which binds Cldn1, -6 and -9 EL1 (Lal-Nag and Morin 2009) and 
HIV, which has been shown to bind to Cldn7 (Zheng et al. 2005). 
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1.8.4.1.1 Claudins and cancer 
The breakdown of cell-cell junctions is an integral step in tumorigenesis, as cells 
depolarise and dedifferentiate, disrupting the organised tissue format to give way to the 
proliferative, migratory tumour phenotype. Approximately 85% of cancers are 
epithelial in origin so many expression studies have used carcinomas specifically 
(Saeki et al. 2010). Both over- and under-expression of claudins has been noted in 
cancer samples, indicating that different proteins in the family may play very different 
roles. Some claudin protein expression findings are summarised in Table 1.2. Of 
particular note is that “claudin-low” is a rare breast cancer subtype that was classified 
in 2007, with a poor prognosis compared to other subtypes (Prat et al. 2010). The 
subtype is characterised by low expression of claudins 3, 4 and 7, as well as occludin, 
E-cadherin and cingulin, and overexpression of certain immune response genes, which 
may indicate elevated immune cell involvement (Eroles et al. 2012). 
 
Claudin expression appears to correlate with tumour invasiveness in some cases, for 
example: Cldn4 overexpression is associated with more invasive pancreatic neoplasms 
(Tsutsumi et al. 2011), but Cldn11 silencing and Cldn6, 7 or 9 overexpression is 
correlated with the invasive function of gastric cancer cell lines (Agarwal et al. 2009, 
Zavala-Zendejas et al. 2011). Cldns 1 and 4 were also found to be upregulated in 
metastasis (Singh et al. 2010). Cldn3 and Cldn4 expression in ovarian cells appears to 
confer increased invasive, motile and survival properties (Agarwal et al. 2005). As 
well as differences in expression, abnormal claudin subcellular localisation has been 
noted, for example the nuclear localisation of Cldn1 in colon carcinoma and associated 
metastases (Singh et al. 2010, Zavala-Zendejas et al. 2011). However, claudin 
expression does not always have prognostic significance, for example, in non-small 
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cell lung cancer, no correlation between patient survival and changes in expression of 
Cldn1, 3, 4 or 5 was found (Jung et al. 2009). 
Cancer Claudin gene Expression 
CLDN1, CLDN7 Down 
CLDN1, CLDN3, CLDN4 Variable Breast 
CLDN3, CLDN4 Up 
Breast and Paget's disease CLDN2, CLDN3, CLDN4, CLDN5 Variable 
Colon CLDN1 Variable 
Gastric CLDN4, CLDN11 Down 
Gastric adenocarcinoma  
(cell line) CLDN6, CLDN7, CLDN9 Up 
Hepatocellular carcinoma CLDN10 Up 
Hepatocellular carcinoma  
(mouse model) CLDN7 Up 
Head and neck squamous cell 
carcinoma CLDN7 Down 
CLDN1 Up 
CLDN7, CLDN4, CLDN3 Down Squamous cell carcinoma 
CLDN5 Negative 
CLDN1, CLDN7, CLDN4, CLDN3 Down 
Lung adenocarcinoma 
CLDN5 Positive 
Ovarian CLDN3, CLDN4, CLDN16 Up 
Pancreatic CLDN4 Up 
Pancreatic (intraductal papillary 
mucinous neoplasms) CLDN4 Up 
CLDN5 (membrane) 
CLDN2 (cytoplasmic) Up 
CLDN3, CLDN4 Negative Pancreatic SPT 
CLDN1, CLDN7 (cytoplasmic) Variable 
CLDN7 (membrane) Up 
CLDN5 Negative PET, Pancreatic ACC, PB 
CLDN1-4 Variable 
Prostate CLDN3, CLDN4 Up 
Thyroid papillary cancer CLDN10 Up 
Glioblastoma multiforme CLDN1 Down 
 
Table 1.2 Claudin protein expression in different cancer types. 
Expression of claudin proteins in different cancer types compared to normal tissues. SPT = solid 
pseudo-papillary tumour, PET = pancreatic endocrine tumour, ACC = acinar cell carcinoma, PB = 
pancreatoblastoma. (Table adapted from Comper et al. 2009, Hewitt et al. 2006, Liebner et al. 2000, 
Morin 2005, and Paschoud et al. 2007, with additional data from Zavala-Zendejas et al. 2011). 
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1.8.4.1.2 Claudins and therapy 
Our understanding of the claudin protein family is still relatively limited but what has 
been uncovered so far presents claudins as potentially useful in human medicine; in 
diagnosis, prognosis and treatment. The possibility of targeting claudins 
therapeutically has been explored recently. The localisation of claudin proteins at the 
cell surface, as well as their known small-molecule binding capabilities presents them 
as a potential drug target. For example, the Clostridium perfringens enterotoxin (CPE) 
C-terminal fragment (C-CPE) has been used as a carrier molecule, both for vaccination 
and cytotoxic therapy. The CPE protein binds Cldn3 and Cldn4 and thus delivers the 
attached drug molecule into the cell (Lo et al. 2012, Morin 2005, Saeki et al. 2010, 
Suzuki et al. 2012). The claudin extracellular loops (Figure 1.12) also present the 
opportunity to develop blocking antibodies.  
 
In particular, the tissue-specific expression patterns of claudins mean that drugs could 
possibly be targeted efficiently to desired organs and tissues with minimal off-target 
effects. Also, targeting specificity may be further aided by the fact that claudin 
extracellular domains in normal tissues are less exposed due to their participation in 
mature TJs, compared to cells with a more migratory phenotype and disrupted 
junctions (such as tumour blood vessel ECs) where claudin extracellular loops may be 
unobscured and therefore more effectively bound by targeting molecules (Saeki et al. 
2010). This same location-specific expression quality may allow claudins to be used as 
diagnostic or prognostic molecular biomarkers in some situations, due to the altered 
claudin expression in some cancers as illustrated by Table 1.2. Tumour-specific drug 
targeting may be feasible following in-depth clinical studies to thoroughly characterise 
claudin expression changes in different tumours and use of these data to inform 
therapeutic decisions. 
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1.8.4.2 Endothelial claudins 
Cldn5 is typically thought to be the major endothelial claudin protein, but its 
expression has now also been noted in rat pancreatic acinar cells, stomach and gut 
epithelia, and in human immune cells (Mandel et al. 2011, Morita et al. 1999, Rahner 
et al. 2001). Cldn5 is known to be vital in maintaining the integrity of the endothelial 
BBB, since knockout mice display size-selective loosening of the barrier (Nitta et al. 
2003). Cldn5 expression appears to be dependent on the adhesion of endothelial cells 
to the ECM via β1-integrin, and is controlled by adherens junctions via VECAD, 
FoxO1 and β-catenin transcriptional regulation (Gavard and Gutkind 2008, Osada et 
al. 2011, Taddei et al. 2008). Its expression also lowered in hypoxic conditions, along 
with Cldns 1 and 3 and occludin (Koto et al. 2007), and regulated by the ETS-family 
transcription factor ERG (Yuan et al. 2011). Internalisation of Cldn5, together with 
occludin, has also been reported in brain ECs during inflammatory stimulation of TJ 
remodelling (Stamatovic et al. 2009). Cldn5 overexpression also correlated with 
aggressive ovarian cancer (Turunen et al. 2009). 
 
Other claudins found in endothelial cell lines and human tissue samples have included 
Cldn1, -3, -10, -12, -15, -17, -19, -20, -22 and -23 (Brown et al. 2007, Glienke et al. 
2000, Gonzalez-Mariscal et al. 2008, Ohtsuki et al. 2008). Cldn11 was found to be 
enriched in human corpus cavernosum ECs (HCCEC) compared to arterial and 
umbilical vein cells (HCAEC and HUVEC respectively), and hypothesised to be 
important in the haemodynamic properties of penile blood vessels (Wessells et al. 
2009). Most expression studies have been performed in vitro and the tissue-specificity 
of claudins in vivo is not well characterised at present. It is therefore likely that more 
information will emerge in the coming years as detection techniques are improved. 
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1.8.4.3 Claudin14 
In my studies I have focussed on one particular claudin, namely Cldn14. Cldn14 
protein is 239 amino acids in length in both mouse and human, with 93.3% identity 
between the two species, and it is expressed in both epithelial and endothelial cell 
layers. Cldn14 was also found to participate in an unusual TJ/AJ hybrid junctional 
structure in inner ear cells (Nunes et al. 2006). Most recently it has been suggested as a 
regulator of calcium ion transport in the kidney (Gong et al. 2012). Mutations in the 
CLDN14 gene have primarily been identified as a key cause of human autosomal 
recessive deafness, and the hair cells layers in the murine ear were found to degenerate 
in a knockout model, as described in 1.8.4.1 (Belguith et al. 2009, Ben-Yosef et al. 
2003). 
 
Cldn14 was found to be upregulated in microvascular endothelial cell (MVEC) tubules 
in vitro, but not in proliferating sub-confluent monolayers of these cells (Glienke et al. 
2000). Overexpression of Cldn14 was found to elicit a change in nuclear shape and cell 
morphology in kidney epithelial cells, while Cldn17 overexpression was not seen to 
have an effect (Hu et al. 2006). Palmitoylation of Cldn14 was found to be required for 
its localisation at tight junctions in MDCK cells, with mutants localising less 
efficiently, which correlated with decreased TJ barrier function (Van Itallie et al. 
2005). 
 
Relatively little so far has been discovered regarding the functions of Cldn14 in 
different tissues but together these studies suggest a possible role for this molecule in 
angiogenic processes, given that it has been identified in endothelial cell types in 
different morphological states (Glienke et al. 2000). However, its precise functions in 
vivo, including any role in tumour blood vessels, have not been described. 
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1.9 Studying angiogenic regulators 
In order to study the molecular basis of angiogenesis in detail, a process about which 
much still remains to be understood, model systems are required. Mouse models 
provide a whole organism system in which tumour biology can be studied. The use of 
murine models (while expensive and, by necessity, highly regulated) allows us to 
observe the effects of particular targeted genetic changes on cancer development and 
pathological angiogenesis in part due to the relative ease of genetic manipulation in 
mice and their closer genetic relationship to human beings than zebrafish or fruit flies, 
for example. In this study we began by using a mouse model of a human genetic 
condition, Down’s Syndrome, to further our knowledge of molecular regulators of 
angiogenesis in cancer. 
 
1.9.1 Down’s Syndrome and cancer 
One of the few viable human aneuploidies (abnormal chromosome number) is trisomy 
21; having 3 copies instead of 2 of human chromosome (Hsa) 21, which occurs at the 
frequency of approximately 1/750 live births. With more than 80 clinically recognised 
phenotypes, some of which are common to all cases while some are not, the condition 
is collectively referred to as Down’s Syndrome (DS) (Reeves 2006). Features include: 
mental retardation from a mild to moderate degree; abnormal craniofacial bone 
structure; diminished stature; significant hearing loss in 90 % of cases (OMIM); 
development of Alzheimer’s (senile plaques and neurofibrillary tangles) by the fourth 
decade; heart defects in ~ 40% of patients (O'Doherty et al. 2005, Reeves 2006); 
weakened immune system and increased risk of developing Leukaemia (Miller 2005, 
O'Doherty et al. 2005, Reeves 2006). However, this risk lowers with age and the 
chance of developing a second malignancy is significantly reduced (Hasle et al. 2000). 
It has also been confirmed, using both epidemiological data from humans and studies 
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of DS mouse models, that solid tumour incidence is decreased in DS individuals 
(Hasle 2001, Satgé and Bénard 2008, Satgé and Vekemans 2011, Threadgill 2008, 
Zorick et al. 2001). DS children and adults are at lower risk of developing solid 
tumours, with some exceptions (such as retinoblastoma) as shown in Figure 1.13 
(Hasle 2001, Sund et al. 2005). A woman living to age 90 has a one in eight chance of 
developing breast cancer and around 54,000 women die from the disease each year in 
the UK and USA alone. It is, however, the rarest of solid tumours in DS individuals 
with mortality due to only lung and colon cancers higher in the general population. 
 
It appears that trisomy 21 somehow protects against the growth of some solid tumours 
and there are several theories as to why this may be. Environmental factors have been 
acknowledged, such as the lower prevalence of smoking in the DS population, 
healthier eating habits and decreased sexual activity. Accurate measures of the 
decrease in incidence for different tumour types have been difficult to obtain, given the 
low frequency of malignancy in DS. Different studies have reported that digestive tract 
tumours, for example, are less common, while others have reported close to the 
expected incidence in the DS population (Satgé et al. 1998, Satgé et al. 2006, Scholl et 
al. 1982). For those malignancies that can confidently be said to be underrepresented 
in the DS population, it is reasonable to speculate that pathological angiogenesis may 
also be impaired in the context of DS since most tumours, when they do arise, only 
grow to a small size (Sussan et al. 2008).  It is possible that the extra genes present in 
trisomic stromal cells cause a net anti-angiogenic effect, restricting tumour growth as a 
result. Our aim is to discover which Hsa21 genes are responsible for this potential anti-
angiogenic effect. 
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Figure 1.13 Cancer incidence in human DS and non-DS populations.  
Data from age- and sex-matched individuals for 5 cancer types whose prevalence has been assessed in 
DS and non-DS populations. It is important to note that the small sample sizes from the DS population 
has been an ongoing difficulty in assessing the real decrease in tumour incidence accurately. Other 
epidemiological studies have reported a decrease in digestive malignancies (Satgé et al. 2006). Data 
from Hasle 2001. 
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1.9.2 DS Mouse Models 
The genes of Hsa21 have orthologs found mainly on mouse chromosome (Mmu) 16 
but also on Mmu10 and 17 (Miller 2005, O'Doherty et al. 2005, Reeves 2006). To 
study the effects of trisomy 21, several mouse models have been created (Figure 1.15). 
Mmu16 trisomy is lethal and equivalent to partial trisomy of Hsa3, 16, 21 and 22 and 
so was never a viable model (O'Doherty et al. 2005). 
 
Ts65Dn mice with partial trisomy of Mmu16 (equivalent to triplication of 
approximately 50% of Hsa21 genes) and effects on CNS function and facial 
development were created in 1990 at The Jackson Laboratories (Miller 2005, 
Threadgill 2008). Saran et al. (2003) carried out microarray analysis of Ts65Dn 
cerebellar gene expression. They concluded that the genetic background of the mice 
had significant effects on the trisomic expression profile (Saran et al. 2003). 
 
Sago et al. (1998) created the Ts1Cje model with partial trisomy of Mmu16 
corresponding to Hsa21q22.1-22.3 (Sago et al. 1998). Shinohara et al. (2001) 
attempted to create mice containing Hsa21 with limited success, but the chimaeric 
mice with varying levels of mosaicism did recapitulate some DS phenotypes 
(Shinohara et al. 2001). Olson et al. (2004) created mouse lines trisomic and 
monosomic for 33 Hsa21 orthologs, named Ts1Rhr and Ms1Rhr respectively (Sussan 
et al. 2008, Threadgill 2008). 
 
Sussan et al. (2008) investigated the influence of DS on solid tumour growth by 
crossing Ts65Dn, Ts1Rhr and Ms1Rhr mice with the APCMin mouse model of 
colorectal cancer and comparing actual and expected tumour incidence. The Ts65Dn 
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and Ts1RhR progeny developed fewer tumours than the expected frequency while 
Ms1Rhr progeny developed more, confirming the influence of gene dosage.  
 
A recent study by Baek et al. also used the Ts65Dn model and a Dscr1 transgenic 
mouse to examine the role of Dscr1 in pathological angiogenesis. They concluded that 
an extra copy of Dscr1 is sufficient to inhibit angiogenesis and tumour growth in DS 
and that DSCR1 and DYRK1A, via the calcineurin-NFAT pathway, mediate this effect 
(Baek et al. 2009). However, on crossing Ts65Dn with Dscr1-/+ mice, tumour blood 
vessel density increased only very slightly and tumour growth was about 50% of 
euploid control size, showing that other factors are clearly at play. 
 
O’Doherty et al. (2005) attempted the generation of trans-chromosomic mice again 
and generated a trans-species aneuploid mouse line with stable transmission of a 
freely-segregating Hsa21 fragment containing most of the coding regions, which they 
named Tc1 (O'Doherty et al. 2005). 
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1.9.2.1 The Tc1 Mouse 
The Tc1 mouse was the most accurate representation of human DS at the time of 
writing and took 12 years to develop (Reeves 2006). It carries a large fragment (~92 
%) of Hsa21 resulting in effective partial trisomy of Mmu16, 17 and 10 (Miller 2005, 
Reeves 2006). Included on the fragment are 242/298 Hsa21 coding genes (56 missing, 
see Table 1.3) and 24/29 non-coding RNAs (five missing), six being miRNAs 
(personal communication from T. Broughton and V Tybulewicz). The mice were 
generated by taking human chromosomes from fibroblasts, injecting them into mouse 
embryonic stem cells (ESCs) and introducing the ESCs into early mouse embryos, 
which were then implanted in surrogate mothers (Miller 2005, O'Doherty et al. 2005). 
 
Tc1 mice show many phenotypic similarities with human DS; learning disabilities in 
terms of decreased spatial learning and memory (defective long-term potentiation, a 
form of synaptic plasticity also altered in the Ts65Dn mouse); lower cerebellar granule 
cell density (where total reduction in brain volume is seen in human DS); a tendency 
towards hyperactivity; heart defects in approximately 64 % of mice; smaller mandibles 
in most cases and defective T lymphocyte activation (also seen in DS) (Miller 2005, 
O'Doherty et al. 2005, Reeves 2006). With over 80% of Hsa21 genes and their 
accompanying regulatory elements represented in the Tc1 mice, it is a comprehensive 
model of human Down’s Syndrome, as evidenced by these shared phenotypes (Figure 
1.14). 
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Figure 1.14 Human chromosome 21, mouse orthologs and the Tc1 mouse Hsa21 fragment.   
A: Human chromosome 21 (Hsa21), Hsa21 genes present on the Tc1 fragment in the Tc1 mouse and 
orthologous Mus musculus (Mmu) chromosomes relative to Hsa21. The fragment lacks Hsa21 p arm 
genes. Three deletions were identified, including the genes Dscr1 and ColXVIIIa (Table 1.3). Genes of 
interest are labelled and dotted lines indicate orthologs on murine chromosomes. Yellow asterisks show 
Hsa21 microRNAs (Hsa-mir-99a, Hsa-mir-let7c, Hsa-mir-125b2, Hsa-mir-155, Hsa-mir-802). Previous 
partial Mmu16 trisomy DS mouse models Ts65Dn, Ts1Cje and Ts1Rhr are shown with approximate 
gene numbers. B: Schematics of normal and Down Syndrome (DS): a normal human cell with two 
copies of Hsa21; a DS cell with three copies of Hsa21; a normal mouse cell with two copies of Mmu10, 
17 and 16; and a Tc1 mouse cell, containing the normal complement of mouse chromosomes plus the 
Tc1 Hsa21 fragment, effectively making it trisomic for the three mouse chromosomes orthologous to 
Hsa21 i.e. a model of DS. Other autosomes and allosomes are omitted for clarity. 
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Deletion Region (Mb) Genes within region 
Del1 17.65-18.68 C21orf37, CXADR, BTG3, C21orf91, C21orf39, CHODL, PRSS7 
Del2 32.56-35.29 
C21orf45, MRAP, URB1, C21orf63, C21orf77, TCP10L, 
C21orf59, SYNJ1, C21orf66, C21orf49, C21orf62, OLIG2, OLIG1, 
IFNAR2, IL10RB, IFNAR1, IFNGR2, TMEM50B, C21orf55, 
GART, SON, DONSON, CRYZL1, ITSN1, ATP50, AP000569.1, 
MRPS6, SLC5A3, KCNE2, C21orf51, KCNE1, RCAN1 (DSCR1), 
CLIC6, RUNX1 
Del3 45.69-46.15 COLXVIIIA1, SLC19A1, AL592528.1, PCBP3 
 
Table 1.3 Genes within deleted regions of the Hsa21 sequence in Tc1 mice.  
Data from F. Wiseman (personal communication). 
 
As well as deletions, there are some duplicated regions of the Tc1 Hsa21 fragment that 
are also being characterised. The data available at the time of writing are shown in 
Table 1.4. 
 
Duplication Region (Mb) Genes that may be affected 
Dup1 14.48-16.69 LIPI, RBM11, ABCC13, STCH, SAMSN1, NRIP1, C21orf116, USP25, C21orf34 
Dup2 19.81-21.54 NCAM2, C21orf74 
Dup3 22.11-22.22 None 
Dup4 23.38-23.65 None 
Dup5 24.96-25.30 None 
Dup6 N/A* DIP2A, S100B, PRMT2 
 
Table 1.4 Genes located in possible duplicated regions of the Tc1 Hsa21 fragment.  
*Dup6 was not seen on arrays but during the whole chromosome sequencing project the observed read 
frequency for the genes indicated was increased, compared to the rest of Hsa21, indicating that they may 
be duplicated. Data from F. Wiseman (personal communication). 
 
It is likely that the missing ~8 % of genes (an approximation since putative Hsa21 
genes are still being confirmed as true coding sequences, or otherwise, and at the time 
of writing the exact genes present on the fragment are also being confirmed) contain 
some important factors relevant to DS and its effect on malignancy specifically. 
However, the use of the near-complete human chromosome means that regulatory 
DNA elements including non-coding RNAs are present, unlike small fragment or 
single-gene models (O'Doherty et al. 2005). 
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A study by Wilson et al. has shown that expression of genes from the human 
chromosome within mouse cells is determined by the DNA sequence, not the host cell 
environment; that is, mouse-encoded transcription machinery (TFs, RNA polymerase, 
epigenetic modifiers) binds in the same fashion as human transcription machinery 
binds to the sequences in human cells. Thus, it appears that DNA has species-specific 
directions for how it is to be transcribed (known as cis-direction rather than trans-
direction). They found that the expression profile from Hsa21 in Tc1 hepatocytes 
matches the profile of Hsa21 expression in human liver tissue, not that of the 
orthologous mouse chromosomes in murine liver tissue (Wilson et al. 2008). In 
addition, Kahlem et al. confirmed that increased gene dosage in the Ts65Dn model led 
to approximately 50% stable upregulation of transcripts in almost all cases, with only a 
small number of gene transcript levels unaffected by the extra copy, this subset 
seeming to be under tissue-specific or other modes of control (Kahlem et al. 2004). 
 
Up to 50 % of cells lose the human chromosome fragment during development 
resulting in variable mosaicism, which is also seen in humans with DS. Analysis of the 
model by O’Doherty et al. showed roughly 65 % of brain nuclei and 50 % of spleen 
nuclei were positive for the Hsa21 fragment (Miller 2005, O'Doherty et al. 2005). The 
mosaicism varies between tissues and individual mice, which may complicate 
interpretation of results. Nevertheless the Tc1 mouse provides proof-of-principle that 
mouse models of whole Hsa aneuploidies can be created and it is a valuable tool for 
characterising the effects of trisomy 21. 
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1.10 SUMMARY 
Pathological angiogenesis is an integral part of solid tumour growth and progression, 
in which the normal regulators of angiogenesis are disrupted and the delicate balance 
maintaining endothelial cell quiescence is shifted in favour of new vessel growth. 
 
Endothelial cell signalling, response to the environment and cell-cell adhesion are key 
processes in angiogenesis; in order to study these on a cellular and molecular level, we 
require in vivo models and in this thesis we have started with a model of Down’s 
Syndrome, the Tc1 mouse. This model allows us to observe the effects of increased 
gene dosage of human chromosome 21 genes, not in tumour cells but in the stroma, on 
tumour growth and endothelial cell function in tumour angiogenesis. 
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1.11 HYPOTHESIS 
Since individuals with Down’s Syndrome have a decreased incidence of solid tumours, 
impaired angiogenesis may be responsible. If so, the extra copy of Hsa21 is likely to 
contain anti-angiogenic genes, some of which may not have been linked previously to 
this process. 
 
1.12 RESEARCH AIMS 
The aims of this project are: 
1. Investigate whether the presence of additional human chromosome (Hsa21) genes in 
a mouse model of Down’s Syndrome (the Tc1 mouse) affects tumour angiogenesis and 
tumour growth. 
 
2. Identify gene dosage effects of candidate endothelial cell-specific and angiogenesis-
modulating genes on the angiogenic response ex vivo.  
 
3. Elucidate gene dosage effects of the non-endothelial cell-specific Hsa21 gene 
Claudin-14 on tumour growth and angiogenesis in vivo. 
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Antibodies and reagents 
IgG from the same species as the primary antibody host was used as a negative control 
for each antibody tested to ensure specificity and assess background staining. Primary 
antibodies used in the study are listed below in Table 2.1. 
Primary antibody 
specificity 
Raised 
in 
Reactive 
species Company Cat. No. 
CD102 Rat Mouse BD Pharmingen 557444 
FcγRIII/II Rat Mouse BD Pharmingen 558636 
Endomucin Rat Mouse Santa Cruz V.7C7 sc-65495 
PE-PECAM Rat Mouse BioLegend 102408 
FITC-BS1 lectin  
(Isolectin B4) 
- - Sigma-Aldrich L2895 
Cy5-αSMA Mouse Mouse Sigma-Aldrich C6198 
TRITC-BS1 lectin 
(Isolectin B4) 
- Mouse Sigma-Aldrich L5264 
pp42/44 MAPK  
(Erk 1/2, Thr 202 / Tyr 204) Rabbit Mouse Cell Signalling 9101 
p42/44 MAPK  
(Erk 1/2) Rabbit Mouse Cell Signalling 9102 
Cy3-Pimonidazole Rabbit - HPI, Inc. HP2-1000 
Ki67 Rabbit Hu, Ms, Rat AbCam Ab15580 
Claudin-5 Mouse Mouse Invitrogen 35-2500 
VE-Cadherin Rat Mouse BD Pharmingen 550548 
ZO-1 (mid) Rabbit Hu, Ms, Rat Invitrogen 40-2200 
PE-Flk1 Rat Mouse BD Pharmingen 555308 
PE-Rat IgG2b κ Isotype Rat - BD Pharmingen 553989 
Claudin14 Rabbit Mouse Sigma-Aldrich 36-4200 
Hsc70 Mouse Mouse Santa Cruz sc-7298 
Table 2.1 Primary antibodies.  
All primary antibodies used in the experiments presented, their host species (except for lectins), reactive 
species (except for lectins and IgGs), company the antibodies were purchased from and the catalogue 
number. Company locations: BD Pharmingen, Oxford, UK. Santa Cruz Biotechnology Inc., Heidelberg, 
Germany. BioLegend, London, UK Sigma-Aldrich Company Ltd., Dorset, UK. Cell Signalling 
Technology Inc., New England Biolabs (UK) Ltd., Hitchin, UK. HPI, Inc., Burlington, MA, USA. 
AbCam, Cambridge, UK. Invitrogen Life Technologies, Ltd., Paisley, UK.  
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Fluorochrome-conjugated secondary antibodies were used to visualise proteins by 
immunofluorescence in cultured cells, ex vivo explant cultures and tissue sections 
(Table 2.2). Horseradish peroxidase-conjugated secondary antibodies were used to 
visualise protein bands by Western blot analysis (Table 2.3). 
 
Invitrogen Alexa 
Fluor® IgG-bound 
fluorochromes 
488 
(green) 
546 
(red) 
555 
(red) 
594 
(red) 
Goat Goat Donkey - 
Anti-Rabbit 
A-11034 A-11035 A-31572 - 
Donkey Goat - Donkey 
Anti-Rat 
A21208 A-11081 - A-21209 
Goat Goat Donkey - 
Anti-Mouse 
A-11001 A-21123 A-31570 - 
 
Table 2.2 Alexa Fluor® IgG-bound fluorochromes used for immunofluorescence staining.  
The light emission colour and excitation frequency are shown, with host species and catalogue number 
on first and second horizontal rows respectively for each IgG type. All fluorochrome-conjugated 
antibodies were purchased from Invitrogen, UK. 
 
 
Horseradish Peroxidase-
conjugated IgG for 
Western Blot 
Raised in Reactive species Company 
Cat. 
No. 
Rabbit Mouse P0161 
Swine Rabbit P0217 IgG-HRP 
Rabbit Rat 
DAKO 
P0450 
 
Table 2.3 Horseradish peroxidase-conjugated IgG antibodies used for Western Blotting.  
All horseradish peroxidase-conjugated IgGs were purchased from DAKO, Aachen, Germany. 
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2.2 Mice 
The Tc1 mice were created by V. Tybulewicz and L. Fisher (National Institute for 
Medical Research, London and University College London respectively) (O'Doherty et 
al. 2005). Mice, initially for experiments only and later for separate colony generation, 
were provided by the National Institute for Medical Research, and maintained by 
crossing female F1 progeny with C57bl6/129 mixed background males. 
 
Claudin14 knockout (null) mouse pairs were kindly donated by T. Ben-Yosef 
(Technion, Israel) (Ben-Yosef et al. 2003). Cldn14 null mice crossed with wild-type 
pure C57 animals purchased from Charles River Laboratories International, Inc. to 
create Cldn14-heterozygous progeny. Cldn14-het animals were crossed together to 
produce all three genotypes and finally colonies of wild-type, Cldn14-het and Cldn14-
null animals were generated. 
 
 
2.2.1 Genotyping mice by PCR analysis 
DNA samples extracted from ear/tail snips were individually analysed by PCR in order 
to confirm the genotypes of experimental animals. 
 
2.2.1.1 Tc1 
Tc1 mouse ear/tail snips were first digested in 500 µl Tail buffer (0.1 M Tris-HCl pH 
8.5, 0.2% SDS, 5 mM EDTA, 0.2 M NaCl) supplemented with Proteinase K (0.1 
mg/ml, Roche, Lewes, UK) at 55 °C overnight. 400 µl of isopropanol was added to 
precipitate DNA. Samples were centrifuged at full speed (10,000 g) for 10 minutes, the 
supernatant aspirated and DNA pellets washed with 500 µl 70% ethanol. Samples were 
spun at 10,000 g for 6 minutes then the supernatant was aspirated and pellets air-dried 
at room temperature overnight or for 1-2 hours at 72 °C. DNA was resuspended in 50-
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100 µl TE buffer and stored at 4 °C. The Tybulewicz group designed two sets of 
primers: D21F and D21R for a 202 bp Tc1 band (amplifying Hsa21 base pairs 
39,084,433 - 39,084,640), as well as MyoD1 and MyoD2 primers for a 245bp Mmu 
control band that detects the presence of the human chromosome fragment. The primer 
sequences for Tc1 genotyping are as follows: 
D21S55F: 5’- GGT TTG AGG GAA CAC AAA GCT TAA CTC CCA -3’ 
D21S55R: 5’- ACA GAG CTA CAG CCT CTG ACA CTA TGA ACT -3’ 
MyoF: 5’- TTA CGT CCA TCG TGG ACA GCA T  -3’ 
 MyoR: 5’- TGG GCT GGG TGT TAG TCT TAT  -3’ 
 The PCR reaction mix was prepared as follows for each DNA sample, with the 
amplification performed in a PCR cycler (Applied Biosystems, Life Technologies Ltd., 
Paisley, UK) as shown: 
 
Table 2.4 Tc1 genotyping and PCR programme.  
PCR ingredients are shown in the left column with reaction conditions on the right. *Reagents (dNTPs, 
MgCl2, Taq buffer and Ex-Taq DNA polymerase enzyme) were purchased from Invitrogen, UK. 
25 µl Reaction           (µl) PCR Programme 
 
*dNTPs (5mM)  0.4 
MgCl2 (25mM)  2.5 
10x Taq buffer  2.5 
Ex-Taq polymerase 3 
H2O   16.8 
D21S55F primer  0.5 
D21S55R primer  0.5 
MyoF primer  0.25 
MyoR primer  0.25  
DNA or H2O   1 
Denaturing: 
94 ºC       5 minutes 
------- 
Annealing and elongation: 
94 ºC       45s 
65 ºC       45s 35 cycles 
72 ºC       60s  
------- 
Elongation: 
72 ºC       7 minutes 
24 ºC 5 minutes 
10 ºC          cooling before storage 
4 ºC             ∞ (storage) 
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PCR products were evaluated by agarose gel electrophoresis. 1.8% agarose gels were 
prepared by dissolving 1.8% w/v agarose powder (Gibco, Invitrogen, Paisley, UK) in 
TBE buffer (89 mM Tris Base, 89 mM boric acid, 2mM EDTA, pH 8.3). The solution 
was heated in a microwave for 4 minutes, swirling the flask to mix at 1-minute 
intervals, then allowed to cool to 50 °C before 4 µl 10 mg/ml ethidium bromide 
(Sigma) was added. The gel was then poured into a gel tank (Scotlab-Anachem, Luton, 
UK) and lane combs inserted to create wells for loading the PCR products. Once 
cooled, the combs were removed carefully and the tank filled with TBE buffer. 20 µl 
PCR product was loaded into each individual well of the gel and 10 µl Hyperladder I 
DNA ladder (BioLine Reagents Ltd., London, UK) was run alongside to determine the 
correct band size for the PCR products. Gels were run at 100 V to separate the samples 
and stopped when the loading dye reached the end of the gel. PCR product and 
molecular weight marker bands were visualised under UV light using LabWorks 
software and UV Camera. 
 
2.2.1.2 Claudin14 
Cldn14 colony ear/tail snips were digested in 100 µl Tail buffer with Proteinase K at 
55 °C overnight and the DNA precipitated by adding 100 µl isopropanol. Samples 
were spun at full speed, the supernatant aspirated and the DNA pellets left to dry either 
at room temperature overnight or at 55 °C for 1-3 hours. DNA was then resuspended in 
100 µl TE buffer ready for analysis. Two separate PCR reactions were run for each 
sample, to identify wild-type Cldn14 (Reaction 1: 380 bp WT band, amplifying Mmu 
16 base pairs 93,919,129-93,919,506) and null Cldn14 (Reaction 2: 275 bp mutant 
band) alleles (Figure 3.9), using three primers as follows: 
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Cldn WT: 5’- GTA CAG GCT GAA TGA CTA CGT G -3’ 
Cldn Mutant: 5’- CAG CTC ATT CCT CCC ACT CAT GAT C -3’ 
 Common: 5’- GGC TGC ATA ACC AGG ATA CTC  -3’ 
The PCR reaction mixes were prepared as follows for each DNA sample, with the 
amplification performed in a PCR cycler (Applied Biosystems) as shown: 
 
25 µl Reaction 1: WT Cldn14         (µl) PCR Programme 
 
MegaMix~Blue™     22 
Cldn WT primer   1 
Common primer   1 
Template/H2O   1 
 
25 µl Reaction 2: Cldn14 null         (µl) 
 
MegaMix~Blue™   22 
Cldn Mutant primer   1 
Common primer    1 
Template/H2O   1 
 
Denaturing: 
94 ºC       5 minutes 
------- 
Annealing and elongation: 
94 ºC       45s 
65 ºC       45s 35 cycles 
72 ºC       60s  
------- 
Elongation: 
72 ºC       7 minutes 
10 ºC           cooling before storage 
4 ºC             ∞ (storage) 
 
Table 2.5 Cldn14 genotyping and PCR programme.  
PCR ingredients for wild-type Cldn14 and Cldn14 null alleles are shown in the left column with reaction 
conditions, which are the same for both reactions, on the right. MegaMix~Blue™ is supplied by Cambio 
Ltd., Cambridge, UK. 
 
PCR products were evaluated by agarose gel electrophoresis as described in 2.2.1.1. 
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2.3 Tissue culture media and solutions 
All centrifugation steps during tissue culture were performed using an Eppendorf 5810 
centrifuge and A-4-62 rotor (Eppendorf UK Limited, Stevenage, UK). 
 
2.3.1 Endothelial cell medium 
Primary mouse lung endothelial cells were fed using MLEC medium: a 1:1 mixture of 
HAMS F-12 (Gibco): 1 g/L glucose DMEM (Gibco), 20% v/v FBS (EU-approved 
heat-inactivated foetal bovine serum (PAA Laboratories, GE Healthcare, Yeovil, UK), 
100 mg L-1 heparin (Heparin sodium salt, from porcine intestinal mucosa, Sigma), 1% 
v/v glutamine (GlutaMAX™ 100x, Gibco), 1% v/v Penicillin/Streptomycin (Gibco), 1 
bottle Endothelial Growth Supplement (AbD Serotec, Oxford, UK) per litre of 
medium. Medium to be replaced every 3-4 days or when required was aspirated, cell 
layers washed with sterile PBS and new medium warmed to 37 °C added to the flask. 
 
2.3.2 Aortic ring medium 
Aortic ring explants embedded in a collagen matrix in 96-well plates (as in 2.6) were 
fed with 150 µl OPTI-MEM® (Gibco) + 2.5% FBS (PAA Laboratories) ± 30 ng/ml 
VEGF (produced in-house). In early experiments with the Tc1 mice, feeding medium 
was based on DMEM but later changed to OPTI-MEM® following further 
optimisation (as performed by S. D. Robinson; data not shown). 
  
2.3.3 Tumour cell growth medium 
Both B16F10 melanoma and Lewis Lung carcinoma (LLC) tumour cells were grown 
in DMEM + 4 g/L glucose (Gibco) supplemented with 10% v/v FBS (PAA 
Laboratories) and 1% v/v Penicillin/Streptomycin (Gibco). 
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2.4 Cell culture 
2.4.1 Tumour cells 
B16F10 melanoma and LLC tumour cells were grown in T175 tissue culture flasks 
(BD Falcon, Oxford, UK) and passaged when 90% confluent. For B16F10 cells, 
growth medium was aspirated and discarded. The cell layer was then washed with 
sterile PBS and cells detached by adding 5 ml trypsin and incubating at 37 °C until 
cells had fully detached from the tissue culture plastic surface. After cell detachment, 
10 ml tumour cell growth medium (2.3.3) was added to neutralise the trypsin and the 
suspended cells transferred to a 50 ml falcon tube (BD Falcon). Cells were spun down 
at 1,200 rpm for 3 minutes, the supernatant aspirated and cells resuspended in 20 ml 
growth medium. 1-5 ml (depending on the desired level of confluence after passaging) 
of resuspended cells was transferred to a fresh T175 flask containing 25 ml fresh pre-
warmed growth medium and flasks were returned to the incubator at 37 °C and 8% 
CO2. For LLC cells, which grow both in suspension and as an adherent layer, the 
growth medium was aspirated and transferred to a 50 ml falcon tube. The adherent 
layer was then washed carefully with sterile PBS then cells were trypsinised as 
described above and transferred to a separate 50 ml falcon tube. Both supernatant and 
trypsinised adherent cells were spun down at 1,200 rpm for 3 minutes and cell pellets 
each resuspended in 20 ml growth medium. 0.5-5 ml of each cell suspension was 
added to a new T175 flask containing 25 ml pre-warmed growth medium and flasks 
returned to the incubator. 
 
2.4.2 Primary endothelial cells 
2.4.2.1 Coating tissue culture flasks 
T75 tissue culture flasks were pre-coated with coating solution to prepare the surface 
for endothelial cells to adhere using the following solution: 10 ml 0.1% gelatin 
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(Porcine skin – 300 bloom, Sigma), 100 µl collagen (5005-B, 3 mg/ml, Advanced 
Biomatrix, Sandiego, CA, USA), 100 µl 1 mg/ml human plasma fibronectin 
(Calbiochem, Merck Millipore, Germany). Flasks were incubated at 37 °C and 8% 
CO2 with the coating medium for 2-3 hours, or at 4 °C overnight. Since the coating 
medium is not neutral pH, immediately prior to seeding endothelial cells the coating 
solution was aspirated off, with as much as possible removed so as not to significantly 
alter the pH of the growth medium. 
 
2.4.2.2 Isolation of primary endothelial cells from mouse lungs 
6- to 9-week old mice were killed by cervical dislocation and sprayed with 70% 
ethanol. Lungs were dissected out in a sterile environment using sterilised instruments 
and stored in OPTI-MEM® medium on ice prior to endothelial cell isolation. Lungs 
were then rinsed in ethanol followed by one wash in MLEC medium. 0.1% w/v Type I 
Collagenase (Gibco) for digestion of mouse lung tissue was prepared as follows: the 
collagenase was first made dissolved in DPBS + CaCl2 + MgCl2 (Gibco) at 2x the 
desired final concentration (0.2% w/v), incubated at 37 ºC for 1 hour to auto-digest and 
then diluted 1:2 with DPBS + CaCl2 + MgCl2 prior to use. Lungs were minced with 
scalpels and transferred to 15 ml tubes containing approximately 10 ml 0.1 % w/v 
Type I Collagenase for every 3 sets of lungs. The tubes were incubated at 37 ºC for 30 
minutes with occasional agitation until sufficiently digested (indicated by sinking of 
tissue).  
 
MLEC medium was added to inhibit collagenase activity and cell/tissue clumps were 
separated into a single-cell suspension by syringing up and down with a 21 gauge 
needle and syringe, which was followed by passage through a cell strainer of 70 µm 
pore size (BD Falcon). The strainer was then rinsed with 6 ml MLEC medium. Cells 
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were then spun down at 1,200 rpm for 3 minutes, the supernatant was removed and the 
cell pellet resuspended in 10 ml medium to create a cell suspension. Cells were plated 
(in pre-coated T75 flasks for every 3-4 sets of lungs) and incubated at 37 °C/8% CO2 
Approximately 5 hours later the flask was gently agitated to remove red blood cells 
layered on the bottom of the flask, and half the medium was removed and replaced 
with fresh MLEC. The following morning, the medium still containing a high 
proportion of erythrocytes was aspirated and the adhered cells washed with PBS 4-5 
times or until the wash remained clear, before adding fresh MLEC medium. 
 
2.4.2.3 Cell sorting 
To isolate endothelial cells from the heterogeneous population obtained by the initial 
extraction method, sorting was carried out using antibody-conjugated magnetic beads 
(Dynal, Invitrogen): typically, the day after the cell preparation, a negative sort was 
performed to remove macrophages. A positive sort for endothelial cells was then 
carried out 2-4 days later, depending on the number and size of endothelial colonies in 
each preparation. 
 
Cells were first incubated at 4 °C in MLEC for 20 minutes to prevent internalisation of 
surface proteins. The MLEC medium was removed, cells washed with PBS, and rat α-
mouse primary antibody (either to the macrophage marker FcγRII/III (BD 
Pharmingen) for negative sorts, or the endothelial marker CD102 (BD Pharmingen) for 
positive sorts) diluted in PBS was then added and the cells incubated at 4 °C for 30 
minutes. After washing once with PBS to remove unbound antibodies in solution, 
magnetic beads conjugated to sheep α-rat secondary antibody were added and cells 
incubated for a further 30 minutes at 4 °C with occasional agitation. Cells were washed 
3x with PBS before trypsinisation for 1 minute at 37 °C. Medium was added to 
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neutralise the trypsin and the suspension was transferred to a tube which was kept in a 
magnetic holder for ≥5 minutes to allow cells with beads attached to be held to the 
wall of the tube. Movement of the tube in the next step was avoided to prevent 
detachment of beads. 
 
Negative sort: beads attach to macrophages and adhere these cells to the tube. Medium 
was carefully removed and transferred to a pre-coated flask to allow EC adhesion. 
Negative sorts were typically performed 1-2 days after initial cell isolation. 
Positive sort: beads attach to endothelial cells and adhere to the tube so medium 
containing other cell types was aspirated and discarded. Tubes were carefully washed 
with fresh MLEC medium to resuspend ECs attached to beads and cells were then 
transferred to a pre-coated flask. Typically 2-3 positive sorts were performed on EC 
cultures before their use in experiments. EC preparations were shown to be 
approximately 95% pure for endothelial cells by FACS analysis (as described in da 
Silva et al. 2010). 
 
2.4.2.4 Passaging 
Primary endothelial cell colonies were monitored closely and only passaged when 
large enough cobblestone colony areas had grown, so as not to seed EC populations 
too sparsely. MLEC medium was aspirated and the cell layer washed with sterile PBS. 
Cells were detached by incubating T75 flasks with 500 µl trypsin at 37 °C for 1-5 
minutes. Flasks were washed with 10 ml medium and suspended cells transferred to 15 
ml falcon tubes (BD Falcon) then spun down at 1,200 rpm for 3 minutes. The 
supernatant was aspirated, cell pellets carefully resuspended in 12 ml medium and 
transferred to a new pre-coated flask (2.4.2.1). Flasks were returned to the incubator at 
37 °C and 8% CO2. EC preps were routinely used up to passage 5. 
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2.5 Dunn Chamber chemotaxis assay 
Dunn Chamber assays were performed in collaboration with M. Parsons (Randall Cell 
Division of Cell and Molecular Biophysics, Kings College London) (King et al. 2011, 
Zicha et al. 1997). Primary endothelial cells grown in culture as described in 2.4.2 
were seeded on 22mm x 25mm x 0.17 mm glass coverslips (Hawksley Scientific, 
Sussex, UK) cleaned with 70% ethanol and dried in a sterile environment and pre-
coated in 6-well plates. Cells were seeded at a density of 10,000, 20,000 and 30,000 
cells per well, and serum-starved in OptiMEM® overnight. Coverslips chosen for 
imaging had single endothelial cells adhered in sufficient numbers and in good health, 
but not so confluent as to be forming larger colonies. A range of densities are used to 
ensure sufficient coverslip numbers for analysis, since endothelial cells grow poorly in 
sparse cultures but must not be over-confluent for the assay, and primary cell growth 
rates can vary between preparations. 
 
Coverslips were then sealed to glass slides containing consecutive circular chambers 
(Hawksley Chemotaxis Dunn counting chamber, DC100) as follows: both slide 
chambers were first rinsed with serum-free OptiMEM® to coat the chambers’ 
hydrophobic surfaces and aid assembly of the chamber. Both chambers were then 
filled to overflowing with OptiMEM® supplemented with 25mM HEPES to buffer 
against changes to ambient CO2 levels. A coverslip as prepared above was taken and 
inverted over the slide leaving a small gap at the edge of the outer chamber only large 
enough to insert a 200 µl pipette tip. The coverslip was dried thoroughly with tissue 
whilst being held in place to remove as much liquid as possible. Three edges were 
sealed with wax (1:1:1 mixture of beeswax (Fluka, Sigma-Aldrich), paraffin wax 
(Sigma-Aldrich) and petroleum jelly (Vaseline™); melted together in a glass beaker 
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on a heat block at 70 °C) using a paintbrush to leave an accessible gap. The slide was 
then tilted and the outer chamber medium removed with tissue by capillary action. The 
outer chamber was rinsed slowly once with chemoattractant medium (OptiMEM® 
supplemented with 100 ng/ml VEGF), avoiding air bubbles, and drained again with 
tissue. The outer chamber was then refilled with chemoattractant medium to create a 
migration-stimulating growth factor gradient. Any excess medium was carefully dried 
from the slide. The final coverslip edge was then sealed with wax. 
 
Assembled slides were placed on a Zeiss Axiovert 100 inverted microscope within a 
perspex environmental chamber (Solent Scientific, Segensworth, UK) heated to 37 °C. 
Several fields were selected for overnight image capture at intervals of 10 minutes over 
16 hours. Images were acquired by phase contrast imaging using a 10x N-Achroplan 
Phase contrast objective (numerical aperture 0.25). Cell images were collected using a 
Sensicam (PCO Cook, Indianapolis, IN, US) charge coupled device (CCD) camera. 
Chamber assembly and imaging were performed by M. Parsons at KCL. 
 
Movie files were then imported into Andor IQ acquisition software (Andor 
Bioimaging, Belfast, Northern Ireland) to obtain individual cell track data from each 
movie. Resulting cel files were then analysed in Mathematica™ software (v6, 
Wolfram Research, Oxfordshire, UK) using the Dunn chamber Notebook (written by 
Prof. Graham Dunn, Kings College London). Instances of apparent cell division and 
cell death were also quantified visually from the movie files. 
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2.6 Aortic ring assay 
For more a more detailed analysis of aortic ring assay protocols, please see Baker et al. 
2012 (attached in Appendix 7.3). 
 
Briefly, in a sterile tissue culture hood, thoracic aortas were removed from 6- to 24-
week old mice following cervical dislocation and were transferred to OPTI-MEM® 
medium (Invitrogen). Extraneous fat, blood and other tissue were removed and aortae 
were then transferred to fresh medium. Aortae were sliced transversely into rings 
approximately 0.5 mm in width, visualised using a dissecting microscope. All rings 
from individual aortae were then placed in OPTI-MEM® in a 10 cm culture dish to be 
serum-starved overnight in an incubator at 37 ºC/8% CO2. 
 
Sterile water was added to sterile 10x DMEM (Gibco) and the mix chilled on ice for 
approximately 5 minutes. Collagen (type 1 rat tail, Millipore) was added to the chilled 
water/DMEM to a final concentration of 1.1-1.2 mg ml-1 and mixed, with the final 
concentration of the DMEM at 1x. The mix was kept on ice to prevent polymerisation. 
Each ring was then transferred to 50 µl of unpolymerised rat-tail collagen + 10x 
DMEM; one per well of a 96-well plate. Plates were incubated for one hour at 37 °C to 
allow polymerisation. 
 
Plates were then allowed to return to room temperature and 150 µl of growth medium 
(as in 2.3.2) or equivalent volume PBS for no treatment) was added per well and the 
plate returned to the incubator. The aortic rings were fed every 3-4 days by removing 
120 µl medium from each well and adding 150 µl fresh medium. Endothelial sprouts 
were counted at 5-11 days by live microscopy, focusing up and down through all 
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planes of the explant culture, counting each sprout emerging from the aortic ring and 
each branching sprout. 
 
2.6.1 RNA interference in aortic rings ex vivo 
Aortae were isolated as described previously and cut. A maximum of 24 rings were 
transferred to one well of a 24-well plate containing OPTI-MEM®. Mixtures A and B 
for Oligofectamine™ (Invitrogen) transfection were prepared and left to stand for 5 
minutes: 
  A: 2.5 µl 40 µM siRNA + 182.5 µl OPTI-MEM®       
  B: 3 µl Oligofectamine + 12 µl OPTI-MEM® 
 
Solutions A and B were mixed together and left to stand for 20 minutes. Culture 
medium was removed from rings and replaced with 800 µl OPTI-MEM® + 200 µl 
transfection mixture per well. Rings were left at 37 ºC/8 % CO2 in the medium + 
siRNA overnight and embedded in collagen the next day, fed and counted at 5-11 days 
as described in 2.6.  
 
SMARTpool siRNA sets were ordered from Dharmacon Inc., Chicago, IL, USA. For 
additional siRNAs used in the Tc1 study (section 3.6), please see Reynolds et al. 2010, 
included in Appendix 7.3. 
 
Mouse CLDN14 siRNA pool (Dharmacon): 
 
1: GUG CAC ACG CUG CGC CAA A 2: GGA GCU ACC ACC ACG GCU A 
3: GGU ACA GGC UGA AUG ACU A 4: GGA UGG AAU GUG UGU GGC A 
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2.7 Immunofluorescence 
2.7.1 Whole tissue sections 
2.7.1.1 FFPE sections 
8 µm sections were cut from FFPE tumour blocks and mounted onto glass slides. Prior 
to staining, sections were first deparaffinised and hydrated by immersion in a series of 
solutions, as follows: 
 
Excess water was blotted from around rehydrated sections and the tissue area defined 
with a pap-pen (ImmEdge™, Vector Laboratories Ltd., Peterborough, UK). For 
antigen retrieval, sections were boiled in citrate buffer (0.294% w/v Tri-Sodium citrate 
(Fisher) in ddH2O, adjusted to pH 6 with acetic acid) for 10 + 10 minutes. Sections 
were then allowed to cool to room temperature for 10 minutes (aided by addition of 
ddH2O to the boiling container) and rinsed twice with PBS before blocking for 30 
minutes at 37 °C with blocking buffer (2 % v/v Goat serum, 1 % w/v BSA, 0.1 % v/v 
Triton X-100 in PBS). For analysis of blood vessels, sections were then incubated 
overnight at 4 °C with primary α-endomucin antibody diluted 1:500 in blocking buffer 
to identify endothelial cells. Sections were washed three times with PBS before 
incubation for 1 hour at room temperature with 1:200 Alexa Fluor secondary antibody 
in blocking buffer. After three further PBS washes, slides were rinsed once with 
ddH2O and coverslips mounted with ProLong® Gold Antifade with DAPI (Invitrogen, 
cat. no. P36930). 
1: 1st xylene solution 5 minutes 6: 2nd 80 % ethanol 3 minutes  
2: 2nd xylene solution 5 minutes  7: 70 % ethanol 3 minutes 
3: 1st 100 % ethanol 3 minutes  8: 50 % ethanol 3 minutes 
4: 2nd 100 % ethanol 3 minutes  9: distilled water 
5: 1st 80 % ethanol 3 minutes  
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To visualise supporting cell coverage of blood vessels in tumour sections, 8 µm FFPE 
tumour sections were treated as above, with the exception that 1:500 mouse anti-mouse 
Cy5-conjugated αSMA antibody (Sigma) was added to the secondary antibody 
incubation step. Following mounting of slides, pericyte coverage of blood vessels was 
quantified by live microscopy: the total number of endomucin-positive blood vessels 
per unit tumour area and the number of endomucin-positive blood vessels with 
associated αSMA-positive cells was counted and the percentage αSMA/endomucin 
blood vessels calculated. 
 
2.7.1.2 Cryosections 
Staining for the junctional molecule ZO-1, the basement membrane protein laminin 
and the endothelial marker PECAM in 8 µm tumour cryosections: sections were air 
dried at room temperature, rehydrated in PBS for 10 minutes, fixed in -20 °C methanol 
for 10 minutes, and then blocked (5% w/v BSA, 0.1% Triton X-100 in PBS) for 45 
minutes at room temperature or overnight at 4 ºC. After three 5-minute washes in PBS, 
sections were incubated with primary antibody (ZO-1 or laminin 1:100 in blocking 
buffer) for 2 hours at room temperature. After three 5-minute washes in PBS, sections 
were incubated with anti-rabbit Alexa 488 secondary antibody diluted 1:200 in 
blocking buffer for 1 hour at room temperature, and PE-PECAM was diluted to 1:500. 
After three 5 minute washes in PBS, sections were washed briefly with distilled water 
and mounted with ProLong® Gold Antifade with DAPI (Invitrogen). Fluorescent 
images of sections were acquired using a Zeiss Axioplan microscope and Axiovision 
software multidimensional acquisition settings. 
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2.7.2 Immunofluorescence staining of aortic rings 
To quantify and image aortic rings at the end of the ex vivo assay, whole explant 
cultures were stained with the endothelial cell-specific Bandeiraea simplicifolia (BS1) 
lectin conjugated to fluorescein isothiocyanate (FITC). 
 
To fix aortic rings in 96-well plates, the growth medium was removed and wells were 
washed three times in PBS. 50 µl 4% PFA was added to each well chosen for staining 
and left for 15 minutes at room temperature before a further three PBS washes. 50 µl 
1:1000 BS1-lectin in PBS was added per well and plates incubated at 4 °C overnight. 
Wells were then washed a final three times with PBS before removing the cultures 
carefully from the wells to mount on slides (up to 6 explants per slide) using 
ProLong® Gold Antifade with DAPI (Invitrogen). Fluorescent images were acquired 
using a Zeiss Axioplan microscope and Axiovision software multidimensional 
acquisition settings. 
 
2.7.2.1 Ex vivo EdU proliferation assay 
The ClickIT® EdU Proliferation Assay (Invitrogen), which employs a BrdU-like 
molecule capable of incorporating into DNA to assess DNA synthesis and therefore 
cellular proliferation, was modified for use in the ex vivo aortic ring assay (see also 
Baker et al. 2012 for details, attached in Appendix 7.3). Briefly, aortic rings 
embedded in a collagen matrix as described in 2.6 were serum-starved and treated with 
10 µM EdU for 2 hours prior to fixation as described below in 2.7.3.3 and Baker et al. 
Following fixation in 4% formaldehyde, EdU detection was performed as according to 
the manufacturer’s protocol, using reduced reagent volumes (50 µl per well) as well as 
increased washing frequency and duration to remove as much background signal as 
possible, since the collagen matrix picks up some of the green fluorescent reagent 
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provided with the kit. Rings were co-stained with TRITC-conjugated BS1-lectin 
(Sigma), carefully removed from the 96-well plate and mounted on glass slides with 
ProLong® Gold Antifade with DAPI (Invitrogen) following EdU detection. 
Fluorescent images were acquired using a Zeiss Axioplan microscope and Axiovision 
software multidimensional acquisition settings. Proliferation was quantified by 
counting EdU-positive proliferating cell nuclei and total nuclei in BS1 lectin-positive 
endothelial microvessel sprouts during live imaging, with the percentage of 
proliferating cells recorded. 
 
2.7.3 Primary endothelial cells 
2.7.3.1 VEGFR2 immunofluorescence 
Primary endothelial cells were seeded onto coverslips and allowed to attach and grow 
for 24 h in full endothelial cell growth medium. The cells were serum-starved in OPTI-
MEM® overnight and half were stimulated for 10 min with 30 ng/ml VEGF while the 
remainder were used as controls (supplemented with an equal volume of PBS). After 
VEGF- stimulation the cells were rinsed three times with PBS and fixed in 4% 
paraformaldehyde for 5 minutes. Free aldehydes were quenched with 50 mM NH4Cl 
in PBS for 10 minutes. Fixed cells were then permeabilised in PBS containing 0.1 % 
Triton X-100 with 2 % w/v BSA for 15 minutes then incubated at room temperature 
for 1 hour with rabbit anti-human phospho-VEGFR2 antibody (Cell Signaling 
Technology) diluted at 1:100 in PBS with 0.1% Triton X-100. Cells were rinsed and 
incubated with donkey anti-rabbit secondary antibody conjugated to Alexa-488 
(Invitrogen), diluted at 1:1000 for 30 min. Cells were washed three times in PBS and 
once in water and then mounted with ProLong® Gold Antifade with DAPI 
(Invitrogen). Images were acquired using a Zeiss LSM 510 confocal microscope. 
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2.7.3.2 In vitro proliferation assay 
For the labelling of proliferating primary endothelial cells in vitro, the ClickIT® EdU 
Proliferation Assay (Invitrogen) was used in a similar manner to that described for 
aortic rings in 2.7.2.1. The 10 mM EdU reagent stock was diluted to create a 2x stock 
at 20 µM; typically, 80 µl of 2x stock was added to 40 ml proliferation assay medium 
(see below). Cells were seeded on pre-coated coverslips in 6-well tissue culture plates 
24 hours before the assay and were tested at 50-60% confluence. 
 
Two hours prior to addition of the EdU reagent, half of the cell growth medium was 
replaced with starvation medium (1:1 F12:DMEM medium, 1% v/v FBS, 1 mg ml-1 
Heparin, 1:100 Penicillin/Streptomycin, without EdU) to serum-starve the cells. Two 
hours later, half of the starvation medium was removed and replaced with starvation 
medium containing EdU to provide 1x (10 µM) EdU in the wells (1:1 F12:DMEM 
medium, 1% v/v FBS, 1 mg ml-1 Heparin, 1:100 Penicillin/Streptomycin, with EdU). 
Cells were also supplemented with 30 ng/ml VEGF or PBS as a control. EdU 
incorporation was allowed to proceed for 1.5 hours before plates were placed on ice, 
the medium removed, coverslips washed with PBS and 4% formaldehyde fixative 
added. Plates were incubated with fixative at room temperature for 15 minutes before 
washing in PBS three times.  
 
The EdU detection protocol was performed according to the manufacturer’s 
instructions (Invitrogen), only with all reagent volumes reduced by a factor of 10, for 
example 50 µl incubation reagent was used per well instead of the suggested 500 
during the staining protocol. Explants were mounted on glass slides with ProLong 
Gold™ Antifade with DAPI and images were acquired using a Zeiss Axioplan 
microscope and Axiovision software multidimensional acquisition settings. The 
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percentage of proliferating (EdU-positive) cells was calculated by counting total 
DAPI-positive nuclei per field and then total EdU-positive nuclei in the same field. 
 
Assessment of proliferation in siRNA-transfected cells (as in 2.8) was carried out as 
above except that cells were seeded on pre-coated 15 mm coverslips in 10 cm tissue 
culture plates (BD Falcon) and allowed to adhere overnight as detailed above, before 
moving coverslips to 6-well plates and following the protocol as previously described. 
 
2.7.3.3 TUNEL apoptosis assay in vitro 
The Invitrogen ClickIT® TUNEL Apoptosis Assay was used to quantify TUNEL-
positive (apoptotic) primary endothelial cells transfected with siRNA as described in 
2.8. Transfected cells were seeded on pre-coated 15 mm coverslips in 10 cm tissue 
culture plates (BD Falcon) and allowed to adhere overnight. Coverslips were 
transferred to 6-well tissue culture plates containing starvation medium for 1.5 hours. 
30 ng/ml VEGF or PBS as a control was added to the wells to stimulate cells for 1.5 
hours. Plates were then placed on ice, the medium removed and coverslips washed 
with PBS, then fixed with 4 % paraformaldehyde for 15 minutes at room temperature. 
Following three PBS washes to remove fixative, coverslips were processed with the 
TUNEL staining protocol provided by the manufacturers. As in 2.7.2.1, reagent 
volumes were reduced 10 x. 
 
Coverslips were mounted with ProLong Gold™ Antifade with DAPI and fluorescent 
images were acquired using a Zeiss Axioplan microscope and Axiovision software 
multidimensional acquisition settings. The percentage of apoptotic (TUNEL-positive) 
cells was calculated by counting total DAPI-positive nuclei per field and then total 
TUNEL-positive nuclei in the same field. 
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2.8 Transient siRNA transfection of primary endothelial cells in vitro 
Primary endothelial cells to be transfected were grown to 70-90% confluence in T175 
tissue culture flasks (or containing approximately 3 million cells). An AMAXA 
Nucleofector™ 2b Device (Lonza, Basel, Switzerland) was sterilised and transferred to 
the sterile tissue culture hood then set to programme T-27 for endothelial cells. To 
prepare for transfection, 40 µM siRNA pool stocks were thawed on ice and 3 µl of 
siRNA stock (3 µg siRNA) was transferred to an appropriately labelled 1.5 ml 
Eppendorf tube. 
 
Cells were trypsinised and resuspended in 30 ml MLEC medium. Cells were counted 
and 1 million cells for each transfection reaction aliquoted to 15 ml tubes (for example, 
where 6 transfections using the same siRNA pool were required, 6 million cells were 
transferred). Cells were spun down at 1,200 rpm for 3 minutes and medium carefully 
aspirated, with as much as possible removed from the cell pellet using a p1000 Gilson 
pipette tip after initial aspiration.  
 
For transfection, the cell pellet was carefully resuspended in 100 µl endothelial cell 
transfection buffer provided with the AMAXA kit (or 600 µl for 6 million cells) and 
100 µl resuspended cells was transferred to the appropriate Eppendorf containing the 
siRNA. The cell/siRNA suspension was then transferred to an AMAXA plastic cuvette 
using the provided pipettes to ensure no air bubbles were formed, placed in the 
Nucleofector and transfected using the set programme. The cuvette was immediately 
removed from the machine and the transfected cell suspension transferred to a pre-
coated 10 cm tissue culture plate containing 15 mm coverslips and 5 ml MLEC 
medium. Cells were returned to the incubator at 37 °C and 8% CO2 and allowed to 
recover overnight. 
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2.9 Flow cytometric analysis of cell surface receptor levels 
Primary endothelial cells were seeded in individual wells of a 24 well plate (3 x 105 per 
well), cultured overnight, and stimulated the following day with 30 ng/ml VEGF. 
Stimulation was ceased by placing cells on ice, followed by rinsing with ice-cold 
DMEM. Cells were kept on ice for the subsequent steps. To dissociate GF/receptor 
interactions, cells were treated for 10 minutes with cold acidified E4 medium (pH 4) 
supplemented with 1% BSA and washed in FACS buffer (2% FBS in PBS). Cells were 
stained with PE-conjugated rat α-mouse VEGFR2 antibody (1/50, BD Pharmingen) or 
with a corresponding isotype control (PE-conjugated rat α-mouse IgG, BD 
Pharmingen) in FACS buffer for 45 minutes. Cells were then washed three times and 
detached from the well by incubating with 5 mM EDTA in PBS and scraping. Surface 
antibody binding was analysed by flow cytometry using a FACScalibur® flow 
cytometer (Becton Dickinson, Oxford, UK) and Cellquest Pro software. The geomean 
fluorescence intensity of the population was measured to determine the percentage of 
receptor remaining at the plasma membrane over time. 
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2.10 Western blot analysis 
 
2.10.1 Cell lysis 
Primary endothelial cells grown in pre-coated culture plates to comparable confluence 
were incubated on ice for 10 minutes and scraped into RIPA buffer (2% Triton X-100, 
2% sodium deoxycholate (Sigma), 0.2% SDS, 316 mM NaCl, 20 mM Tris-base pH 7.3, 
2 mM EGTA (BDH Laboratory Supplies, UK), 2 mM sodium orthovanadate (Sigma), 
10 mM NaF (Sigma), 1 mM PMSF (Sigma). Lysate was transferred to an eppendorf 
and spun in a benchtop microcentrifuge (Eppendorf) at 20,000 g for 10 minutes at 4°C. 
The supernatant was removed and transferred to a fresh eppendorf, discarding the 
pellet. 
 
2.10.2 Protein assessment 
BSA standards of known concentrations: 0, 0.1, 0.2, 0.4, 0.8, 1.2, 1.6 and 2.0 mg/ml 
were prepared by serial dilution in RIPA buffer. 5 µl of cell lysates and duplicate 
standard samples were transferred to a 96-well plate. The DC-Biorad Protein Assay Kit 
was used according to manufacturer’s instructions: 1 ml Reagent A was supplemented 
with Reagent S and 25 µl of this solution was added to each protein sample. 200 µl 
Reagent B was then added to each well and the plate incubated for 15 minutes at room 
temperature. A spectrophotometer (LabTech International LDT, East Sussex, UK) was 
used to read sample absorbance at 650 nm, to determine protein concentration by 
comparison with the BSA standards. A standard curve was created in Excel 
(Microsoft) and the equation of the line used to find the protein concentrations of the 
test samples. 
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2.10.3 SDS-PAGE 
Polyacrylamide gel electrophoresis (PAGE) was performed using the Novex gel 
apparatus Xcell IITM Mini-Cell (Novex Electrophoreses GmbH, Invitrogen). Gel 
cassettes were prepared prior to loading by pouring the running gel (10 ml prepared 
per 8 % gel: 2.7 ml 30 % Protogel Acrylamide, 2.5 ml v/v Protogel 4x Resolving 
buffer, 4.7 ml v/v H2O + 100 µl fresh 10 % w/v APS + 6 µl TEMED) into an empty 
cassette (Invitrogen), overlaying with distilled water and leaving the gel to polymerise 
for 30 minutes. The distilled water was then removed and replaced with stacking gel 
(2ml prepared per gel: 330 µl 35% Protogel Acrylamide, 500 µl Protogel Stacking 
buffer, 1.15 µl H2O, 20 µl APS, 2 µl TEMED), into which a lane comb was carefully 
inserted and the gel left to polymerise for a further 30 minutes. The lane comb was 
then removed and the gel tank apparatus assembled, with the addition of running 
buffer (see 2.1). Cell lysates of equal concentration were added to 5 % volume 5x 
sodium dodecyl sulphate (SDS) loading buffer (10 % w/v SDS, 20 % w/v glycerol, 
312.5 mM Tris pH6.8, 10 % w/v 2-ME, few crystals bromophenol blue). Samples were 
boiled at 100 °C for 5 minutes prior to loading. Gel wells were washed with running 
buffer and samples loaded into the wells. Rainbow Marker (GE Healthcare) was used 
for molecular weight determination and loaded gels were run in running buffer at 200 
volts (V) for approximately 20 minutes to run samples through the stacking gel, then at 
125V to run samples to the end of the gel. 
 
2.10.3.1 NuPAGE system 
Detection of Cldn14 was achieved using a modified Western Blot protocol from that 
described in 2.9.3, employing instead the Invitrogen NuPAGE system as optimised by 
myself and S. D. Robinson. Samples were prepared after determination of protein 
concentration and aliquoting volumes containing 15-20 µg protein by addition of 4x 
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NuPAGE LDS Sample Buffer and 10x NuPAGE Sample Reducing Agent each to a 
final concentration of 1x. Samples were then heated to 100 °C for 5 minutes prior to 
loading. 
 
Running cassettes were assembled 1 mm x 12-well pre-cast 12% Bis-Tris gradient 
polyacrylamide gels (Invitrogen). Samples were loaded into the wells along with 
Rainbow Marker (GE Healthcare). The cassette was assembled as detailed above using 
different buffer solutions to allow proper separation of proteins in the gradient gel; 1 
litre 1x MES-SDS buffer was prepared by diluting Invitrogen NuPAGE 10x stock with 
H2O and 200 ml was removed, to which 500 µl NuPAGE antioxidant was added in 
order to keep protein samples denatured within the gel. The outer chamber of the 
cassette was filled with the remaining 800 ml 1x MES-SDS buffer and the inner 
chamber was filled with the 200 ml buffer + antioxidant. Gels were run at 120 V for 2 
hours at 4 °C to separate samples sufficiently before proceeding to the transfer step.  
 
 
2.10.4 Blotting 
Separated proteins were transferred from the gel to Hybond ECL™ nitrocellulose 
membrane (Amersham Life Science) using the Novex Xcell II™ Mini-Cell transfer 
module. Before setting up the transfer, the membrane, sponges and 3MM Whatmann 
paper were placed in transfer buffer (12 mM Tris, 96 mM Glycine, MeOH pH 8.3, in 
H2O) for pH equilibration. The cassette was assembled and transfer carried out at 30V 
for 1 hour.  
 
For NuPAGE gels, transfer to nitrocellulose membranes was set up and run as 
described above except that 20x NuPAGE Transfer Buffer was diluted to 1 x with H2O 
and used to run the transfer at 30V for 2 hours also at 4 °C. 
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2.10.5 Probing 
Membranes were blocked for 1 hour in 5 % w/v Marvel™ skimmed milk powder in 
PBS, washed 3x 5 minutes in 0.1 % PBS-Tween then incubated with primary rabbit 
anti-mouse phospho- or total-ERK antibody diluted 1:100 in blocking solution at 4 °C 
overnight. A further 3 5-minute washes in PBS-Tween were followed by incubation 
with HRP-conjugated secondary antibody with agitation for one hour at room 
temperature. After 3x 5-minute washes with PBS-T, excess liquid was removed and 
signal detected with the ECL Western Blot Detection reagents (GE Healthcare, 
Amersham). Bands were visualised using Hyperfilm ECL (Amersham) and a Konica 
SRX-101A developer. To re-probe, blots were stripped by incubation at room 
temperature in Re-Blot Plus Mild Solution 10x (Millipore) diluted 1:10 in ddH2O, with 
agitation, for 5-10 minutes. Strip buffer was rinsed off with water and blots re-blocked 
before primary antibody incubation or stored in PBS at 4 °C. 
 
From NuPAGE gels, following transfer to the membrane, blots were blocked for 1 
hour in 5% Marvel milk in PBS and then incubated overnight at 4 °C with primary 
rabbit anti-mouse Cldn14 antibody (Sigma) diluted 1:100 in 5% BSA in PBS with 
0.1% Tween-20. Following three 15-minute washes in PBS with 0.1% Tween-20, blots 
were incubated with 1:200 secondary anti-rabbit HRP antibody for 1 hour at room 
temperature. Blots were then developed as described above, stripped and reprobed for 
Hsc70 as a loading control. 
 
 
2.10.6 Densitometry 
Densitometry was performed on scanned film images using ImageJ. Lanes were 
defined and bands selected then the areas of the peaks measured. Results were 
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normalised to corresponding total protein values for ERK or to Hsc70 loading control 
band values for Cldn14. 
 
2.11 Reverse transcription PCR 
2.11.1 Confirmation of siRNA-mediated knockdown in WT and Tc1 cells 
The RTPCR method used to confirm expression and RNAi knockdown of mouse and 
human target genes in wild-type and Tc1 cells is shown in Reynolds et al. 2010 
Supplementary Information (Appendix 7.3). Briefly, primary lung endothelial cells 
isolated from wild-type and Tc1 mouse lungs were grown to 60-70% confluence. RNA 
was extracted using either the Trizol method (according to the manufacturer’s 
instructions) (Invitrogen, UK) or the QIAGEN RNeasy mini kit (QIAGEN, Crawley, 
UK). cDNA was synthesised from equal concentrations of RNA isolated from both 
genotypes (Superscript III RT kit, Invitrogen). Primer sequences and cycling 
conditions are detailed in the Supplementary Information (Appendix 7.3). PCR 
products were run on a 1.8% agarose gel and the bands were visualised under UV 
light. 
 
2.11.2 Assessment of claudin mRNA levels 
A different method for RNA extraction and detection of claudin mRNAs was 
optimised by D. Lees, as described below. 
2.11.2.1 RNA extraction 
Organs were harvested from WT, Cldn14-het and Cldn14-null mice and snap-frozen in 
liquid N2 then stored at -80 °C. Samples were weighed and ground to powder in liquid 
N2 using a pestle and mortar. Powdered samples were halved and transferred to 1.5 ml 
tubes. The sample for RNA extraction was homogenised with a 1 ml pipette, then a 20 
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G x 1 1/2 in needle and 3 ml syringe. Samples were spun for 3 minutes at 13,000 g and 
the supernatant collected, frozen on dry ice and stored at -80 °C. 
 
The Qiagen RNeasy mini kit, with a DNaseI digestion step, was used to extract RNA 
from the tissue supernatants, according to the manufacturer’s instructions. Samples 
were eluted in 33 µl RNase-free H2O and passed twice through the final elution 
columns. RNA concentration was analysed using a ND-1000 Spectrophotometer 
(Nanodrop, Delaware, USA). RNA integrity was checked by running 4 µl sample with 
1 µl 5x loading buffer on a 1% agarose gel (Figure 2.1). 
 
2.11.2.2 Reverse transcription 
For the reverse transcription reaction to generate cDNA, the High-Capacity cDNA 
Reverse Transcription Kit (Applied Biosystems) was used according to the 
manufacturer’s instructions, but without RNAse inhibitor. 1.5 µg RNA was used per 
20 µl reaction volume. Reactions were run in a StepOne™ Real-Time PCR cycler 
(Applied Biosystems) with the following conditions: 25 ºC for 10 minutes, 37 ºC for 
120 minutes, 85 ºC for 5 minutes and finally cooling to 4 ºC for storage. 
Figure 2.1 RNA sample integrity 
The integrity of purified RNA samples as prepared in section 2.10.2.1 was checked by running 4 µl 
RNA sample from either powdered mouse brain or kidney from WT, Cldn14-het and Cldn14-null mice 
(W, H and N respectively) with loading buffer on a 1% agarose gel. RNA samples were allowed to 
separate and the presence of 28S and 18S bands verified. No samples displayed a smear in the lane 
characteristic of degraded RNA samples (performed by D. Lees). 
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2.11.2.3 Quantitative PCR 
Pre-designed primers for Cldn14 and Cldn5 were purchased from Origene (qSTAR 
expression detection system). β-actin primers were used as controls: 
ACTB forward: 5’ – AAG GCC AAC CGT GAA AAG AT – 3’ 
ACTB reverse: 5’ –  GTG GTA CGA CCA GAG GCA TAC – 3’ 
Reactions were performed with the SYBR Green PCR master mix (Applied 
Biosystems) in optical qPCR plates. A 40 ng to 0.625 ng standard curve was set up 
using sequential 2x dilutions of cDNA. To amplify Cldn cDNA: 0.8 µl primers were 
used, as recommended by Origene, with 100 ng cDNA. 1 µl (50 nM) ACTB primers 
were used with 10 ng cDNA. Reactions were run in a StepOne RTPCR cycler 
(Applied Biosystems). Relative Cldn message quantities (r) were calculated using the 
following formula, which includes the efficiency of each gene amplification: 
Efficiency = 10^-(1/slope) 
r = [e(target)ΔCt (control-sample)] / [e(reference)ΔCt(control-sample)] 
 
2.12 Syngeneic tumour growth assay 
2.12.1 Injection of cells 
B16F0 (a low metastatic variant of the B16 melanoma cell line) and Lewis Lung 
Carcinoma (LLC) were grown and described in 2.4.1 with medium specified in 2.3.3 
and were trypsinised for counting using a Millipore Scepter 2.0 Handheld Automated 
Cell Counter, which provides the concentration of cells present in the sampled 
suspension. The appropriate volume of tumour cell suspension was then transferred to 
a fresh tube, spun down at 1,200 rpm for 3 minutes and resuspended in sterile PBS 
ready for injection: 1×106 B16F0 or 0.5×106 LLC cells per 100 µl of PBS. A mixture 
of LLC cells growing both in suspension and adhered (as described in 2.4.1) was used 
for injections. Mice were prepared for tumour cell injections one day prior to the start 
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of tumour growth experiments by shaving along the flank with electric clippers. A 
single subcutaneous injection of 100 µl of PBS containing either 1×106 B16F0 or 
0.5×106 LLC cells was given on day 0. Tumours were allowed to grow for 10 (B16) or 
12 days (LLC) then excised and photographed following cervical dislocation of the 
mice. 
 
2.12.2 Tumour growth and bioluminescence 
The tumour dimensions were measured with electronic callipers (including length and 
width measurements every two days for growth kinetics). For bioluminescence 
measurements, luciferase-tagged cell lines were used (as described in Salako et al. 
2011). From day 3 post-inoculation and every 2-3 days thereafter, mice were injected 
with 200 µl Luciferin (Caliper Lifesciences D-Luciferin Firefly, Potassium salt 1.0 g 
diluted to 15 mg ml-1 in PBS + CaCl2 + MgCl2 (Gibco)) intra-peritoneally and imaged 
in a VivoVision® IVIS® scanner (Xenogen, Caliper Lifesciences) after 10 minutes 
whilst under light anaesthetic (isofluorane). Photon emission data were analysed using 
Living Image V3.2 software.  The luciferase expressed by the tumour cells is able to 
oxidise luciferin taken up by the tumour cells so long as sufficient oxygen is available, 
which releases photons that can be detected by the camera. Bioluminescence is not a 
measure of tumour mass or size but a combination of tumour oxygenation and 
metabolic activity. 
 
At the end of the experiment, mice were killed by cervical dislocation. Tumours were 
dissected out, measured in 3 dimensions then bisected and either: (1) snap-frozen by 
embedding in OCT (Fisher Scientific, Loughborough, UK) and freezing in liquid N2-
cooled isopentane or (2) fixed in 4 % formaldehyde in PBS for histological analysis; 
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24 hours post-fixation, formaldehyde was replaced with 70% ethanol and tumours 
were then arranged in cassettes to be embedded in paraffin.  
 
2.12.3 Ante-mortem processing 
In some experiments ante-mortem procedures were carried out prior to tumour 
harvesting as described below. 
 
2.12.3.1 Pimonidazole hypoxyprobe assay 
The Pimonidazole hypoxyprobe was used to assess hypoxia in tumours. Pimonidazole 
binds thiol-containing proteins specific to hypoxic cells and can be visualised with a 
commercially-available antibody (Varia et al. 1998,). This reagent has been optimised 
extensively for use in vivo (Rosenberger et al. 2009) Tumour-bearing mice were given 
intravenous injections via the tail vein of 60 mg/kg pimonidazole hydrochloride 
(Hypoxyprobe™-1 HPI, Inc., diluted in ddH2O to a final concentration of 10 mg/ml) 1 
hour prior to sacrifice. Tumours were processed immediately after cervical dislocation 
by snap-freezing. 8 µm cryosections were thawed, rehydrated and fixed for 10 minutes 
in -20 °C acetone. Sections were washed once in PBS and incubated with antibodies 
diluted in PBS (1:10 anti-pimonidazole Cy3-conjugated antibody and 1:500 PE-
PECAM) overnight, then washed three times with PBS and mounted with ProLong 
Gold™ Antifade with DAPI (Invitrogen). Fluorescent images were acquired using a 
Zeiss Axioplan microscope and Axiovision software multidimensional acquisition 
settings. 
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2.12.3.2 Hoechst leakage assay 
10 minutes prior to sacrifice, tumour-bearing mice were injected with 100 µl PE-
PECAM antibody (undiluted, BD Pharmingen) to label blood vessels with active blood 
flow. Hoechst dye (Sigma bisBenzimide H33342 trihydrochloride, B2261) was 
prepared at 4 µg/ml final concentration by dilution in H2O, following resuspension and 
storage of the product at 10 µg/ml. 1 minute before sacrifice, the same mice were 
injected with 100 µl Hoeschst dye to label cell nuclei. Tumours were processed 
immediately after cervical dislocation. Thick (100 µm) sections of frozen tumour 
samples were thawed, rehydrated and fixed for 10 minutes in -20 °C methanol then 
mounted with ProLong Gold™ Antifade without DAPI (Invitrogen, cat. no. P36930). 
 
2.12.4 Assessment of hypoxia in tumours 
To convert pimonidazole staining to an “hypoxic index” a 4x5 grid was used to divide 
images of pimonidazole-immunostained tumour sections into 20 sectors. The distance 
from several PECAM-positive blood vessels per sector (at least 5 sectors per image) to 
the closest pimonidazole-positive (hypoxic) areas were measured in Adobe Photoshop 
CS5. The inverse values of these distances were taken and averaged to give the 
hypoxic index. 
 
2.12.5 Blood vessel quantitation 
Immunofluorescence images of endomucin-immunostained sections were captured 
using an epifluorescence microscope (Carl Zeiss, Jena, Germany) equipped with a 
Zeiss AxioCam MRc 5 digital camera (Carl Zeiss Ltd., Welwyn Garden City, UK) and 
AxioVision V4.8.1.0 software (Carl Zeiss Imaging Studios). The mean number of 
endomucin//PECAM-positive blood vessels present in entire tissue sections was 
counted and divided by the area of the section to determine blood vessel density. 
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Whole tumour sections are used in order to avoid selection bias due to choosing 
individual fields, and multiple tumours are counted to collect a high number of data 
points that should represent the actual vessel density of the tumours. It is also thought 
that this method should avoid methodological problems such as collapsing vessels 
during the sectioning process. Mid-sections are counted to avoid the more variable 
vessel densities found at the tumour extremities. After confirming that counts 
correlated well with those made by more experienced lab members, all counts were 
performed by myself, to avoid differences due to changing observers. “Lumenated” 
(vessels showing clear lumens within endomucin-positive endothelial walls, indicating 
vessels likely to carry blood flow) and “non-lumenated” (endomucin-positive 
structures without clear lumens indicating blind vessel ends, poorly-formed or 
collapsing/regressing vessels) vessels were identified by eye, following guidance from 
Prof. Hodivala-Dilke, and counted across whole tumour midsections in the same 
manner as the total vessel counts. Results are given as the number of vessels per mm2 
of section. All counts were carried out in a double blind fashion. 
 
Unchallenged skin was also taken from mice, fixed and embedded in paraffin in the 
same way as tumour samples, and immunostained for endomucin. Blood vessel density 
was also quantified in this unchallenged tissue to confirm that any observed effects on 
blood vessels in tumours were due to pathological angiogenesis. 
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2.12.6 Assessment of Hoechst delivery into tumours 
Following ante-mortem injections of Hoechst and PECAM into tumour-bearing mice 
and tumour processing as described in 2.11.3.2, 100 µm Z-stacks (stack interval 0.5 
µm, 20x magnification) of a representative tumour area were taken using a Zeiss LSM 
510 confocal microscope. LSM images were analysed using ImageJ: for each image, 
the red (PECAM) and blue (Hoechst) channels were split [Image -> Hyperstacks -> 
Channels Tools, click More -> Split Channels]. For the red channel, a threshold was 
set [Image -> Adjust -> Threshold] to remove background noise, which was applied to 
each image in the stack (Figure 2.2). The same threshold was used for images of 
similar staining intensities.  
 
Figure 2.2 Thresholding confocal image stacks in ImageJ 
Screenshot of confocal .lsm file opened in ImageJ displaying the red (PECAM-positive blood vessels) 
channel. In the Threshold window (accessed from the Image menu), the top slider is used to adjust the 
pixel intensity threshold and remove background noise, or left as an automatic selection made by the 
program. Clicking apply allows the application of the same threshold value to all image slices in the 
stack.  
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Using Plugins -> Stacks -> Measure Stack, the area of pixels meeting the threshold 
value was measured, with slices at the top and bottom limits of the section excluded 
(Figure 2.3).  
 
 
Figure 2.3 Measurement of pixel intensity in a confocal image stack in ImageJ 
Screenshot of confocal .lsm file opened in ImageJ displaying the red (PECAM-positive blood vessels) 
channel and thresholded (as shown in Figure 2.2). In the Plugins menu, Measure Stack directs the 
program to measure the area of pixels of higher intensity than the minimum threshold set. Displayed 
under Area next to the slice number, slices 10 and above have been selected for analysis; slices at the 
upper and lower edges of the tissue section often display a weaker staining intensity and are not 
analysed to avoid skewing the data. 
 
The thresholding and measuring process was repeated for the blue channel and these 
sets of values were analysed in Microsoft Excel: first, by subtracting positive pixels in 
the red channel (PECAM-positive blood vessels) from the positive pixels in the blue 
channel (Hoechst-positive nuclei), blue-red values exclude Hoechst remaining inside 
vessels, since it is the ‘leaked’ dye that is to be analysed. To normalise for vessel 
density in the sections, blue-red values were then divided by the red channel values 
blue-red/red to account for variations in the amount of PECAM-positive vessels in the 
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image. This calculation produced relative intensity values, which were analysed for 
mean and standard error to visualise results. 
 
2.12.7 Quantification of cellular proliferation in tumours 
Proliferation of both tumour and endothelial cells was quantified in tumour sections by 
immunostaining for the proliferation marker Ki67. Cryosections were thawed and 
rehydrated with PBS. Sections were then fixed with -20 °C acetone for 10 minutes, 
permeabilised with 0.5% v/v NP40 in PBS for 10 minutes and washed once with 0.1% 
Triton X-100 in PBS. Sections were blocked (1% w/v BSA, 0.1% Triton X-100 in PBS) 
for 45 minutes at room temperature and then incubated with rabbit anti-Ki67 antibody 
(1:100 in wash buffer) overnight at 4 °C. Slides were washed three times with wash 
buffer as above then incubated with secondary anti-rabbit Alexa Fluor 488 antibody 
(1:200) and PE-PECAM (1:500) for 1 hour at room temperature. Following three final 
washes and one H2O wash, slides were mounted with ProLong Gold™ with Antifade 
and DAPI (Invitrogen). Fluorescent images were acquired using a Zeiss Axioplan 
microscope and Axiovision software multidimensional acquisition settings. 
 
Counting PECAM-negative nuclei and the number of those nuclei that were also Ki67-
positive across several fields allowed quantification of tumour cell proliferation. To 
quantify endothelial cell proliferation in the same fields, the PECAM-positive cell 
nuclei were counted as well as the number of those that were Ki67 positive. 
 
2.13 Subcutaneous sponge assay 
This in vivo assay for growth factor-induced angiogenesis was based on a technique 
developed in rats (Andrade et al. 1987). Sterile polyether sponge cylinders were cut 
from sponges (Caligen Foam Ltd. Sample 611-7 polyether grade XE1700V 16 kg/m3) 
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first with a large heavy-duty hole-punch (5 mm hole size) and further cut into 8 mm - 1 
cm length cylinders. The sponge cylinders were autoclaved at 121 °C. 
 
Day 0: sponge implantation. Mice received a subcutaneous injection of 
Vetergesic/Rymadil prior to anaesthesia with fluothane and the abdomen was shaved 
with electric clippers. A small subcutaneous incision was made in the abdomen and the 
sterile sponge inserted with a sterile trocar. The incision was closed using vet-bond 
surgical glue or sterile wound clips. The same procedure was repeated for the opposite 
flank. 
 
Day 1: injection of the test reagents. Reagents were injected through the skin directly 
into the sponges following a similar timetable to the example: Day 1, Day 4, Day 6, 
Day 8 and Day 11. Sponges were injected with 10 ng ml-1 VEGF in 100 µl of PBS 
(shown previously to be the maximum effective dose, as in Hodivala-Dilke et al. 1999) 
or PBS only as control.  
 
Day 13: harvesting. At the end of the experiment, all animals were killed by cervical 
dislocation. Sponges were excised rapidly with underlying connective tissue/fat 
removed from each sponge. Each sponge was cut in half with a scalpel and fixed in 10 
% formalin solution overnight and immersed in 70 % ethanol the next day. Samples 
were then paraffin-embedded for immunohistochemical staining to identify 
endomucin-positive blood vessels infiltrating the sponges. Blood vessel numbers 
across whole cross-sections of the immunostained sponge were counted and divided by 
the total area of the sponge section to give blood vessel densities. 
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2.14  
2.15 Statistical Analysis 
P values were obtained using the Student’s paired T-test and values of P < 0.05 were 
considered statistically significant. 
 
2.16 Home Office regulations 
All animals were housed and used in experiments according to UK Home Office 
regulations; all experiments were performed in accordance with our laboratory’s 
Project Licence and all individuals involved held valid Personal Licences. Animal 
wellbeing was monitored daily by the resident qualified technicians and experimental 
animals by myself additionally. Animals were humanely killed by experienced 
qualified technicians and any animals that fell sick during experiments were treated 
appropriately or killed if required. 
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CHAPTER 3 IDENTIFICATION OF NOVEL REGULATORS 
OF ANGIOGENESIS USING THE TC1 MOUSE MODEL OF 
DOWN’S SYNDROME 
 
The Tc1 model of Down’s syndrome gave us an opportunity to investigate the possible 
effects of stromal trisomy for Hsa21 genes on tumour growth. Injectable tumour 
models were used to dissect the role of trisomic Hsa21 genes within the stromal 
compartment from the tumour cell compartment. 
 
3.1 RESULTS 
 
3.1.1 Tumour growth is reduced in Tc1 mice 
To examine whether the Tc1 mice could recapitulate the epidemiological observation 
of reduced tumour growth in DS patients, 1x106 B16F0 melanoma or 0.5x106 Lewis 
Lung Carcinoma mouse cells were injected subcutaneously into age and sex-matched 
Tc1 and wild-type (WT) control mice. B16F0 and LLC tumours were grown for 10 or 
12 days respectively. Mice were killed and tumour size assessed. Results showed that 
syngeneic tumour growth in Tc1 mice is decreased significantly when compared to 
WT mice (P < 0.05) (Figure 3.1). 
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Figure 3.1 Tumour size is reduced in Tc1 mice.  
A: Average size of subcutaneous B16F0 and LLC tumours, at 10 and 12 days growth respectively, in 
WT and Tc1 animals. Bars represent mean tumour volume ±SEM. Two independent experiments, n = 
14-18 mice per genotype. B: Panels of representative B16F0 and LLC tumours. Scale bar = 1cm. * P < 
0.05. 
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3.1.2 Pathological angiogenesis is attenuated in Tc1 mice  
In order to determine whether tumour size correlated with blood vessel infiltration, 
vessel density was quantified by counting the number of endomucin-positive blood 
vessels, per unit area, across entire midline sections of size-matched FFPE tumours. 
We found that B16F0 and LLC tumours from Tc1 mice had significantly decreased 
tumour vessel density when compared to WT mice (Figure 3.2 A, B). There was no 
significant difference in vessel density in unchallenged skin from mice of either 
genotype, suggesting the angiogenic phenotype was specific to the tumour (Figure 3.2 
C). 
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Figure 3.2 Pathological angiogenesis is attenuated in Tc1 mice. 
A: Size-matched and age-matched B16F0 and LLC tumours from WT and Tc1 mice were sectioned and 
immunostained for the endothelial marker endomucin. Blood vessel density was quantified across entire 
midline sections; bars represent mean numbers of blood vessels per mm3 of tumour section ±SEM. B: 
Representative images of endomucin-positive vessels in B16F10 and LLC tumour sections from WT 
and Tc1 mice. C: Blood vessel density in unchallenged skin from WT and Tc1 animals. Blood vessel 
density across whole skin sections was quantified. Bars represent mean numbers of blood vessels per 
mm3 of skin section ±SEM. n = 5-10 mice per group and two independent experiments. Scale bar = 150 
µm. * P < 0.05. NSD = not statistically different. 
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3.1.3 VEGF-induced angiogenic responses are impaired in Tc1 mice 
Given that VEGF is a potent proangiogenic factor, we next sought to examine VEGF-
stimulated angiogenic responses using three independent assays. Firstly, sponges were 
implanted subcutaneously in the flanks of Tc1 and WT mice and injected with VEGF 
(or PBS as a control) over 14 days; this method has been shown previously to 
encourage blood vessel growth in vivo (Andrade et al. 1987). Sponges were excised, 
fixed and sectioned for immunostaining. Endomucin-positive blood vessel density was 
quantified histologically over whole sponge sections for each genotype and it was 
found that VEGF stimulated an angiogenic response in WT but not Tc1 mice (Figure 
3.3). This result provided in vivo evidence that VEGF-stimulated responses were 
impaired in Tc1 mice. 
 
Secondly, we used an ex vivo method to examine VEGF stimulation in this model 
(Baker et al. 2012). Tc1 and WT aortic rings were embedded in collagen and fed with 
medium supplemented with either PBS or VEGF. The numbers of emerging 
microvessels were counted and results showed that, while WT rings showed a 
significant increase in sprouting upon VEGF stimulation, no significant difference was 
observed for Tc1 aortic rings after VEGF stimulation (Figure 3.4). These data 
corroborated our in vivo findings. Thirdly, we examined the effect of extra Hsa21 gene 
copies on VEGF-stimulated downstream signalling in vitro. Primary endothelial cells 
(pMLEC) were extracted and cultured from Tc1 and WT mouse lungs. Endothelial 
cells were stimulated with VEGF, or PBS as a control, lysed and proteins were 
analysed by Western blotting. Results showed that VEGF-stimulated ERK 
phosphorylation was increased in WT but not Tc1 pMLEC, suggesting that signalling 
downstream of VEGF is impaired by the presence of additional Hsa21 gene copies 
(Figure 3.5).  
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Figure 3.3 VEGF-induced neoangiogenesis is impaired in Tc1 mice. 
A: Sponges were implanted subcutaneously in the flanks of WT and Tc1 mice and injected either with 
PBS or VEGF every 2 days for 14 days. Sponges were fixed, sectioned and immunostained for 
endomucin. Blood vessel density was quantified across whole sponge sections and shown as number of 
vessels per mm2 of sponge. VEGF-induced angiogenesis is impaired significantly in Tc1 mice. Bars 
show mean ±SEM. n = 20 mice per group and two independent experiments. B: Representative images 
of endomucin-positive blood vessels in VEGF-treated sponge implant sections in WT and Tc1 mice. 
Scale bar = 100 µm. ** P < 0.01 * P < 0.05. NSD = not statistically different. 
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Figure 3.4 VEGF-stimulated microvessel outgrowth is reduced in Tc1 aortic rings.  
A: VEGF treatment did not induce a significant increase in microvessel sprout numbers from collagen-
embedded Tc1 aortic rings. Bars represent mean numbers of microvessel sprouts per aortic ring after 9 
days of culture ±SEM. B: Representative images of VEGF-treated FITC-BS1 lectin stained aortic rings 
(aortic vessel wall indicated by black asterisks). Arrows: microvessel sprouts. Scale bar = 200 µm. ** P 
< 0.05. NSD = not statistically different. 
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Figure 3.5 Tc1 pMLEC show no increase in ERK phosphorylation upon VEGF treatment.  
A: Quantification of Western blot analysis for phospho-ERK1/2 (pp44/pp42) and total ERK (p44/p42). 
WT and Tc1 pMLEC were cultured to 80% confluence, starved in OptiMEM® and treated with PBS or 
30 ng/ml VEGF for 5 minutes before lysis in RIPA buffer. Data represent averages of three independent 
experiments. P-ERK (pp44) levels shown relative to total ERK. Bars show mean relative densitometric 
readings ±SEM. B: Representative Western blot shows that VEGF-stimulated endothelial cells from Tc1 
mice do not exhibit an increased ERK1/2 phosphorylation response. * P < 0.05 
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3.1.4 Surface levels of VEGFR2 are higher in Tc1 endothelial cells 
To investigate the reason for the defect in VEGF-induced downstream signalling, 
surface levels of VEGFR2 on Tc1 and WT primary endothelial cells were assessed by 
flow cytometry following VEGF stimulation for 0, 5, 15 and 30 minutes. We 
hypothesised that reduced VEGF-stimulated responses may correlate with decreased 
VEGFR2 expression. Total VEGFR2 protein levels were also analysed by L. Reynolds 
and no significant difference was found between the genotypes (Reynolds et al. 2010). 
Surprisingly, we found that surface receptor levels were significantly higher in Tc1 
cells at all timepoints (Figure 3.6 A). Surface VEGF receptor data is presented here as 
mean fluorescence measured in the different cell types over time, rather than relative 
fluorescence normalised to time zero (no VEGF stimulation), because the latter 
method would obscure the differences between the genotypes. While the relative 
surface receptor levels appear similar over time, these data show that surface levels are 
consistently higher in Tc1 cells, despite no difference in total VEGFR2 protein levels 
(Reynolds et al. 2010, Supplementary information). The aberrant subcellular 
localisation of VEGFR2 was not observed in all cells, likely due to mosaicism for the 
Hsa21 fragment within populations of Tc1 cells isolated and grown in culture. 
 
Recent work has described that VEGF signalling is prolonged by the internalisation of 
phosphorylated VEGFR2. WT and Tc1 pMLEC were stimulated with VEGF for 5 
minutes before fixation and incubation with anti-VEGFR2 antibody. It was observed 
that upon VEGF stimulation VEGFR2 was internalised as expected in WT cells, but 
the receptor appeared to accumulate at the cell surface rather than in the cytoplasm in 
many Tc1 cells (Figure 3.6 B). This suggested that the presence of additional Hsa21 
genes could block the internalisation of VEGFR2 and that this correlates with reduced 
VEGF-induced signalling. 
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Figure 3.6 Surface levels of VEGFR2 are consistently higher in Tc1 pMLEC than in WT.  
A: Tc1 and WT pMLEC were stimulated with VEGF for 5, 10 and 30 minutes, rinsed with ice-cold PBS 
to prevent receptor internalisation and labelled with anti-VEGFR2 antibody following an acid rinse to 
dissociate growth factors from receptors. Surface antibody binding was analysed by flow cytometry. 
Geomean values showed that Tc1 cells had significantly higher surface VEGFR2 at all timepoints. 
Graph shows mean expression levels ±SEM. B: Cultured pMLEC, separate from those used in the 
experiment depicted in A, were treated with VEGF for 5 minutes before fixation. They were then 
incubated with anti-phospho-VEGFR2 antibody (green) and imaged using a confocal microscope 
(nuclei stained blue with DAPI). Arrowheads: internalised VEGFR2. Arrows: VEGFR2 at the cell 
membrane. Scale = 5 µm. * P = 0.0009-0.06. 
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3.1.5 Endothelial-specific and angiogenesis-regulating Hsa21 candidate 
genes 
We wished to discover which genes on Hsa21 contribute to the tumour-repressing 
phenotype of DS. To this end we employed bioinformatic techniques to identify 
candidate genes to investigate further in silico, in vitro and in vivo. In collaboration 
with the Bicknell lab (University of Birmingham) endothelial-specific or -enriched 
genes on the Tc1 Hsa21 fragment were identified in silico (the full gene list is 
presented in Appendix 7.2). Five genes were chosen for further study as listed below. 
Erg (v-ets avian erythroblastosis virus E26 oncogene related) is an endothelial cell-
specific ETS-family transcription factor involved in angiogenesis and endothelial cell 
survival via its transactivation of the VE-Cadherin promoter (Birdsey et al. 2008). 
Ets2 (v-ets avian erythroblastosis virus E26 oncogene homolog 2) is a transcription 
factor shown to be involved in tumorigenesis and the reduction of tumour incidence in 
the Ts65Dn/APCMin mouse model of DS and other models (Sussan et al. 2008, 
Wolvetang et al. 2003). Ets2 has not previously been implicated in angiogenesis. 
Pttg1ip (pituitary tumour-transforming 1 interacting protein) is a transcription factor 
that facilitates transcription of bFGF. It was identified as highly endothelial cell-
enriched in the EST results. Pttg1ip is a designated proto-oncogene in breast and 
thyroid cancer but not previously implicated in angiogenesis (Chien and Pei 2000, 
Read et al. 2011). Jam-b is an endothelial cell-specific tight junction adhesion 
molecule present in tight junctions, also described in section 1.8.2 (Aurrand-Lions 
Michel et al. 2001). Adamts1 is a disintegrin and metalloproteinase with 
thrombospondin motifs. It is known to inhibit angiogenesis via binding to VEGF165 
(Lee et al. 2006, Liu et al. 2006, Luque et al. 2003). It has also been shown to inhibit 
tumour growth and expression is often downregulated in breast, pancreas and liver 
cancer (Liu et al. 2006, Porter et al. 2005). 
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3.1.6 Knockdown of endothelial cell-specific and angiogenesis-
modulating candidate genes can rescue the Tc1 phenotype. 
Since the Tc1 model possessed both the human Hsa21 fragment and mouse 
chromosomes orthologous to Hsa21 (Mmu10, 16 and 17) we had the opportunity to 
use species-specific siRNA to deplete either the human or mouse candidate genes and 
test the effect of reducing gene dosage from 3 to 2 and from 3 to 1. To assess gene 
dosage effects of the extra gene copies present on the Hsa21 fragment in Tc1 mice, we 
knocked down the human transcripts of each of the genes described in 3.5 in Tc1 aortic 
rings, effectively reducing the copy number from 3 to 2. Knockdown of candidate 
genes in cultured primary endothelial cells was confirmed by RT-PCR by A. Watson 
and L. Reynolds and is shown in the figures here. Knockdown of all genes except for 
Ets2 in Tc1 aortic rings reversed the VEGF-stimulated microvessel-sprouting defect in 
aortic ring assays suggesting that vascular Ets2 is not involved in the Tc1 impaired 
microvessel-sprouting phenotype (Figure 3.7). To examine further the dosage effects 
of these genes, Tc1 aortic rings were transfected with siRNAs designed to target 
mouse transcripts specifically, effectively reducing their copy number from 3 to 1 
(Figure 3.8). The VEGF-stimulated angiogenic defect in aortic ring assays was 
reversed when Erg, Adamts1, Jam-b and Pttg1ip were knocked down. However, 
knockdown of mouse Erg transcripts had no effect. This suggests that two copies of 
Erg are required for wild-type angiogenic responses.  
 
Taken together, these results confirm that one extra copy of the candidate genes on 
Hsa21 can provide an anti-angiogenic effect. They also show that manipulating the 
dosage of particular genes can restore defective angiogenic phenotypes to wild-type 
levels. 
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Figure 3.7 Human-specific siRNA transfection can restore the angiogenic potential of Tc1 aortic 
rings (reducing gene dosage from 3 to 2). 
A: RT-PCR analysis of mouse transcripts in WT samples treated with human-specific (Hu) siRNA for 
any one of five candidate genes: Ets2, Erg, Adamts1, Jamb or Pttg1ip. No effect on mouse (Ms) mRNA 
is seen, as expected. Actin message levels were measured as a control. B: WT aortic rings were 
transfected with scrambled (Scr) or human transcript-targeting siRNAs as indicated and treated with or 
without VEGF as indicated. No treatment (NT) rings were treated with the Oligofectamine™ 
transfection reagent alone. Microvessel sprouts were counted under phase contrast microscopy at day 7. 
C: RT-PCR analysis of human transcript levels in Tc1 samples treated with human-specific siRNA. 
Depletion of human transcripts is visible in all cases. Actin transcript levels were measured as a control. 
D: Tc1 aortic rings transfected with Scr control or with human transcript-specific siRNAs against Ets2, 
Erg, Adamts1, Jamb or Pttg1ip. n = 20-40 aortic rings per condition, 3 independent experiments. Bar 
charts show mean microvessel sprout number per aortic ring ±SEM. ** P < 0.005. NSD = not 
statistically different. A and C: data from L. Reynolds and A. Watson. 
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Figure 3.8 Mouse-specific siRNA transfection can restore the angiogenic potential of Tc1 aortic 
rings (reducing gene dosage from 3 to 1). 
A: RT-PCR analysis of mouse (Ms) transcript levels in Tc1 samples treated with mouse-specific 
siRNAs targeting Ets2, Erg, Adamts1, Jamb or Pttg1ip transcripts. Decreases in message levels were 
observed in all four cases. Performed by A. Watson and L. Reynolds. B: Tc1 aortic rings were 
transfected with scrambled (Scr) mouse-specific siRNAs as indicated. (NT) controls were treated with 
Oligofectamine™ only. Microvessel sprouts were counted under phase contrast microscopy at day 7. n 
= 20-40 aortic rings per condition, 3 independent experiments. Bar chart shows mean microvessel sprout 
number per aortic ring ±SEM. ** P < 0.005. NSD = not statistically different. 
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3.2 DISCUSSION 
Down’s syndrome is caused by trisomy of human chromosome 21 (Hsa21) and DS 
individuals are reported to have a decreased incidence of several solid tumour types, 
which suggests that the dose of Hsa21 genes may affect cancer initiation and growth. 
Here we demonstrate, using the Tc1 model of Down’s syndrome, that an extra copy of 
Hsa21 can reduce tumour angiogenesis and that this may be part of the reason why DS 
individuals are protected from many solid tumour types.  
 
This notion was first tested in mouse models by Sussan et al., who crossed mouse 
models of Down’s syndrome (Ts65Dn, Ts1Rhr and Ms1Rhr) with the APCMin mouse 
model of colorectal cancer to compare tumour incidence. The Ts65Dn and Ts1Rhr 
mice have extra copies of approximately 100 and 33 genes on Mmu16, respectively, 
whereas Ms1Rhr has only one copy of the same genes triplicated in Ts1Rhr. The 
trisomic Ts65Dn/APCMin and Ts1Rhr/APCMin mice developed fewer tumours than 
expected while monosomic Ms1Rhr/APCMin progeny developed more, confirming the 
influence of gene dosage and suggesting that Hsa21 orthologs do have an anti-tumour 
protective effect. They identified that mutation of Ets2 in a trisomy/APCMin model, 
effectively reducing its copy number from 3 to 2, could significantly increase tumour 
incidence when compared to trisomic APCMin mice with 3 functional copies of Ets2. 
This study therefore provided proof of principle that extra copies of Hsa21 genes could 
affect tumour growth (Sussan et al. 2008).  
 
However, the limitation of this report is that all mouse cells, including those in the 
tumour cell compartment, had their gene dosage altered and therefore the authors were 
not able to dissect the role of trisomy in the tumour cell compartment from the stromal 
compartment. Our studies in the Tc1 mice provide a significant advance over this 
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work, since the use of injectable tumour models lacking Hsa21 trisomy meant we 
could examine the effects of Hsa21 trisomy in the stroma alone. Our results indicate 
that aneuploidy in stromal cells directly affects pathological angiogenesis and, as a 
consequence, tumour growth. We have concluded that trisomy for Hsa21 genes in the 
tumour stroma (including vascular endothelial cells) is sufficient to repress 
pathological angiogenesis. 
 
Another study by Baek et al. tested the effect of increased Hsa21 gene dosage on 
tumour growth. They confirmed a reduction in tumour growth in Ts65Dn mice and 
focussed on the overexpression of one gene that is triplicated in the model: Dscr1. 
They went on to create Dscr1 transgenic mice with 3 copies of Dscr1 on an otherwise 
normal gene dosage background, finding a 2.4-fold increase in DSCR1 expression. 
This increase is considerably higher than the 1.5-fold increase expected for one extra 
gene copy. Tumour growth and angiogenesis were reduced in these mice as compared 
to wild-type controls with only 2 copies of Dscr1, confirming that DSCR1 has an anti-
angiogenic effect. However, when Ts65Dn Dscr1+/- were generated (mice trisomic for 
approximately 103 genes but with normal Dscr1 copy number), tumour growth and 
angiogenesis was only increased to approximately half the wild-type level when 
compared to the Ts65Dn Dscr1+/+ controls, suggesting that the remaining anti-tumour 
effect in Ts65Dn mice is mediated by genes other than Dscr1 (Baek et al. 2009). 
Furthermore, DSCR1 has been known for some time to negatively regulate VEGF 
signalling and angiogenesis via the calcineurin/NFAT signalling pathway, with the 
effect characterised extensively in 2004 by several groups (Hesser et al. 2004, Iizuka et 
al. 2004, Minami et al. 2004, Yao and Duh 2004). 
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We confirmed that tumour size was reduced in Tc1 mice, and that this correlated with 
reduced blood vessel density in Tc1 tumours. The effect was shown to be independent 
of co-option (use of pre-existing vessels by tumour cells) using a longer-term tumour 
growth experiment that showed consistently smaller Tc1 tumours over time (Reynolds 
et al. 2010). We also found that responses of Tc1 tissues to VEGF stimulation, both in 
vivo and ex vivo, were impaired. So far we have seen that this effect is limited to 
VEGF-A responses; Tc1 endothelial cells did not activate downstream MAPK 
signalling in response to VEGF, whereas signalling initiated by bFGF was comparable 
in both WT and Tc1 cells (Reynolds et al. 2010). The cause of the specific VEGF-
stimulated phenotype has not yet been confirmed, though possible contributors include 
two observed phenomena: the overexpression of ADAMTS-1, a VEGF-sequestering 
secreted fragment protein discussed further below, and the possible defective VEGF 
receptor internalisation observed in Tc1 cells. 
 
Since the Tc1 mouse does not contain an extra copy of Dscr1, our results indicate that 
Dscr1 is not the only significant player in trisomy 21-mediated repression of 
angiogenesis. Our study is also more novel in that, while Dyrk1a/Dscr1-calceneurin-
NFAT signalling has already been shown to regulate VEGF-induced angiogenesis, we 
identified several other genes that had not yet been implicated in angiogenic processes. 
We have provided a significant advance over the DSCR1 study by identifying novel 
and more therapeutically relevant angiogenesis regulators. Dscr1 is thought to be 
involved in a wide range of pathologies including Alzheimer’s disease and auto-
immune conditions (comprehensively reviewed in Harris et al. 2005), so it may not be 
a favourable choice for anti-angiogenic therapy.  
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Regarding which elements of the stroma are the main effectors of the reduced tumour 
growth in Tc1 mice, it has not been fully confirmed that the phenotype is entirely 
mediated by vascular endothelial cells. However, it was found that immune cell 
infiltration into tumours did not differ between the genotypes and no significant 
decrease in tumour size was observed when transplanting Tc1 bone marrow into wild-
type tumour-burdened mice, although Hsa21-positive cells were identified in the 
tumour stroma (Reynolds et al. 2010). Therefore neither differences in immune cell 
behaviour nor recruitment of cells from the bone marrow to the tumour vasculature are 
likely to be responsible for the Tc1 angiogenic phenotype. 
 
Of the phenotypes observed, the impaired response to VEGF stimulation was 
particularly interesting. Two explanations for this are discussed here: the increased 
expression of ADAMTS-1 (due to its presence on the Tc1 Hsa21 fragment) and the 
altered VEGFR2 trafficking phenotype observed in Tc1 endothelial cells. 
 
ADAMTS-1 has been shown previously to inhibit tumour growth and its expression is 
often downregulated in breast, pancreatic and liver cancer, but contrarily upregulated 
in aggressive metastatic disease (Liu et al. 2006, Porter et al. 2005). The full-length 
110 kDa ADAMTS-1 zymogen requires processing to become an 87 kDa active 
metalloproteinase enzyme, which binds to and cleaves ECM proteins such as versican 
and aggrecan in a Zn2+-dependent fashion (Liu et al. 2006, Luque et al. 2003, Porter et 
al. 2005). The 87kDa fragment binds to the heparin-binding domain of VEGF165 via its 
C-terminal TSP motifs, sequestering the growth factor in the ECM, thereby preventing 
VEGFR2 autophosphorylation and downstream signalling, which has been shown to 
inhibit EC proliferation (Iruela-Arispe et al. 2004, Liu et al. 2006, Luque et al. 2003, 
Porter et al. 2005, Shindo et al. 2000, Xu et al. 2006). VEGF signalling has even been 
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found to activate expression of ADAMTS-1 in a PKC-dependent manner, suggesting 
that ADAMTS-1 is important in the attenuation of angiogenic responses (Xu et al. 
2006). In support of this finding, ADAMTS-1 null mice display defective wound 
healing and overactive vascularisation (Lee et al. 2006, Shindo et al. 2000). 
Interestingly, Satgé and Bénard also examined the effects of ECM produced by 
fibroblasts trisomic for Hsa21 on the growth of the MDA-MB 431 breast cancer cell 
line and neuroblastoma cell lines (an uncommon neoplasm in DS individuals), 
compared with ECM from euploid fibroblasts. The result was a decrease in tumour cell 
growth of approximately 30% (Satgé and Bénard 2008). This suggests that the ECM 
secreted by fibroblasts with an extra copy of Hsa21 creates an unfavourable 
environment for tumour growth. Since ADAMTS-1 is a secreted component of the 
ECM and we have verified its expression at the mRNA level in Tc1 primary 
endothelial cells, its effect could be significant.  
 
Furthermore, ADAMTS-1-/+ aortic rings were found to sprout significantly more in 
response to VEGF when compared to wild-type controls (Reynolds et al. 2010). The 
anti-angiogenic potential of the 87 kDa ADAMTS-1 fragment has been reported to be 
greater than both endostatin and TSP-1 on a molar basis, which are known endogenous 
angiogenesis inhibitors (Luque et al. 2003, Porter et al. 2005, Xu et al. 2006). It is 
therefore a strong candidate for mediating some, if not the majority, of the observed 
anti-tumour effects seen in DS. Endostatin is commonly cited as a major anti-
angiogenic factor in DS with reference to a study by Sund et al., which showed that its 
overexpression in transgenic mice was sufficient to inhibit tumour growth (Sund et al. 
2005). However, endostatin is not triplicated in Tc1 mice and so cannot be solely 
responsible for the anti-tumour DS phenotype. 
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It was unexpected to find that the individual knockdown of four of the five chosen 
candidate genes (Erg, Pttg1ip, Adamts1 and Jamb) successfully restored Tc1 aortic 
ring microvessel sprouting to normal levels. Approximately 200 genes are present on 
the Tc1 Hsa21 fragment and, assuming proportional overexpression of all or most of 
those genes, it was not expected that knocking down a single candidate gene would 
fully restore Tc1 VEGF-stimulated responses. This would be more accurately 
described as “mRNA dosage”, since the reduction is via RNAi and not genetic 
ablation, but “gene dosage” is used to describe the concept more simply, since we 
could not measure the level of each mRNA in every aortic ring. Unfortunately, 
knockdown at the protein level could not be confirmed in all cases due to limited 
antibody availability and performance. However, reduced protein levels of human 
ADAMTS1, mouse JAM-B, mouse ERG, mouse PTTG1IP and mouse ADAMTS1 
were confirmed in Tc1 primary endothelial cells (Reynolds et al. 2010, Supplementary 
information). Ideally, RNA and protein levels would be assessed in siRNA-treated 
aortic rings and not only in cultured endothelial cells. 
 
The candidate genes (Erg, Ets2, Pttg1ip, Jamb and Adamts1, as introduced in 3.1.5) 
were chosen based on their known functions as well as their increased expression in 
endothelial cells. No explanation has been settled upon for the high rate of rescue 
success upon knockdown of these individual candidate genes in the Tc1 aortic ring 
assay. Ingenuity® Pathway Analysis was performed to investigate whether the current 
published knowledge base could indicate that all four gene products function in a 
common signalling pathway upstream of ERK, which could explain the similar 
restorative effects of targeting the genes individually by RNAi in aortic rings. 
Unfortunately, while some signalling functions were shared by subsets of the genes, no 
single pathway was found to involve all of them together, therefore this hypothesis was 
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incorrect. However, it may be that such links have not yet been reported and future 
studies may link these genes in a common pathway.  
 
It is possible that the ex vivo aortic ring assay is not sufficiently sensitive to reveal 
subtleties that would more accurately reflect the contributions of these different genes 
to the VEGF-insensitive Tc1 phenotype. It may be that instead of knockdown ex vivo, 
reducing gene copy numbers by genetic ablation, with other genes still over-
represented, would present the most influential candidates in tumour growth and 
angiogenesis in vivo. The effects of single gene targeting certainly were not due to 
siRNA transfection alone, since non-transfected and scrambled controls as well as Ets2 
knockdown had no effect.  
 
Considering the results presented in Figure 3.7 and the Sussan et al. study (discussed 
further in 4.1), in which loss of Ets2 is shown to increase tumour incidence in the gut, 
together, our results imply that the cancer-specific role of Ets2 is in the tumour cell 
compartment and not the stroma. In our study, targeting the human Ets2 in Tc1 aortic 
rings failed to restore the VEGF response, suggesting that Ets2 does not play a role in 
the Tc1 angiogenic phenotype. It is also possible, however, that the human Ets2 
protein is non-functional in mouse tissue, but this still suggests that Ets2 is not 
important in the repression of angiogenesis and tumour growth in the Tc1 mice. 
 
In further Tc1 experiments, we decreased dosage of one of our candidates, Jam-b, 
alone: both through the use of Jam-b heterozygous mice and a function-blocking 
antibody to assess the anti-angiogenic potential of this tight junction molecule. We 
found that targeting this protein alone, either post-translationally or through gene 
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dosage, significantly increased tumour growth and angiogenesis to levels comparable 
with the wild-type situation (Reynolds et al. 2010).   
 
Together the studies of angiogenesis and tumour growth in Down’s syndrome and the 
Tc1 mouse prove that the addition of many extra gene copies induces, as expected, a 
complex phenotype and the roles of individual genes are still being investigated. Our 
results have confirmed that the overexpression of Hsa21 genes negatively affects 
tumour growth and angiogenesis and highlighted genes not previously implicated in 
the regulation of angiogenesis. 
 
 
3.3 FUTURE PERSPECTIVE 
Work is ongoing in the laboratory to examine the regulation of VEGFR2 
internalisation in Tc1 cells. To further characterise the nature of the possible VEGFR2 
trafficking defect in Tc1 endothelial cells, flow cytometric assessment of surface 
receptor levels, confocal microscopy to observe receptor subcellular localisation and 
assessment of ERK phosphorylation may be repeated using Dynasore™ (an inhibitor 
of dynamin-dependent vesicle formation: Macia et al. 2006) in wild-type cells. If 
blocking receptor internalisation upon VEGF stimulation elicits phenotypes reflecting 
those seen in Tc1 cells, including membrane-proximate receptor aggregation and 
decreased downstream ERK phosphorylation, it would suggest that defective receptor 
internalisation may be responsible for the VEGF insensitivity in Tc1 cells. The 
vesicular recycling inhibitor Primaquine™ could also be used to block recycling of 
internalised vesicles back to the cell membrane in WT endothelial cells stimulated with 
VEGF, to examine further the effects of restricting VEGFR2 trafficking.  
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It would be ideal to be able to track the movement of the receptor during VEGF 
stimulation in real-time using fluorescent tags and timelapse microscopy. This would 
give a more accurate picture of receptor trafficking and changes to the internal receptor 
pool over time, as compared to snapshots. Additional staining of endosomal markers 
such as EEA1 would also enable further scrutiny of the internal trafficking pathways 
of VEGFR2 in Tc1 and wild-type cells. 
 
VE-Cadherin (VECAD) may also be involved in the Tc1 phenotype, considering that 
VECAD inhibits VEGFR2 internalisation through direct interaction (as shown in 
Figure 1.10), and that receptor internalisation is mainly clathrin-dependent 
(Lampugnani et al. 2006). Further immunostaining studies of VECAD in Tc1 
endothelial cells could be performed to identify differences in the VEGFR2/VECAD 
signalling complexes visually. It may be that VECAD association with activated 
VEGFR2 is increased, thus inhibiting internalisation of the receptor. Birdsey et al. 
showed that ERG (also an Hsa21 gene present in Tc1 mice) promotes VECAD 
expression (Birdsey et al. 2008). Thus, ERG overexpression in Tc1 cells may lead to 
increased VECAD levels and inhibition of VEGFR2 internalisation as described 
above. 
 
3.3.1 Hsa21 microRNAs 
One area of interest that has as yet not been explored at all is the role of Hsa21 
microRNAs (miRs) in DS phenotypes. Five miRs have been identified on the Hsa21 
fragment (Hsa-mir-99a, Hsa-let-7c, Hsa-mir-125b-2, Hsa-mir-155 and Hsa-mir-802), 
as indicated in Figure 1.14, and if these are overexpressed in Tc1 stromal cells 
(including endothelial cells), they may have a significant impact on protein levels, 
secreted factors, signalling pathways, proliferation, migration and other cell functions. 
All five miRs have been shown to be overexpressed in human DS tissue samples 
141 
 
(Kuhn et al. 2008) and have murine equivalents on Mmu16 with very high sequence 
similarity. While none have so far been shown to be endothelial-specific, not all are 
well studied. Other endothelial-specific and angiogenesis-regulating miRs have 
recently been characterised, for example Hsa-miR-126, which increases vascular 
integrity (Wang and Olson 2009). Therefore, in future studies, investigations of the 
roles of Hsa21 miRNAs in tumour angiogenic processes would be of interest. 
142 
 
 
CHAPTER 4 ELUCIDATING THE ROLE OF CLAUDIN14 IN 
ANGIOGENESIS 
 
Following the unexpected result of restoring angiogenic potential in Tc1 aortic rings 
by knocking down four different genes independently, I selected further genes from 
the Hsa21 gene list; not endothelial-specific genes, but possible players in the tumour-
repressing aspect of DS with potential roles in angiogenesis, based on their known 
functions. The genes identified in the Tc1 project were studied further by L. Reynolds. 
There are three claudin genes on Hsa21, whose protein products are cell-cell adhesion 
molecules found in tight junctions (as described in 1.8 and 1.8.4): Cldn8, Cldn17 and 
Cldn14. Of these three, the previously published data suggested Cldn14 may 
participate in the regulation of angiogenesis, and a knockout mouse model has been 
generated (Ben-Yosef et al. 2003). Preliminary RNAi experiments in Tc1 and WT 
aortic rings using siRNA pools directed against Cldn14 and other chosen genes (not 
shown) suggested that Cldn14 levels might affect the angiogenic reponse to VEGF. 
Consequently, the following results describe our study of the requirement for Cldn14 
in angiogenic processes. 
 
Cldn14 is a component of tight junctions and possible mediator of vascular 
permeability. Its potential involvement in angiogenesis is highlighted by a study that 
demonstrated it is overexpressed in microvascular endothelial cells (MVEC) grown on 
Matrigel in 2D forming tubes, compared to proliferating subconfluent monolayers 
(Glienke et al. 2000). Little other functional data have been collected for Cldn14, other 
than that overexpression led to a change in nuclear shape, decreased membrane 
protrusions, and stimulated apoptosis in human embryonic kidney (HEK) cells (Hu 
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2009, Hu Y et al. 2006). It has also been described in the regulation of kidney tubule 
permeability, as described in 1.8.4.3. 
 
4.1 RESULTS 
To test the requirement of Cldn14 in angiogenic processes in vivo, I moved from the 
Tc1/WT aortic ring siRNA method to a Cldn14 genetic ablation mouse model. 
Cldn14-heterozygous (Cldn14-het) mice were inter-crossed to produce wild-type 
(WT), Cldn14-het and Cldn-14 null progeny. No effects on Mendelian ratios or 
male:female ratios were observed in litters (Figure 4.1 A and B). Over 400 mice were 
generated and genotyped in this manner during this project, with an example result 
shown in Figure 4.1 C. RT-PCR analysis confirmed that Cldn14 transcript levels in 
Cldn14-het organs were approximately half those detected in WT mice, with 
undetectable levels in Cldn14-nulls (Figure 4.1 D). Considering the known role of 
Cldn5 in the regulation of endothelial tight junctions, we looked for evidence of Cldn5 
upregulation as a possible compensatory mechanism in the Cldn14-ablated mice. 
However, RT-PCR analysis of mRNA levels in kidney and brain showed no 
differences in Cldn5 levels between the genotypes (Figure 4.2), although there may be 
as yet unconfirmed differences in tumour blood vessel endothelial cells. 
 
4.1.1 Claudin14 depletion affects endothelial junctions and basement 
membrane organisation in B16F10 tumours 
Given that Cldn14 is a tight junction protein, we first asked whether deletion of 
Cldn14 could affect endothelial cell-cell junctions and blood vessel leakage in 
tumours. Firstly, WT, Cldn14-het and Cldn14-null mice were injected subcutaneously 
with 0.5x106 B16F10 melanoma cells. At 10 days post tumour cell inoculation the 
tumours were snap-frozen and cryosections were immunostained for the tight junction 
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adapter protein ZO-1 and for the endothelial cell marker PECAM to identify blood 
vessels. While clear, continuous junctional staining was observed for ZO-1 in sections 
from WT and Cldn14-null tumours, a more discontinuous pattern was observed 
frequently in Cldn14-het sections (Figure 4.3). This suggests that ZO-1 localisation to 
endothelial tight junctions may be affected by partial loss of Cldn14. 
 
Loss or disruption of endothelial cell-cell junctions could reasonably be associated 
with destabilisation of the blood vessels in Cldn14-heterozygous tumour blood vessels. 
Vessel destabilisation is associated with changes in the endothelial basement 
membrane. Therefore we also asked whether the basement membrane was affected by 
changes in stromal Cldn14 levels. B16F10 tumour sections were immunostained for 
laminin and the degree of “shorelining” (laminin-positive areas radiating from 
PECAM-positive vessels at varying distances) was observed. Although the pattern of 
laminin staining appeared similar in WT and Cldn14-null blood vessels, i.e. closely 
associated with the PECAM-positive endothelium in both cases, a higher degree of 
laminin “shorelining” was observed in sections from Cldn14-het tumours; the laminin 
staining often appeared to extend away from the vessels for a greater distance (Figure 
4.4). This suggested that the organisation of the laminin within the basement 
membrane may be affected by partial loss of Cldn14. Together these results indicated 
that two key features of vessel stabilisation: cell-cell junctions and basement 
membrane organisation are altered in Cldn14-het, but not Cldn14-null, tumour blood 
vessels. 
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Figure 4.1 Statistics and genotyping of Cldn14 mouse colonies  
A: The relative proportions of WT, Cldn14-heterozygous and Cldn14-null mice in litters from Cldn14-
heterozygous breeding pairs exhibit near Mendelian ratios. B: Proportions of male and female pups in 
the Cldn14 colony are approximately 50%. n = 192 pups at 8-12 weeks. C: A representative agarose gel 
with paired PCR reactions, for Cldn14 wild-type and Cldn14-null alleles. Each DNA sample is 
genotyped separately for the presence or absence of Cldn14 WT and/or Cldn14-null alleles. PCR 
reaction for WT allele (380 bp) in lanes 1, 3 and 5. PCR reaction for null allele (275 bp) in lanes 2, 4 
and 6. Wild-type (lanes 1 and 2), Cldn14-heterozygous (lanes 3 and 4) and null (lanes 5 and 6) DNA 
samples are shown. Hyperladder-1 in leftmost lane with 400 and 200 bp bands identified. D: RT-PCR 
analysis of whole mouse brain and kidney from WT, Cldn14-het and Cldn14-null mice. Cldn14 mRNA 
levels shown relative to β-actin (ACTB) controls, with approximately half as much transcript detected in 
Cldn14-het organs and undetectable levels in Cldn14-nulls. Bars show relative transcript levels ±SEM. n 
= 3 separate animals per genotype. 
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Figure 4.2 Cldn5 mRNA levels do not differ in brain or kidney between Cldn14 genotypes 
RT-PCR analysis of whole mouse brain and kidney from WT, Cldn14-het and Cldn14-null mice. Cldn5 
mRNA levels shown relative to β-actin (ACTB) controls, with approximately equal mRNA levels 
detected in WT, Cldn14-het and Cldn14-null organs. Bars show relative transcript levels ±SEM. n = 3 
separate animals per genotype. 
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Figure 4.3 ZO-1 staining appears disrupted in tumour blood vessels from Cldn14-het mice 
Sections of B16F10 tumours grown for 10 days in WT, Cldn14-het and Cldn14-null mice were 
immunostained for the tight junction adapter protein ZO-1 and the endothelial cell marker PECAM, 
with nuclei DAPI-counterstained. Junctional morphology was observed in 3 tumours from each 
genotype. A more discontinuous staining pattern was observed in Cldn14-het blood vessels, where 
vessels from WT and Cldn14-null mouse tumours more often showed continuous ZO-1 junctional 
staining; see higher power insets. Scale bars: main figure  = 50 µm, insets = 10 µm. 
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Figure 4.4 Tumour blood vessels display a greater laminin basement membrane “shoreline effect” 
in Cldn14-het mice 
Sections of B16F10 tumours grown in WT, Cldn14-het and Cldn14-null mice were immunostained for 
the basement membrane protein laminin and the endothelial cell marker PECAM, with nuclei DAPI-
counterstained. A greater “shorelining” effect of laminin deposition further away from the main vessels 
was observed in tumours from Cldn14-het mice when compared to tumours from WT and Cldn14-null 
mice. White brackets indicate range of laminin staining radiating from PECAM-positive vessels. Scale = 
50 µm. 
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4.1.2 Claudin14 levels affect tumour blood vessel leakage 
Considering the possible destabilisation of junctions and the basement membrane in 
tumour blood vessels from Cldn14-het animals, we next asked whether this would 
affect vascular permeability in tumours. Cohorts of both B16F10 and Lewis lung 
carcinoma (LLC) tumour-bearing mice of each genotype were selected to receive end-
point intravenous injections of phycoerythrin-labelled anti-PECAM (PE-PECAM) 
antibody and Hoechst dye. These injections allowed visualisation of functional tumour 
blood vessels and assessment of vessel leakage, in terms of vessel-proximate Hoechst-
positive nuclei, respectively. Once again no consistent differences in leakage were 
observed between WT and Cldn14-null mice, but a significant increase was observed 
in the Cldn14-heterozygous mice (Figure 4.5), suggesting that partial loss of Cldn14 
can enhance blood vessel leakage in B16F10 and LLC tumours. 
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Figure 4.5 Stromal Cldn14 heterozygosity increases tumour blood vessel leakage.  
A: Wild-type (WT), Cldn14-heterozygous and Cldn14-null mice were injected subcutaneously in the 
flank with 0.5x106 B16F10 melanoma or Lewis Lung Carcinoma (LLC) cells. At the experimental 
endpoint, PE-conjugated anti-PECAM antibody and Hoechst dye were injected IV in the tail vein. 100 
µm midline sections of tumours were fixed, mounted and Z-stack images taken using a Zeiss LSM 510 
confocal microscope. The extent of Hoechst leakage from PECAM-positive vessels in both tumour 
types and across the three genotypes was measured in using ImageJ. Bars show mean Hoechst intensity 
per image stack ±SEM. B: Representative flattened Z-stack images of tumour blood vessels and 
Hoechst-stained local nuclei. Scale bar = 50 µm. n = 3-4 tumours per genotype. *** P  < 0.001 
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4.1.3 Claudin14 heterozygosity decreases tumour hypoxia without 
affecting tumour size 
Changes in vascular density or leakage may affect tumour hypoxia. We next tested the 
effect of Cldn14 deletion on these parameters. Tumour-bearing WT, Cldn14-
heterozygous and Cldn14-null mice were given intravenous injections of 
pimonidazole, a marker of hypoxia (Varia et al. 1998), one hour before the 
experimental end point. Frozen tumour sections were stained with anti-pimonidazole 
antibody and anti-PECAM to observe areas of tumour hypoxia and the tumour blood 
vessels respectively. An hypoxic index was calculated by taking the inverse average 
distance from blood vessels to pimonidazole-positive areas. Although the relative 
hypoxic index was unchanged between WT and Cldn14-null mice, it was reduced 
significantly in B16F10 and LLC tumours from Cldn-14 het mice when compared to 
controls (Figure 4.6). 
 
The B16F10 and LLC tumour cells used in these assays were luciferase tagged. 
Luciferase tagged cells are detected in vivo by bioluminescence imaging following 
intraperitoneal injection of luciferin. The bioluminescence signal emitted from the 
tumour is a result of luciferase oxidation of luciferin, so the process is dependent on 
oxygen availability. Therefore bioluminescence imaging is a surrogate method for the 
measurement of tumour oxygenation. Bioluminescence was measured at 48-hour 
intervals from day 3 post-tumour cell inoculation using an IVIS scanner. In vivo 
bioluminescence readings were increased significantly in Cldn14-het mouse tumours 
when compared to tumours grown in WT mice (Figure 4.7). These results 
corroborated the hypoxia readings and suggested that partial loss of stromal Cldn14 is 
sufficient to increase oxygenation of subcutaneous tumours.  
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Interestingly, despite the bioluminescence readings, B16F10 tumour sizes were similar 
in WT, Cldn14-het and Cldn14-null mice over the course of the experiment. In 
addition, no difference in LLC tumour growth was observed between the genotypes 
either (Figure 4.8). Together the results demonstrate that the decrease in tumour 
hypoxia in Cldn14-het mice does not correlate with a change in tumour growth. 
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Figure 4.6 Stromal heterozygosity for Cldn14 decreases tumour hypoxia.  
A: Wild-type, Cldn14-heterozygous and Cldn14-null mice were injected subcutaneously in the flank 
with 0.5x106 luciferase expressing B16F10 melanoma or Lewis Lung Carcinoma (LLC) cells. At the 
experimental endpoint, pimonidazole was injected IV in the tail vein prior to sacrifice. Midline sections 
of bisected and immediately snap-frozen tumours were fixed, immunostained with an anti-pimonidazole 
antibody and PE-conjugated anti-PECAM antibody to identify blood vessels. The proximity of hypoxic 
areas to tumour blood vessels was quantified and the inverse of these values are plotted as Hypoxic 
index. Bars show mean ±SEM. B: Representative images of pimonidazole-positive tumour areas (rare in 
tumours from heterozygous mice). n = 3 - 5 mice per genotype. Scale bar = 200 µm. * p < 0.05 ** p < 
0.01 *** p < 0.001. 
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Figure 4.7 Tumours grown in Cldn14-Heterozygous mice have increased bioluminescence signal. 
A: Luciferase-expressing B16F10 melanoma or B: Lewis Lung Carcinoma (LLC) cells were injected 
subcutaneously into wild-type and Cldn14-heterozygous mice and luminescence signal monitored on 
live mice over time. Images were taken using a VivoVision® IVIS® scanner (Xenogen) scanner and 
were quantified using Living Image V3.2 to obtain Average Radiance values. X-axis shows days post-
tumour cell inoculation: injection on day 0 and measurements from day 3; day 0 plotted as zero though 
no measurement was taken. C: Representative bioluminescence images of WT and Cldn14-het mice 
from days 3, 5, 7 and 10 after B16F10 injection and 12 after LLC injection. Bioluminescence readings 
are shown as average radiance (photons/second/cm2/steradian ×105) and the colour scale is shown. n = 
5-8 mice per genotype. * P < 0.05 
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Figure 4.8 Stromal Cldn14 levels have no effect on subcutaneous tumour growth. 
A: B16F10 melanoma or B: Lewis Lung Carcinoma (LLC) cells were injected subcutaneously into the 
flank of wild-type, Cldn14-heterozygous (Cldn14-Het) and Cldn14-null mice. Calliper measurements 
were taken every two days. No difference in tumour growth was observed between the genotypes in 
either tumour cell line. Mean tumour volume is plotted for each time point, error bars ±SEM. C: 
Representative images of tumours from each genotype. n = 12-18 tumours per genotype. NSD = not 
statistically different. 
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4.1.4 Claudin14 heterozygosity affects the proportion of lumenated 
tumour blood vessels  
Since Cldn14 deficiency did not appear to affect tumour size, but tumour hypoxia 
appeared to be altered, we next sought to examine the blood vessels within these 
tumours. Tumour blood vessels are dynamic structures that go through phases of 
lumen formation when they are likely to be functional. Lumenated and non-lumenated 
blood vessel numbers were counted across whole midline tumour sections and results 
are shown in Figure 4.9 B as percentage of non-lumenated (or less likely to be 
functional) blood vessels. However, when lumenated (more likely to be functional) 
vessels per mm2 of tumour section is analysed, no significant difference in vessel 
density is seen between any of the genotypes in either B16F10 or LLC tumours 
(Figure 4.9 C).  
 
In contrast, when both lumenated and non-lumenated vessels were counted together, 
the total number of blood vessels was found to be elevated in B16F10 tumours grown 
in Cldn14-het mice (Figure 4.10 A), but was unchanged in LLC tumours (Figure 4.10 
B, C). To examine the effect of Cldn14 depletion on blood vessel density in non-
tumour tissue, we next counted blood vessel density in unchallenged skin from WT, 
Cldn14-het and Cldn14-null. Results showed that there were no significant differences 
in vascular density in the skin between the genotypes (Figure 4.10 C). 
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Figure 4.9 More non-lumenated vessels are present in Cldn14-heterozygous tumour sections. 
Wild-type, Cldn14-heterozygous and Cldn14-null mice were injected subcutaneously with 0.5x106 
B16F10 melanoma or Lewis Lung Carcinoma (LLC) cells. Tumour sections were immunostained for 
blood vessels using anti-endomucin antibody. A: Representative images of endomucin positive blood 
vessels in B16F10 and LLC tumours growth in WT, Cldn14-het and Cldn14-null mice. Arrows: 
lumenated vessels. Arrowheads: non-lumenated vessels. Scale bar = 50 µm B: Lumenated and non-
lumenated vessels were counted across entire midline sections. Bars show percentages of non-lumenated 
vessels C: Total numbers of lumenated vessels were normalised to tumour area. * P < 0.05. NSD = not 
statistically different. 
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Figure 4.10 Cldn14 heterozygosity increases the total number of blood vessels in B16F10 tumours 
but does not affect blood vessel density in unchallenged skin   
A: B16F10 and B: LLC tumour sections were analysed for total blood vessel density; i.e. both 
lumenated and non-lumenated endomucin-positive structures, as indicated in Figure 3.17. Bars show 
mean numbers of blood vessels across entire midline sections per mm2 of tumour section ±SEM. C: 
Blood vessel density was quantified in WT, Cldn14-het and Cldn14-null skin sections taken from non-
tumour burdened mice. Bars represent mean ±SEM. n = 3 mice per genotype. * P < 0.05  ** P < 0.01. 
NSD = not statistically different. 
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4.1.5 Supporting cell association is affected by partial loss of Claudin14 
Blood vessel functionality is partially dependent on the association of supporting cells 
or pericytes. To assess the degree of pericyte association with B16F10 or LLC vessels 
from WT, Cldn14-het and Cldn14-null mice, tumour sections were double-stained for 
the pericyte marker αSMA (expressed by a subset of supporting cells (Bondjers et al. 
2003, Hall 2006)) and the endothelial cell marker endomucin. The proportion of 
endomucin-positive blood vessels showing αSMA-positive cell association was 
counted. Results showed that the percentage of blood vessels with αSMA-positive 
cells associated was unchanged between WT and Cldn14-null mice but reduced 
significantly in both B16F10 and LLC tumour types when grown in Cldn14-het mice 
(Figure 4.11). These data suggest that heterozygous, but not homozygous, deletion of 
Cldn14 may be sufficient to affect blood vessel stability. 
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Figure 4.11 Supporting cell association with tumour vessels is decreased in tumour blood vessels 
of Cldn14-heterozygous mice.   
A: Wild-type, Cldn14-heterozygous and Cldn14-null mice were injected subcutaneously with 0.5x106 
luciferase expressing B16F10 melanoma or Lewis Lung Carcinoma (LLC) cells. Tumour sections were 
immunostained with anti-endomucin and αSMA antibodies to visualise endothelial cells and supporting 
cells. The percentage of αSMA+ vessels was quantified across ≥5 fields per section. Bars show means 
±SEM. B: Representative images of sections from each tumour type. Arrowheads: blood vessels with 
associated αSMA+ supporting cells. Arrows: blood vessels lacking association of αSMA+ cells. n = 7-
22 tumours per genotype. Scale bar = 50 µm.  * p < 0.05 ** p < 0.01. 
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4.1.6 Claudin14 heterozygosity increases endothelial cell proliferation in 
vivo, ex vivo and in vitro  
To test whether the increase in tumour blood vessel density in Cldn14-het mice 
correlated with a change in endothelial proliferation, tumour sections from WT, 
Cldn14-het and Cln14-null mice were stained for the proliferation marker Ki67. A 
significant increase in numbers of proliferating endothelial cells was found in tumours 
grown in Cldn14-het mice but no differences between WT and Cldn14-nulls were 
observed. No significant changes in cellular proliferation were observed in the tumour 
cell compartment (Figure 4.12). 
 
To examine further the effect of Cldn14 heterozygosity on growth factor-specific 
angiogenic responses ex vivo, the aortic ring assay was employed (Baker et al. 2012). 
WT, Cldn14-het and Cldn14-null aortic rings were embedded in collagen and treated 
with either PBS or VEGF. In the absence of VEGF, microvessel sprouting was barely 
detectable and unchanged between the genotypes. The level of VEGF-stimulated 
microvessel sprouting in WT and Cldn14-null aortic ring cultures was similar. In 
contrast, VEGF-stimulated aortic ring sprouting was enhanced significantly in Cldn14-
het aortic rings when compared with WT and Cldn14-nulls (Figure 4.13 A, C). In 
addition, the resulting mean sprout length was enhanced in Cldn14-het aortic rings 
(Figure 4.13 B, C). 
 
Similar to my findings in vivo, endothelial cell proliferation in ex vivo aortic ring 
assays, as indicated by EdU incorporation into cellular DNA, was also found to be 
elevated in Cldn14-het aortic ring BS1 lectin-positive microvessel sprouts when 
compared with WT and Cldn14-null aortic rings (Figure 4.14). Furthermore, cells 
isolated and cultured from WT, Cldn14-het and Cdn14-null mice were tested for their 
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proliferative capacity with and without VEGF stimulation, using EdU incorporation as 
a marker. EdU incorporation was unchanged between WT and Cldn14-null endothelial 
cells but increased in Cldn14-het endothelial cells when compared to controls (Figure 
4.15).  
 
Changes in angiogenesis may relate not only to altered proliferation but also to 
changes in endothelial cell migration. To examine this, pMLEC were plated on Dunn 
chamber slides in a VEGF gradient and were observed over 16 hours to record their 
VEGF-stimulated migratory capabilities. Analysis of cell tracks revealed a small but 
statistically significant decrease in the speed and persistence of cell movement in 
Cldn14-null cells compared to both WT and Cldn14-het cells, though we speculate that 
this very small difference is unlikely to be biologically significant (Figure 4.16). 
Interestingly, careful observations of the cell migration movies revealed that Cldn14-
het cells divided at a higher rate than WT or Cldn14-null endothelial cells, but no 
significant differences in the numbers of apparent cell deaths were observed (Figure 
4.17). 
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Figure 4.12 Tumour endothelial cells proliferate more in Cldn14-het B1610 tumours. 
A: Quantification of Ki67-positive cells in frozen B16F10 tumour sections. Nuclei stained with DAPI 
appearing in PECAM-positive blood vessels were counted and the percentage of Ki67-positive cells 
recorded. The percentage of Ki67-positive cells not associated with PECAM-positivity was also 
counted. Bars represent mean numbers of EdU-positive nuclei ±SEM. B: Representative images of 
tumour sections stained with anti-Ki67 and PE-PECAM with tumour cell nuclei displayed in upper 
panels and PECAM-positive blood vessels in lower panels. Arrowheads = Ki67-positive endothelial cell 
nuclei. Scale bars = 50 µm. n = 3-4 tumours per genotype. ** P < 0.01. 
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Figure 4.13 Heterozygosity for Cldn14 increases VEGF-induced microvessel numbers and length. 
A: Quantification of microvessel sprout number from wild-type, Cldn14-heterozygous and Cldn14-null 
aortic rings embedded in collagen and cultured for 9 days. Rings were treated with either 30 ng/ml 
VEGF or PBS as a control. B: Quantification of microvessel sprout length in VEGF-treated rings using 
the ImageJ line tool on scaled images. Bars show mean ±SEM. C: Representative greyscale images of 
BS1 lectin-stained aortic rings from wild-type, Cldn14-heterozygous and Cldn14-null mice embedded in 
collagen and treated with 30 ng ml-1 VEGF every 3-4 days, then fixed and stained on day 9. Arrows: 
endothelial microvessels. Scale bar = 500 µm. n = 4-24 rings per condition. * P < 0.05. ** P < 0.01. *** 
P < 0.001. 
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Figure 4.14 Cldn14 gene copy number affects endothelial cell proliferation in ex vivo aortic ring 
assays. 
A: Proliferating endothelial cells in wild-type, Cldn14-heterozygous and Cldn14-null collagen-
embedded aortic explants were highlighted by EdU incorporation into the DNA on day 9 post-
explantation. The proportion of proliferating (EdU-positive) endothelial cells (BS1 lectin-positive) was 
counted. Bars show mean ±SEM. n = 6-8 rings per genotype, 513-717 nuclei per genotype. B: 
Representative images of WT, Cldn14-het and Cldn14-null aortic ring sprouts stained with TRITC-BS1 
lectin (red) and DAPI (blue), with nuclei containing EdU in green (Arrows). Scale bar = 50 µm. *** P < 
0.001. NSD = not statistically different. 
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Figure 4.15 Cldn14 heterozygous cells proliferate more in response to VEGF stimulation  
A: Primary endothelial cells purified from Cldn14 WT, het and null mouse lungs cultured and treated 
with EdU for 1.5 hours before fixation in the presence of 30 ng ml-1 VEGF. The number of EdU-
positive cells was quantified and % proliferating cells for each genotype is shown. Bars represent mean 
±SEM. n = 1217-3464 nuclei per genotype, 3 mice per genotype. B: Representative images of EdU-
positive cells visualised using the ClickIT® cell proliferation assay kit (Invitrogen) and counterstained 
with DAPI (blue). Arrows indicate EdU-positive nuclei. Scale bar = 50 µm. *** P < 0.001. 
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Figure 4.16 Cldn14 gene copy number can affect primary endothelial cell behaviour in 2D culture.  
A: Primary endothelial cells were cultured from wild-type, Cldn14-heterozygous and Cldn14-null 
mouse lungs. Cells were plated on coverslips and inverted over Dunn chamber slides filled with serum-
free growth medium and medium containing 100 ng ml-1 VEGF to stimulate cell movement. Cells were 
photographed at 10-minute intervals over 16 hours to create movie files for cell tracking with Andor 
software and analysis using Mathematica software. Spider plots represent raw cell tracking data with all 
cell start positions normalised to a single point of origin. B: Speed of cellular movement. C: Persistence 
of cell movement (tendency of cells to move in a particular direction without diversion). Bars show 
mean ±SEM. n = 12-20 fields per genotype, 280-348 cells per genotype, 2 independent experiments. * P 
< 0.05. ** P < 0.01. NSD = not statistically different. 
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Figure 4.17 Cldn14-heterozygous cells in culture divide more frequently with no effect on cell 
death. 
Primary endothelial cells were cultured from wild-type, Cldn14-heterozygous and Cldn14-null mouse 
lungs. Cells were plated on coverslips and inverted over Dunn chamber slides filled with serum-free 
growth medium and medium containing 100 ng ml-1 VEGF to stimulate cell movement. Cells were 
photographed at 10-minute intervals over 16 hours to create movie files. The total number of cells in 
each movie field was counted and the percentage of cell divisions and deaths were plotted as a 
percentage of the total cells observed. Bars show mean ±SEM. n = 12-20 fields per genotype, 280-348 
cells per genotype, 2 independent experiments. * P < 0.05 ** P < 0.01. NSD = not statistically different. 
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4.1.7 Transient depletion of Cldn14 mimics Cldn14-heterozygous 
angiogenic phenotypes 
In addition to observing the effect of manipulation of Cldn14 gene copy number on 
angiogenic responses, temporary gene knockdown was also tested using RNAi. Wild-
type aortic rings were transfected using Oligofectamine™ with the mouse Cldn14-
targeting siRNA pool (Dharmacon) or scrambled non-targeting control siRNA. The 
degree of Cldn14 depletion was confirmed to be approximately 50% in each case 
(though levels are likely to vary cell by cell) by Western blot analysis, suggesting that 
the RNAi results may correlate with those from Cldn14-heterozygous aortic rings and 
primary cells (Figure 4.18). siRNA-treated rings were embedded in collagen and given 
VEGF to stimulate microvessel outgrowth, which was quantified after 9 days of 
culture. In the absence of VEGF there was no significant difference in microvessel 
outgrowth between scrambled or Cldn14 siRNA-treated aortic rings. VEGF 
significantly enhanced microvessel sprouting in scrambled siRNA-transfected rings. 
Moreover, a significant increase in VEGF-induced microvessel sprouting was 
observed in Cldn14-depleted rings compared to those transfected with scrambled 
control siRNA (Figure 4.19 A). Microvessel length, as in Cldn14-heterozygous 
explants, was also found to be significantly greater in Cldn14 siRNA-transfected rings 
(Figure 4.19 B).  
 
In addition, proliferation assays performed on scrambled and Cldn14 siRNA-treated 
aortic ring cultures revealed an increase in the number of proliferating cells upon 
Cldn14 knockdown (Figure 4.20). To further validate our previous results, primary 
endothelial cells cultured from mouse lungs were also transfected with siRNAs against 
Cldn14 and examined for proliferation and apoptotic profiles using EdU incorporation 
and TUNEL expression respectively. Cldn14-depletion induced an increase in cellular 
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proliferation when compared with Scr siRNA-transfected controls even in the absence 
of VEGF. VEGF stimulation induced an increase in proliferation of Scr siRNA treated 
cells and this was further enhanced in Cldn14 siRNA-transfected cells (Figure 4.21). 
In contrast, no effect on apoptosis was observed (Figure 4.22). 
 
Together these results reveal a novel role for Claudin 14 in regulating endothelial cell 
and microvessel behaviours in vitro, ex vivo and in vivo and suggest that partial loss of 
Cldn14 in the stroma can enhance some angiogenic responses. 
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Figure 4.18 Cldn14 levels were reduced by approximately 50% 72 hours post-transfection. 
A: Thoracic aortae were dissected from wild-type mice and transfected with either scrambled control 
(Scr) or Cldn14-specific siRNA during overnight serum starvation. Protein was extracted from rings 48 
hours later (72 hours post-transfection) according to Baker et al. 2012 and lysates run on gradient 
acrylamide gels. Cldn14 band intensity was quantified for six separate transfections (three with Scr and 
three with Cldn14 siRNA) and normalised to Hsc70 control band intensity. Cldn14 levels appeared to be 
reduced by approximately 50% in all cases. B: Western blot used for densitometry showing Cldn14 
bands and Hsc70 as loading control.  
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Figure 4.19 Knockdown of Cldn14 in wild-type aortic rings embedded in collagen increases 
microvessel sprout number and length. 
A: Quantification of microvessel sprout number in PBS and VEGF-treated wild-type aortic rings 
transfected either with scrambled control (Scr) or Cldn14 specific siRNA pools. B: Average microvessel 
length in VEGF-treated aortic rings transfected with Scr or Cldn14 siRNA and cultured for 9 days. Bars 
represent mean numbers of sprouts per ring ±SEM. C: Representative images of VEGF-stimulated 
microvessel sprouting after knockdown using Scr or Cldn14 siRNA. BS1 Lectin-FITC stained rings at 
low (greyscale) and high power (colour). Scale bars are labelled for each pair of images. n = 14-54 rings 
per condition, 3 independent experiments. * P < 0.05 ** P < 0.01 *** P < 0.001. 
 
 
173 
 
 
 
 
 
Figure 4.20 Knockdown of Cldn14 in wild-type mixed background aortic rings increases 
endothelial cell proliferation. 
A: Quantification of proliferating endothelial cells in wild-type aortic ring explants treated with 
Scrambled (Scr) control or Cldn14 siRNA and EdU prior to fixation. Endothelial cells were then 
labelled with TRITC-conjugated BS1 lectin. Results are presented as the percentage of endothelial 
nuclei positive for EdU in microvessel sprouts. Bars show mean ±SEM. B: Representative images of 
EdU-treated Scr and Cldn14-transfected ring sprouts.  n = 6-8 rings per genotype. * P < 0.05. 
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Figure 4.21 Knockdown of Cldn14 increases primary endothelial cell proliferation in 2D culture.  
A: Primary endothelial cells were cultured from wild-type mouse lungs and treated with scrambled or 
Cldn14 siRNA. Prior to fixation, endothelial cell medium was replaced with EdU-supplemented 
medium either containing 30 ng ml-1 VEGF or PBS as a control and cells incubated for two hours. EdU 
detection was performed and the percentage of EdU-positive DAPI-stained nuclei quantified. Bars 
represent mean ±SEM. n = 3 separate cell populations per condition. B: Representative images of 
primary endothelial cells treated with Scr or Cldn14 siRNA. EdU-positive nuclei highlighted by arrows. 
* P < 0.05. *** P < 0.01. 
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Figure 4.22 Cldn14 knockdown has no effect on pMLEC apoptosis in 2D culture. 
A: Primary endothelial cells were cultured from wild-type mouse lungs and treated with scrambled (Scr) 
or Cldn14 siRNA and stimulated with PBS or VEGF. Cells were fixed and stained using the ClickIT® 
TUNEL Apoptosis detection kit (Invitrogen) and nuclei dyed with DAPI. Bars represent mean ±SEM. n 
= 3 separate cell populations per condition.  B: Representative images of TUNEL-positive and negative 
Scr and Cldn14 siRNA-transfected cells stimulated with VEGF. Scale = 50 µm. NSD = not statistically 
different. 
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4.2  DISCUSSION 
The Claudin family of proteins are not yet fully characterised and their study is a 
relatively nascent field with many open questions. Their role in cell adhesion as 
components of tight junctions is established, but there may be other Claudin functions 
that are still to be defined. This study implicates Claudin14 in endothelial cell 
functions and angiogenesis in vivo, which has not been shown previously. 
 
There are three CLDN genes present on the Hsa21 fragment in Tc1 mice, whose 
protein products are components of cell-cell tight junctions (as detailed in 1.8.4): 
CLDN8, CLDN14 and CLDN17. Cldn8 is thought to be involved in kidney nephron 
permeability (Li et al. 2004). Little is known about Cldn17, but a recent study 
suggested it might regulate paracellular uptake of anions in kidney nephrons (Krug et 
al. 2012). Cldn14 also is not well-studied but mutation of the gene is known to cause 
human non-syndromic autosomal recessive deafness (Arican et al. 2005, Bashir et al. 
2010, Belguith et al. 2009, Lee et al. 2012, Nunes et al. 2006, Uyguner et al. 2003, 
Wilcox et al. 2001). This human phenotype is recapitulated in the Cldn14-null mouse, 
which is also deaf (Ben-Yosef et al. 2003). Cldn14 has also been implicated in kidney 
functions (Gong et al. 2012, Kirk et al. 2010, Thorleifsson et al. 2009). In vitro, 
Cldn14 was found to elicit a change in nuclear shape and decreased cell membrane 
protrusions, in addition to increasing apoptosis, when overexpressed in human 
embryonic kidney cells, while Cldn17 had no effect (Hu et al. 2006, Hu et al. 2010). 
With respect to angiogenesis, so far only one study has presented evidence for a role 
for Cldn14. Glienke et al. detected higher levels of Cldn14 transcript in endothelial 
cells cultured on Matrigel with a more differentiated (tubular) phenotype, compared to 
proliferating subconfluent monolayers (Glienke et al. 2000). 
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These data and preliminary experiments, together with the results of altering JAM-B 
gene dosage and blocking its function, informed the decision to study Cldn14, another 
tight junction protein, and its potential angiogenic roles. Additionally, one study 
pointed out that while Cldn5 is endothelial “specific”, its function might not be 
particularly influential outside of the BBB, the situation in which it has been most 
thoroughly characterised (Fontijn et al. 2006). However, some data suggest otherwise, 
reporting Cldn5 expression in certain epithelia (Escudero-Esparza et al. 2012) and 
immune cells, as discussed further below (4.2.2). The study investigated barrier 
properties of primary vascular endothelial cell layers both over- and under-expressing 
Cldn5 in vitro, finding that barrier function was enhanced with Cldn5 overexpression 
(but unaffected by silencing) but no effects on immune cell transmigration were found. 
In addition, that the Cldn5-/- mouse only displays vascular defects in terms of a size-
selective loosening of the BBB also suggests that junctions in other endothelial barriers 
may rely on other claudin family members (Nitta et al. 2003). These results suggest 
that other proteins, likely other Cldn family members, can regulate endothelial barrier 
functions in non-BBB endothelial cell layers. Nitta et al. confirmed the expression of 
Cldn12 in brain endothelial cells, for example. The limited data available for Cldn14 
function in endothelial cells and angiogenesis presented it as a favourable candidate to 
study in this context. 
 
Cldn14 has previously been found to be upregulated in endothelial cells arranged in 
organised tubular structures in vitro when compared to cells in 2D culture (Glienke et 
al. 2000). This result is expected since tight junctions are cell-cell contacts. Here I 
have presented findings from the manipulation of Cldn14 gene dosage in vivo, ex vivo 
and in vitro, showing that Claudin14 heterozygosity can influence angiogenic 
processes. 
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I have found that reduction of Cldn14 gene copy number from 2 to 1 affects the 
localisation of the TJ plaque protein ZO1 to endothelial junctions, destabilises the 
tumour blood vessel basement membrane, increases small molecule leakage from 
tumour blood vessels, increases tumour oxygenation, decreases the proportion of 
lumenated blood vessels within tumours, decreases pericyte association with tumour 
blood vessels, and increases endothelial cell proliferation. Together my results have 
clearly demonstrated that Claudin14 gene dosage can affect angiogenesis, altering the 
barrier properties of vascular endothelia in tumours, and interestingly, without 
affecting tumour growth. 
 
Relatively few high-quality reagents are available for Claudin proteins, since their 
antigenicity is reported to be low (Saeki et al. 2010). The lack of a reliable antibody 
against Claudin14 in this study was a major limitation; a very small aliquot of antibody 
developed by T. Ben-Yosef and colleagues was kindly provided early in the study, but 
was insufficient to carry out all assessments of protein levels that were planned. 
Commercially-available antibodies could not be optimised for Western blotting or 
immunofluorescence, meaning protein levels could not be confirmed in the genetic 
models, or in all RNAi experiments, which would have been ideal.  
 
We confirmed that Cldn14 message levels were decreased in proportion with the gene 
dosage. Approximately 50% reduction in Cldn14 mRNA was found in Cldn14-
heterozygous kidney and brain, compared to wild-type samples, and transcript was 
undetectable in Cldn14-null samples. Unfortunately this was not confirmed at the 
protein level, which would ideally be examined in vivo, as mentioned above. Thus, we 
have assumed that approximately half the protein product is present in the Cldn14-
heterozygous mice. Optimisation of the RTPCR detection protocol was achieved only 
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at the very end of the project so could not be shown for all experiments carried out 
previously, though RNA was extracted each time for this purpose. Analysis of Cldn14 
levels in primary endothelial cells of each genotype was planned but could not be 
performed due to restrictions on time, mouse availability and primary endothelial cell 
culture. 
 
A diagram depicting the major results of this Claudin14 study, along with previously 
established phenomena relevant to these results, is presented on the following page 
(Figure 4.23). Questions arising from these observations are detailed and discussed 
below.
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Figure 4.23 Possible influences of claudin14 in angiogenic processes and open questions 
Schematic showing some results of the Cldn14 studies presented in this thesis (purple arrows), in 
context with published data (black arrows) and questions arising (dotted black arrows). (1) We found 
that decreasing Cldn14 gene dosage altered ZO-1 localisation at endothelial junctions in vivo, which 
may contribute to the observed increase in vessel leakage. (2) The basement membrane of tumour blood 
vessels in Cldn14-het tumours was altered; is this a direct effect of Cldn14, and could this indirectly 
affect pericyte coverage? (3) Hypoxia has been reported to decrease expression of occludin and claudins 
1, 3 and 5 (Koto et al. 2007). Conversely, hypoxia was decreased in tumours from Cldn14-het mice, so 
could similar “reverse mechanisms” operate for other parameters? (4) Pericytes have been shown to 
affect Cldn5 expression in the BBB via the secretion of glial cell line-derived neurotrophic factor 
(GDNF) (Shimizu et al. 2012). Since pericyte association was decreased in Cldn14-het tumour blood 
vessels, is Cldn14 directly affecting the recruitment of pericytes? (5) Findings presented in this thesis 
have also shown that Cldn14 can regulate endothelial cell proliferation, possibly stimulating cell cycle 
progression from G1 to S phase. (6) Cldn5 expression is known to be upregulated by VECAD (Taddei et 
al. 2008). Could Cldn14 therefore influence VECAD expression and/or function? (7) Some claudins are 
regulated by the binding of EGF to EGFR (Singh and Harris 2004). Could Cldn14 regulate the 
expression, internalisation or signalling of activated VEGFR2? GF = growth factor. GFR = growth 
factor receptor. VECAD = vascular endothelial cadherin. CLDN = claudins. 
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4.2.1 Cldn14, cell-cell contacts and the basement membrane 
It may be that, with lateral cell connections affected by Cldn14 heterozygosity or 
knock-down, cell contact with the ECM may compensate, or also be negatively 
affected; a similar phenomenon is reported by Delom et al., who found that Hsa21 
transchromosomic fibroblasts exhibited defective migration and adhesion, thus 
showing that overexpression of Hsa21 genes can affect cellular adhesion to the ECM 
(Delom et al. 2009). Therefore, as an Hsa21 gene, the abundance of Cldn14 in cells 
contacting the ECM may affect their adhesive properties (indicated in Figure 4.23). In 
addition, Cldn5 expression in brain endothelial cells was found to be regulated by β1 
integrin binding to the ECM (Osada et al. 2011), so it is possible that Cldns may in 
turn regulate integrin expression and adhesion of ECs to the matrix, including laminin 
binding (Figure 4.23). 
 
Eming and Hubbell summarised the effects of the deletion of various basement 
membrane components on vascular integrity, with the loss of most components leading 
to increased vessel leakiness (Eming and Hubbell 2011). Indeed, the delivery of the 
small molecule Hoechst dye to tumour vessel-proximate nuclei was enhanced in 
Cldn14-het mice, which may be a direct result of TJ destabilisation due to Cldn14 loss 
or as an indirect result via alteration of the basement membrane.  This suggests that 
partial loss of Cldn14 alters the barrier function of tumour endothelium. Similarly, 
while loss of Cldn5 increases leakage through the BBB, which ultimately kills Cldn5-
null pups within 10 days after birth, the integrity of the cell layer itself is maintained 
(Nitta et al. 2003). 
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In addition to the observed effects on vessel permeability to the small molecule 
Hoechst dye and disruption of the endothelial layer and basement membrane, we 
observed a decreased proportion of lumenated blood vessels in tumours taken from 
Cldn14-heterozygous mice. While there was an overall increase in endomucin-positive 
vessels in Cldn14-het tumour sections, clearly lumenated vessels in particular were 
less common than in tumours from wild-type or Cldn14-null mice. This suggests that, 
while Cldn14 depletion may enhance angiogenic responses, the resulting vessels may 
not be fully functional. Greater numbers of unlumenated vessels may result in reduced 
flow through these vessels. This is apparently over-compensated for by the lumenated 
vessels, which appear leakier (as demonstrated by the Hoechst assay) and able to 
deliver more oxygen, thus decreasing hypoxia in Cldn14-het tumours. As described in 
2.12.5, the use of multiple tumours and whole midline sections (as opposed to a 
selection of fields and tumour extremities) should have allowed the data collection to 
overcome the influences of artefacts from sectioning and looking at individual planes.  
 
4.2.2 Cldn14 and tumour oxygenation 
As well as improved small molecule diffusion from tumour blood vessels in Cldn14-
het mice, oxygenation was also apparently increased. We showed that Cldn14-het 
tumours had decreased hypoxic areas, detected using the Pimonidazole hypoxyprobe, 
and greater bioluminescence readings from luciferase-tagged tumour cells in Cldn14-
het mice when compared to wild-type controls. Since luciferase can only perform the 
bioluminescent reaction with injected luciferin in the presence of oxygen, this suggests 
improved delivery of oxygenated blood to the tumour and consequently an increase in 
oxygen-dependent metabolism, despite the apparent increase in vessel leakage. 
Unfortunately, bioluminescence experiments could not be carried out with the addition 
of Cldn14-null cohorts due to limited mouse availability. Similar to Cldn5 deletion 
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(Nitta et al. 2005), the observed effect may be due to a size-selective modification of 
the barrier function, in which small molecules are freer to exit the vessel, without 
severe effects on flow. This could be confirmed with the use of varied molecular 
weight tracers and monitoring their movement across Cldn14-depleted endothelial 
barriers, and flow could be monitored by ultrasound in vivo. 
 
The lack of significant difference in hypoxia and total blood vessel numbers between 
Cldn14-WT and Cldn14-het LLC tumours may be due to the different pro-angiogenic 
secretory profile of the cell line, for example compared to the B16F10 melanoma line; 
LLC tumours produce far less placenta growth factor (PlGF), another VEGF family 
member as introduced in 1.5.1 and 1.5.5.1 (Zhang et al. 2008). This suggests that the 
effects of Cldn14 gene dosage, upon tumour hypoxia in particular, may be dependent 
on growth factors other than VEGF, such as PlGF. Future experiments testing the 
direct response to PlGF may clarify this detail. 
 
Decreased tumour hypoxia due to Cldn14 depletion in the stroma may also have 
implications for cancer progression and therapy. Given that hypoxia is known to 
destabilise vessels via the inhibition of adhesion molecules and may stimulate 
metastasis as a result, a transient reduction in tumour hypoxia, similar to that observed 
when Cldn14 was depleted, would be favourable to avoid these negative effects 
(Brockton et al. 2012, Koto et al. 2007, Yuan et al. 2012). Conversely, hypoxia was 
found to decrease the expression of claudins 1, 3 and 5 (Koto et al. 2007), and, 
considering this finding together with our data, a hypothesised two-way regulatory 
system between claudins and hypoxia is depicted in Figure 4.23. 
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4.2.3 Cldn14 and pericytes 
As well as alterations to the endothelial component of tumour vessels, decreased 
pericyte coverage was also observed in Cldn14-het tumour sections, using α-smooth 
muscle actin as a supporting cell marker. This interesting result is difficult to interpret, 
given the lack of detailed knowledge of pericyte-endothelial cell interactions at 
present. It may indicate a greater number of immature tumour blood vessels in Cldn14-
het tumours, or restrictions on blood vessel maturation. The decreased pericyte 
coverage of tumour blood vessels in Cldn14-het mice is intriguing and may indicate 
that EC-pericyte tight junctions involve Cldn14, although other claudins are almost 
certainly involved, given the absence of the phenotype in Cldn14-null mice. Pericyte-
endothelial cell signalling is not yet well understood, but recently pericytes have been 
found to regulate Cldn5 expression in blood-brain barrier endothelial cells via 
secretion of growth factors (Shimizu et al. 2012). Therefore it may be that feedback 
loops exist between the two cell types, and that the levels of TJ proteins can also 
influence pericyte recruitment (Figure 4.23).  
 
Examining the expression of adhesion molecules such as NCAD, EC-pericyte and 
pericyte-ECM integrins and other adhesive proteins in Cldn14-WT, heterozygous and 
null cells and in vivo may also help to illuminate the reason for limited pericyte 
association in Cldn14-het tumours. Interestingly, pericytes in human skin were found 
to secrete laminin and to compensate for differentiating cells that ceased to produce it 
(Paquet-Fifield et al. 2009). This indicates that the basement membrane differences 
around tumour blood vessels in Cldn14-het mice may not be a cause, but rather a 
result, of decreased pericyte association (since endothelial cells and pericytes share the 
matrix in between them). 
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4.2.4 Cldn14, the VEGF response and proliferation 
In three systems (primary endothelial cells in vitro, aortic rings ex vivo and tumour 
endotheial cells in vivo), I have found that heterozygosity for Cldn14 can increase 
endothelial cell proliferation (Figure 4.23). While it is known that tight junctions can 
regulate proliferation (Balda and Matter 2009, González-Mariscal et al. 2007), Cldn14 
in particular has not yet been implicated in the process prior to this study. Experiments 
that could address the mechanistic basis of this effect are discussed in section 4.3.  
 
Despite increased tumour oxygenation and reduced hypoxia in tumours from Cldn14-
het mice, only a statistically insignificant trend in tumour cell proliferation was 
observed, using Ki67 as a marker of cellular proliferation. However, a significantly 
higher number of PECAM-positive endothelial cells were Ki67-positive in Cldn14-het 
tumours compared to controls. In addition, in the ex vivo aortic ring assay, VEGF-
induced endothelial microvessel sprouting was significantly increased in Cldn14-het 
aortic rings, compared to controls. This was found to correlate with an increase in 
endothelial cell proliferation in Cldn14-het aortic ring explants, which could entirely 
explain the increased microvessel sprout length and numbers. Further confirming the 
effect of Cldn14-depletion on endothelial cell proliferation, Cldn14-heterozygous 
primary mouse lung ECs grown in culture exhibited higher proliferation rates than 
Cldn14-WT or Cldn14-null cells. This effect was seen regardless of whether VEGF 
was present or not, though proliferation was significantly increased upon VEGF 
stimulation, compared to PBS-only controls. This baseline increase in EC proliferation 
may be related to in vitro culture; perhaps a specific reaction to the 
collagen/fibronectin tissue culture surface as a result of changes to Cldn14-het EC 
adhesive properties. 
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The increase in aortic microvessel sprout number and length ex vivo may be 
particularly related to the phalanx cells, which form more tight junctions than the 
proliferating stalk and migrating tip cells (Warren and Iruela-Arispe 2010). Decreased 
TJ molecule abundance in quiescent phalanx cells may promote a more proliferative 
stalk cell phenotype, encourage nascent vessel sprouting and inhibit vessel maturation, 
which may also be reflected in the tumour blood vessel phenotypes, including the loss 
of αSMA-positive cell association.  While increased proliferation could be the sole 
reason for increased microvessel sprouting ex vivo in Cldn14-het aortic rings, there 
may be other facets to this response. Monitoring VEGFR2 levels before and during 
VEGF stimulation in primary ECs may provide insight into the increased VEGF 
responses seen in Cldn14-herozygous cells and tissues.  
 
Although we performed Dunn chamber chemotaxis assays, which again confirmed 
increased proliferative capacity of Cldn14-het endothelial cells, the migratory results 
were unlikely to be biologically significant given the very small differences observed. 
In addition, daughter cells were tracked in the experiment; while advice was taken to 
suspend tracking for dividing cells and resume when daughter cells appeared to have 
separated and started moving independently, these data may have obscured real 
differences between the genotypes, due to the changes in speed and directional 
movement inherent in cytokinesis. It is also difficult to perform the Dunn Chamber 
assay effectively with primary endothelial cells, since they do not react well to being 
seeded sparsely, and were often dying before the experiment could be performed. 
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4.2.5 Cldn14 and other cell surface molecules 
Considering the effect on VEGFR2 subcellular localisation in Tc1 cells, the VECAD 
regulation of VEGFR2 internalisation, crosstalk between TJs and AJs, and the fact that 
TJs are also regulated by endocytosis (Gavard and Gutkind 2008, Taddei et al. 2008), 
it would be of interest to discover whether there are any effects of manipulating 
Cldn14 gene copy number on endocytic processes, which may also contribute to 
growth factor sensitivity when Cldn14 gene dosage is altered. Since VECAD can 
increase the expression of Cldn5 (Taddei et al. 2008), it is possible that Cldn14 could 
affect VECAD function in the opposite direction (Figure 4.23). 
 
To understand the effects of manipulating TJ molecules like Cldn14, challenging the 
ideas of directional molecular effects may be required; it was thought that VEGFR2 
regulated β3 integrin in a unidirectional manner, however it was later shown that β3 
integrin could also regulate VEGFR2 (Reynolds et al. 2002, Robinson et al. 2009, 
Tsou and Isik 2001). Similarly, while the binding of EGF to EGFR has been shown to 
affect claudins (Singh and Harris 2004), could it be that manipulating claudins impacts 
on other growth factor receptors, for example Cldn14 affecting VEGFR2 (as shown in 
Figure 4.23)? These questions and experiments addressing them could begin to 
unravel the mechanism of Cldn14-heterozygosity affecting endothelial cell 
proliferation and angiogenic processes more widely. 
 
4.2.6 Cldn14 and tumour growth 
Despite the changes to endothelial cell layer properties that I have reported in tumours 
from Cldn14-het mice, no differences in tumour growth were observed in Cldn14-het 
or Cldn14-null mice, compared to wild-type controls. While initially surprising, this 
may reflect more of a difference in tumour “quality” (parameters such as metabolic 
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and stromal cell proportions) than the tumour’s ability to simply get bigger. It is now 
accepted that overall tumour size alone, which does not account for tumour 
heterogeneity, is not a sufficient measure of cancer progression, tumour grade or 
treatment efficacy (Choi et al. 2007, Kenny et al. 2010, Wieder et al. 2005). The use of 
PET scanning to assess tumour activity in terms of metabolism, in addition to MRI/CT 
scanning to image the tumour bulk, has become more common in order to evaluate 
whether treatments are benefiting the patient or not, in a shorter time scale than has 
been possible previously. Tumour size may not vary significantly in these short 
intervals but active mass may decrease visibly, indicating effective treatment. New 
technologies such as Magnetic Resonance Spectroscopy (MRS) are being developed to 
monitor tumour quality, the behaviour and metabolism of its inner microenvironment, 
as a result (Lodi and Ronen 2011). 
 
Alternatively, it may be that the duration of this tumour assay was not sufficient to 
reveal differences in tumour size resulting from the changes to blood vessels caused by 
Cldn14 depletion. Longer term assays may in fact show a decreased rate of tumour 
growth, a growth plateau or even regression in Cldn14-het and/or null mice. 
Unfortunately restrictions on tumour size and limited animal numbers did not permit 
such experiments. 
 
4.2.7 Cldn14 knockdown 
Knockdown experiment results corroborate those from the genetic ablation 
experiments, particularly differences between WT and Cldn14-het in terms of 
increased proliferation upon Cldn14 depletion. One successful Western Blot analysis 
of Cldn14 knockdown using a Sigma antibody is presented, but unfortunately could 
not be replicated for further experiments, despite collection of protein and RNA in 
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parallel for all proliferation, TUNEL and aortic ring procedures. This means we cannot 
be sure of the efficiency of knockdown in all cases, which is likely, for example, to 
differ between cell types within the aortic ring explants. However, the replication of 
results from the genetic ablation experiments suggests that knockdown – probably 
partial rather than to a high degree – was occurring, since results between knockdown 
experiments were also repeatable. Transient knockdown is also likely to identify 
changes that more closely mimic the potential effects of targeting Cldn14 with drugs 
and thus provides some benefit over genetic ablation studies where genetic or 
molecular compensation occurs. 
 
4.2.8 Cldn14-heterozygous vs. Cldn14-null phenotypes 
An intriguing aspect of the Cldn14 study is the near-exact recapitulation of Cldn14-
WT phenotypes in Cldn14-nulls; most results have shown a distinct phenotype in 
Cldn14-het mice, in contrast to little to no effect in the Cldn14-nulls. This lack of 
angiogenic phenotypes is assumed to be due to compensation, although one candidate, 
Cldn5, was not found to be upregulated in kidney or brain at the transcript level. 
However, these are both non-tumour contexts and the protein levels may differ in the 
tumour blood vessels and further investigations would be required to clarify this point.  
Cldn14 is unlikely to be fully compensated for in the heterozygous state, or entirely 
absent, given the phenotypes observed that are significantly different from both the 
wild-type and Cldn14-null mice. Manipulation of Cldn14 gene dosage did not appear 
to impact upon Cldn5 expression, since no significant differences, at least at the 
transcript level, were found between the genotypes. 
 
It may be that other endothelial claudins such as Cldn12 redistribute in order to 
counteract the absence of Cldn14, while this does not occur in the heterozygous state. 
190 
 
Importantly, the deletion is organism-wide and permanent. Other compensation 
mechanisms have been noted in other knockout models, a particularly relevant 
example being that of compensation for the loss of FAK in adult mouse ECs by the 
related kinase Pyk2 (Weis et al. 2008). Compensation may also occur through non-
related molecules. For example, VEGFR2 compensates for the loss of β3 integrin in 
β3-null mice (Reynolds et al. 2002). It is possible that Cldn14 deletion is compensated 
for by other non-claudin family molecules. For example, VECAD is known to affect 
Cldn5 expression and VEGFR2 signalling, as indicated in Figure 4.23 (Carmeliet et 
al. 1999, Taddei et al. 2008), so could VEGFR2 or VECAD be involved in 
compensating for Cldn14 loss? Monitoring their expression and subcellular 
localisation in Cldn14-heterozygous, wild-type and Cldn14-null cells could begin to 
answer this question. 
 
The Cldn14-null mice are viable and show no distinctive phenotypes apart from their 
characterised deafness, the onset of which occurs approximately 2-3 weeks after birth 
and does not occur in Cldn14-het littermates (Ben-Yosef et al. 2003). These data 
suggest that Cldn14 is not essential for survival. Inducible genetic ablation is 
sometimes favoured over constitutive deletion, so that temporally controlled acute 
deletion can be achieved when compensation for the deleted gene has not occurred 
during development, and to avoid lethality due to deletion where this occurs.  
 
Cre-lox systems could be employed to reveal different functions of Cldn14 from those 
seen in total knockouts. Driving expression of the Cre recombinase with an endothelial 
cell-specific promoter such as PDGFB or Tie-1 would allow the deletion of Cldn14 in 
endothelial cells, which could dissect out endothelial-specific roles of Cldn14 from any 
functions it performs in other cell types. Combining such strategies with an inducible 
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Cre system, for example the CreERT, which becomes functional upon treatment with 
tamoxifen, would also allow temporal regulation of the deletion (Tavora et al. 2010). 
In this case, Cldn14 targeting as a therapeutic strategy could be tested in a more 
relevant fashion, using temporary gene deletion in the disease situation alone rather 
than from birth. 
 
4.2.9 Cldn14 in non-endothelial cell types 
Considering the range of cell types involved in tumour growth, it is clear from our 
results that Cldn14 expression levels can affect endothelial cell behaviour and EC 
interactions in the tumour types tested, resulting in changes not to tumour size but 
tumour quality. The malignant cells did not mediate these effects because an injectable 
model was used; Cldn14 was not depleted in the tumour cells themselves, thus our 
studies have dissected the requirement for Cldn14 within the stromal compartment. 
The use of spontaneous tumour models would enable us to further investigate whether 
Cldn14 levels in the cancer cells themselves, as well as in the stroma, also affect 
angiogenic processes. For example: 1) the RIP-Tag pancreatic cancer model, in which 
expression of the simian virus 40 (SV40) large-T antigen is driven by the rat insulin II 
promoter specific for pancreatic β-cells, causing pancreatic adenomas (Hanahan 1985). 
2) The APCMin colon cancer model, in which mutation of the adenomatous polyposis 
coli gene causes multiple intestinal neoplasia (Moser et al. 1990). 3) The MMTV-
PyMT breast cancer model, in which expression of the polyoma middle-T antigen is 
driven by the mouse mammary tumour virus promoter, causing breast cancer-like 
disease (Guy et al. 1992). Considering that the “claudin-low” breast cancer subtype 
(described in 1.8.4.1.1) is still being characterised, use of the MMTV breast cancer 
model may be particularly informative. The levels of many claudin family members 
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are altered in human tumours, as summarised in Table 1.2, so Cldn14 may well be an 
important player in the tumour cell compartment. 
 
Although not specific to endothelial cells, since epithelial cells from the host are not 
components of the tumour stroma in the models that we have used, it is unlikely that 
epithelial components significantly influenced the results in our Cldn14 knockout 
study presented in this thesis. 
 
An interesting consideration is the expansion of claudin protein roles beyond what is 
currently known; specifically regarding their functions outside of cell adhesion and the 
tight junctions. These questions are now being asked and, while little data have been 
collected so far, it seems that wider roles for claudins may well exist. 
 
It is not yet known whether Cldn14 in particular has any role in immune cell types, and 
tumours do influence and attract other non-neoplastic cells including inflammatory 
cells such as tumour-associated macrophages (TAMs) and leukocytes (Thurston et al. 
2000, Tlsty and Coussens 2006, Weinberg 2007). Interestingly, some reports of 
claudin expression and function in immune cells are starting to emerge. Mandel et al. 
studied TJ protein expression in circulating white blood cells from multiple sclerosis 
(MS) and type 1 diabetes patients, finding that expression of Cldn1 and Cldn5 
increased in immune cells from MS patients, with Cldn1 also elevated in diabetes 
patients’ cells (Mandel et al. 2011). In MS, immune cells move through the BBB into 
the brain, which causes inflammation. In addition, Van den Bossche et al. detected 
claudins 1, 2 and 11 in alternative differentiation states of macrophages, with Cldn2 
particularly associated with TAMs in mice (Van den Bossche et al. 2012). JAMs are 
known to be important in monocyte, lymphocyte and leukocyte transmigration through 
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endothelial cell layers (Imhof and Aurrand-Lions 2004, Johnson-Léger et al. 2002, 
Lamagna et al. 2005b), so the expression of claudins by immune cells suggests they 
may be involved in immune cell infiltration into tissues and the inflammatory 
response, which is now known to be a central aspect of the tumour environment (Tlsty 
and Coussens 2006). Further to this, decreased Cldn5 expression has been observed in 
the pulmonary (lung) endothelium and the BBB during HIV infection in human and 
mouse (András et al. 2011, Li et al. 2012). In the lung, this correlated with increased 
macrophage infiltration into the lungs. 
 
These preliminary data, together with the work presented in this thesis, make it 
tempting to speculate that reduction of Cldn14 levels in the tumour endothelium could 
stimulate increased macrophage infiltration into the tumour stroma, and/or have effects 
on other members of the immune cell compartment. To test this, macrophage 
recruitment could be observed by staining for the macrophage marker FcγRII/III in 
tumour sections from wild-type and Cldn14-depleted mice, and markers for other 
immune cell types could be used in a similar fashion. 
 
 
4.3 FUTURE PERSPECTIVE 
In the tumour context, disruption of ZO-1 staining patterns in tumour blood vessels 
was observed in Cldn14-heterozygous mice, suggesting that partial loss of Cldn14 may 
affect the localisation of ZO-1 at tight junctions. Though not a direct measure of 
endothelial TJ-mediated barrier integrity, further experiments could be performed to 
test this. Firstly, transmission electron microscopy (TEM) can be carried out to view 
any TJ disruption caused by the depletion of Cldn14. An informative further 
assessment of barrier function in endothelial cell layers is the measurement of 
transendothelial electrical resistance (TEER or TER), which could be performed in 
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order to assess the effect of Cldn14 gene depletion and knockdown on the barrier 
integrity of confluent endothelial monolayers. The expression of Cldn14, along with 
that of Cldn5 and other endothelial claudins, would ideally be monitored over time as 
the confluence of wild-type, Cldn14-heterozygous and Cldn14-siRNA transfected cell 
cultures increased, since Cldn5 expression increases with cell confluence (Osada et al. 
2011). Unfortunately, VECAD staining was not fully optimised and limited time 
meant that VECAD expression and localisation in tumour blood vessels could not be 
analysed. 
 
Disrupted tumour blood vessel basement membranes (specifically surrounding laminin 
deposition) were also observed in Cldn14-heterozygous mice. This indicates that 
cross-talk between Cldn14 and cell-matrix adhesion molecules may occur, since 
adhesion molecules also conduct inside-out signalling that affects the ECM (Ginsberg 
et al. 1992). Given the interactions of tight junctions with adherens junctions via 
occludin and cytoplasmic proteins, and cross-talk with integrin signalling via JAMs, it 
would be interesting to perform adhesion assays, to find out if Cldn14-depleted cells 
have altered ECM adhesion properties. 
 
The comparison of lumenated vs. non-lumenated vessels in the tumour sections hints 
that there may be differences in blood vessel functionality between the Cldn14 
genotypes. To confirm this more precisely and less subjectively, injections of FITC-
dextran of differing molecular weights could be performed to observe both vessel 
perfusion in the tumours and the degree of leakage from vessels. It is also possible to 
analyse vascular diameters, branch point numbers and vessel tortuosity with the 
appropriate software. These data would give more information on the differences in 
tumour vessel functionality in Cldn14-het tumours, compared to controls. 
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Given the disrupted BM and pericyte dissociation results, plating Cldn14-depleted 
cells on various ECM substrates such as collagen, fibronectin, and vitronectin may 
indicate other cell surface proteins involved in adhesion that are linked to Cldn14 
function.  Further to adhesion studies, integrin profiling (for both ECs and pericytes) 
would reveal any significant changes to integrin expression, such as β1 integrin, which 
is involved in laminin and collagen binding. 
 
In addition to testing the permeability and functionality of tumour blood vessels, it 
would be informative to test normal blood vessels as well, for example using the Miles 
assay. In this assay, intravenous injections of Evans Blue dye are followed by 
intradermal injections of VEGF or PBS as a control. The leakage of dye into the skin 
tissue is then quantified as a measure of VEGF-induced vascular permeability 
(Robinson et al. 2004). Characterising the effects of Cldn14 dosage on vascular 
permeability outside of the tumour would be helpful in assessing further both the 
function of Cldn14 in the normal vasculature, and the suitability of TJ molecules such 
as Cldn14 as therapeutic targets.  
 
As well as quantifying tumour hypoxia, the VEGF-dependent retinopathy of 
prematurity (ROP) assay could be performed in further studies to study the effects of 
hypoxia on bloosd vessel growth in non-tumour tissue (Aiello et al. 1995). In this 
assay, newborn mice are exposed to hypoxic conditions for 5 days and then normal air 
for 5 days, which stimulates the production of VEGF and neoangiogenesis in the 
retina. The development and quality of the new hypoxia-induced vascular network can 
be visualised and assessed in several ways; for example retinal vessels are ideal for 
close observation of tip cell morphology, which has not yet been studied in the Cldn14 
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model. Vascular spread, branchpoint frequency, vessel thickness and supporting cell 
association can also be measured. This assay may reveal further effects of Cldn14 
abundance on vascular responses to hypoxia, through the analysis of normoxic and 
hypoxic retinal vasculature (as in da Silva et al. 2010). 
 
Further to ex vivo aortic ring assay studies of growth factor-induced angiogenesis, the 
in vivo subcutaneous sponge assay for VEGF-induced neoangiogenesis would also be 
appropriate to perform with the Cldn14 mice. Since we observed changes to VEGF-
stimulated responses ex vivo and in vitro, this assay could be used to test these 
responses in vivo, free of the influences of tumour cells, which secrete multiple factors 
and recruit immune cells and fibroblasts that also affect the tumour vasculature. It 
would also be interesting to look at different pro-angiogenic growth factors, such as 
bFGF and PlGF, to find out whether altered angiogenic responses in Cldn14-
heterozygous animals are most reliant on the VEGF signalling pathway or not. Such 
experiments would identify the precise responses to individual growth factors in vivo 
when Cldn14 gene dosage is varied. 
 
As well as looking at how endothelial cells with differing Cldn14 gene dosage respond 
to VEGF and adhere to the ECM, it would also be interesting to look more closely at 
how they migrate. Rather than performing Dunn Chamber assays, it may be more 
revealing to assess Rho/Rac small GTPase expression levels, activity, and localisation, 
to assess possible effects of Cldn14 depletion on the actin cytoskeleton and cell 
motility, given their involvement in linking both AJs and TJs to the cytoskeleton 
(Bazzoni and Dejana 2004, Hartsock and Nelson 2008, Wallez and Huber 2008). 
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To understand the molecular regulation of proliferation by Cldn14, Western Blot 
assessment of downstream signalling was attempted. Unfortunately, problems with 
primary endothelial cell culture (including limited mouse numbers, contamination in 
the tissue culture suite and of purchased reagents, all preps of one or more genotypes 
dying before protein could be extracted and low protein yields) did not allow for 
analysis of any blots probed. Interrogation of downstream signalling in the endothelial 
cells of different genotypes was planned, by probing for molecules (and their 
phosophorylated forms where appropriate) such as beta-catenin, VECAD, ERK and 
Akt. It was also hoped that VEGFR2 levels could be monitored, but sufficient protein 
was not obtained from primary cell cultures. For a more far-reaching analysis of the 
downstream effects of Cldn14 gene dosage changes, protein arrays testing for the 
levels of many signalling proteins at once can inform further research decisions. 
 
In addition to analyses of downstream signalling in whole cell lysates, further 
investigation could include the use of fractionation studies to assess the proportions of 
proteins with nuclear localisation signals in the nucleus or cytoplasm upon VEGF 
stimulation. For example, if the concentration of ZONAB were enhanced in the 
nuclear fraction of Cldn14-heterozygous cells, this would indicate greater freedom to 
move from the TJ to the nucleus and promote G1 to S phase transition.  
 
To examine the impact of Cldn14 depletion on interactions between the molecules 
known to influence proliferation, immunoprecipitation of ZONAB or Cdk4 and 
probing for the opposite binding partner may indicate increased ZONAB/Cdk4 
interaction, further demonstrating a role for Cldn14 in sequestering ZONAB at the TJ 
and limiting cellular proliferation. These experiments could be combined with 
immunofluorescence in vitro and possibly in vivo, along with probing for other TJ 
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molecules, to observe effects of Cldn14 levels on their expression and localisation. In 
addition, Cldn14-WT, Cldn14-het and Cldn14-null endothelial cells could be treated 
with propidium iodide to measure DNA content and sorted with a flow cytometer to 
observe the proportions of cells in different phases of the cell cycle. An increase in the 
number of Cldn14-het cells in S phase compared to the other genotypes would further 
support a role for ZONAB/Cdk4 in the regulation of EC proliferation by Cldn14. 
 
4.3.1 Cldn14 and metastasis 
Though beyond the scope of this study, these phenotypes may also have effects on 
metastatic processes. The decreased integrity of the endothelial cell layer may create a 
tumour environment more conducive to intravasation at primary tumour sites. This 
hypothesis is supported by results seen in other models where cell-cell adhesion 
molecule levels or function have been affected. In addition, pericyte coverage is 
known to affect metastasis (Cooke et al. 2012, Xian et al. 2006). Considering the 
reduced supporting cell coverage observed in heterozygous tumours, increased 
metastasis may result. Additionally, the expression levels of claudins 1, 3 and 4 were 
found to correlate with different metastatic potentials of ovarian and colon cancer 
(Agarwal et al. 2005, Singh et al. 2010). Our in vivo lines of investigation have not yet 
considered the impact of Cldn14 manipulation outside of the primary tumour site; 
therefore further work should also examine metastasis in Cldn14-depleted mice. 
Considering the apparent destabilisation of endothelial junctions, it is reasonable to 
postulate that tumour cell intravasation into blood vessels at the primary site may be 
promoted. Also, since Cldn14 is not endothelial-specific, there may be effects on 
metastatic niches. 
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Experimental metastasis studies could be performed to find out which stages of 
metastasis might be affected by changes to Cldn14 gene dosage. The ability of tumour 
cells to “home in” on potential metastatic niches can be assessed by injecting tumour 
cells and looking only a few hours later at tumour cell presence in metastatic sites, 
such as the lung. Extravasation at the metastatic site could well be affected by 
alterations to endothelial cell adhesion molecules; so increased metastases in Cldn14-
het animals might be expected. However, if loss of Cldn14 actually impairs the ability 
of tumour cells to bind to the endothelium whilst circulating in the blood stream, even 
if intravasation is increased, metastatic growth may remain unaffected. 
 
4.3.2 Targeting Cldn14 and disease control 
Our studies may have therapeutic implications in future when further research has 
increased our understanding of claudin roles in cancer. We have shown that greater 
effects can occur upon partial depletion of a cell-cell adhesion molecule than total 
knockout of the gene, which is more relevant to the therapeutic situation where total 
ablation is unlikely to be achieved. In addition, since mutations in Cldn14 causing 
autosomal recessive deafness are known in humans, these findings may be of relevance 
to such individuals, as it is possible they are more susceptible to angiogenic defects 
(Wilcox et al. 2001). 
 
It has been found that decreased pericyte coverage can increase sensitivity to Avastin, 
the anti-VEGF-A antibody (Benjamin et al. 1999). Thus, the partial reduction of 
Cldn14 expression may sensitise tumour vasculature to Avastin 1.5.1.2 (Serve and 
Hellmann 1972). Conversely, VEGF is known to stimulate the delocalisation of 
occludin from endothelial tight junctions and the VEGF inhibitor pegaptanib was 
found to return TJ molecules to the plasma membrane, suggesting that anti-angiogenic 
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therapies can also influence endothelial cell-cell contacts in tumours (Bazzoni and 
Dejana 2004, Deissler et al. 2011). If anti-VEGF therapy stimulates claudin 
presentation at the cell surface, this may present an opportunity to utilise the 
Clostridium perfringens enterotoxin (CPE) claudin extracellular loop binding capacity 
(shown in Figure 1.13 and 1.8.4.1.1) to deliver cytotoxic therapy to endothelial cells, 
and prune back the tumour vasculature. 
 
It is now accepted that combination therapy in cancer, particularly where anti-
angiogenics are concerned, is more likely to be effective than targeting one pathway or 
molecule alone. Such strategies are designed to avoid compensation and the 
development of resistance. Recently dual RTK inhibitors for VEGFR2 and PDGFR 
targeting endothelial cells and pericytes respectively have been trialled, for example in 
the particularly aggressive pancreatic neuroendocrine tumours (Delbaldo et al. 2012). 
This combination doubled progression-free survival and showed that targeting the 
tumour stroma can be an effective strategy. Thus, we speculate that a combination of 
anti-adhesion molecule therapy with traditional anti-angiogenic drugs may serve to 
improve delivery of cytotoxic therapy to the tumour bulk. 
 
It may be that advances could permit the development of gene-specific targeting 
constructs, which could target Cldn14 or other TJ molecules. If this could be achieved 
in the tumour environment alone, oxygenation of the tumour could be increased, 
stimulating tumour cell proliferation and possibly sensitising cells to chemotherapeutic 
drugs and radiotherapy treatment (Bertout et al. 2008, Thomlinson 1977), although the 
notion of enhancing angiogenesis to treat cancer is obviously controversial. This could 
be tested in vivo, for example via the development of shRNA lentiviral vectors, and 
injecting the virus into tumours to observe the effects on parameters such as blood 
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vessel functionality, tumour perfusion, hypoxia, tumour growth and metastasis. This 
knockdown approach could also be combined with chemotherapy or targeted drugs 
against pro-angiogenic molecules, to see if combination therapy conferred further anti-
tumour benefit.  
 
Alternatively, lentiviral vectors could be used to overexpress Cldn14, if overexpression 
were found to efficiently decrease endothelial cell proliferation and improve vessel 
maturity by creating more robust cell-cell contacts. Some straightforward experiments 
could be performed to find out if overexpression of Cldn14 would have the opposite 
effect to Cldn14 deletion or depletion. For example, overexpression of Cldn14 in 
pMLEC would be expected to decrease proliferation. In a longer-term study lentiviral 
particles containing the Cldn14 expression construct (kindly provided by Hu et al., 
2006) could be created to infect aortic rings and also be injected into tumour sites so 
see if endothelial cell proliferation and angiogenesis is decreased and, in the case of 
aortic explants, if microvessel sprout number and length would be inhibited below 
wild-type levels. Although these experiments were planned, time restrictions meant 
that they were not performed. 
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CHAPTER 5 CONCLUDING REMARKS 
My studies have focussed on how gene “dosage”, rather than a simple presence or 
absence, can mediate effects in tumour angiogenesis. Indeed, many genes are regulated 
by their level of expression and not a simple binary on/off mechanism. For example, 
gene dosage effects have been observed for other molecules such as BMPER (bone 
morphogenic protein endothelial cell-precursor-derived regulator) and crossveinless2 
(the Drosophila ortholog of BMPER); this ECM protein has been found to be a dose-
dependent EC activator, which activates ERK signalling (Heinke et al. 2008, Serpe et 
al. 2008). Using a combination of genetically manipulated mouse models, which have 
changes in gene dosage, and injectable tumour models in which gene dosage levels are 
unchanged in the tumour cells, we have dissected the effects of stromal gene dosage on 
tumour angiogenesis and tumour growth.  
 
We first used the Tc1 mouse model of Down’s syndrome with elevated gene dosage of 
a large proportion of Hsa21 genes, and then a genetic ablation of claudin14 mouse 
model in which gene dosage was reduced by half in heterozygous and completely 
absent in nulls. Using both of these models we have discovered novel angiogenic 
regulators, and concluded that increased gene dosage of some Hsa21 genes can affect 
pathological angiogenesis, and therefore may contribute to the tumour protection 
phenotype observed in the Down’s syndrome population. I have also shown that 
Cldn14 is involved in angiogenesis in vivo, which was not previously known. 
 
This study has demonstrated gene dosage effects of chromosome 21 genes on 
angiogenic processes. Extra copies of human chromosome 21 genes in the stroma are 
sufficient to decrease tumour size via the inhibition of angiogenesis. Furthermore, 
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blocking individual Hsa21 genes to restore the normal copy number and reduce gene 
dosage can restore normal angiogenic responses. 
 
This study also reveals novel functions for Claudin14, which has not been shown to be 
involved in angiogenic processes in vivo previously. Depletion but not total ablation of 
claudin14 alone, a chromosome 21 gene, increases small molecule delivery to tumour 
cells, decreases hypoxia and supporting cell coverage, and affects endothelial cell 
proliferation but not tumour size. 
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CHAPTER 7 APPENDICES 
7.1 Abbreviations 
αCat – alpha catenin 
βCat – beta catenin 
A 
Adamts1 – A disintegrin and metalloprotease 
with thrombospondin motifs 1 
AJ – adherens junction 
Akt – also Protein kinase B (PKB) 
APCMin – Adenomatous Polyposis Coli 
multiple intestinal neoplasia mutated 
B 
BBB – blood-brain barrier 
bFGF – basic fibroblast growth factor 
BM – basement membrane 
BS1 lectin – Bandeiraea simplicifolia lectin 
BSA – bovine serum albumin 
C 
CCC – cytoplasmic cell adhesion complex 
Cdk – cyclin-dependent kinase 
cDNA – complementary DNA 
Cldn – claudin 
CPE – Clostridium perfringens enterotoxin 
D 
DAPI – 4',6-diamidino-2-phenylindole 
DMEM – Dulbecco’s modified Eagle’s 
medium 
DS – Down’s Syndrome 
DSCR1 – Down’s Syndrome critical region 1 
DYRK1A – Dual specificity tyrosine-
phosphorylation-regulated kinase 1A 
E 
EC – Endothelial cell 
ECM – extracellular matrix 
EDTA – ethylenediaminetetraacetic acid 
EGFR – epidermal growth factor receptor 
EL1/2 – extracellular loop 1/2 
Erg – v-ets avian erythroblastosis virus E26 
oncogene related 
ERK – extracellular signal-regulated kinase 
ESAM – endothelial cell-selective adhesion 
molecule 
Ets2 – v-ets avian erythroblastosis virus E26 
oncogene homolog 2 
F 
FACS – fluorescence-activated cell sorting 
FAK – focal adhesion kinase 
FCS – foetal calf serum 
FFPE – formalin-fixed paraffin-embedded 
FGFR – fibroblast growth factor receptor 
FHHNC – Familial hypomagnesaemia with 
hypercalciuria and nephrocalcinosis 
FITC – fluorescein isothiocyanate 
Flk1 – foetal liver kinase 1 (VEGFR2) 
Flt1 – FMS-like tyrosine kinase 1 
FN – fibronectin 
G 
GF – growth factor 
GTPase – guanosine triphosphatase 
H 
HCl – hydrochloric acid 
HCV – hepatitis C virus 
HEPES – 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid 
HEK – human embryonic kidney 
HIF – hypoxia inducible factor 
HIV – human immunodeficiency virus 
HRP – horseradish peroxidase 
Hsa21 – Human chromosome 21 
Hsc – heat shock cognate 
HUVEC – human umbilical vein endothelial 
cells 
J 
JAM – junctional adhesion molecule 
K 
KDR – kinase insert domain receptor 
(VEGFR2) 
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L 
LLC – Lewis lung carcinoma 
LSM – laser scanning microscope 
M 
mAb – monoclonal antibody 
MAPK – mitogen-activated protein kinase 
MARVEL – MAL and related proteins for 
vesicle trafficking and membrane link 
MDCK – Madin Darby canine kidney cells 
MEK – MAPK kinase (MAPKK) 
miRNA – microRNA 
MLEC – mouse lung endothelial cells 
MMP – matrix metalloprotease 
Mmu – Mus musculus chromosome 
MRI – magnetic resonance imaging 
MS – multiple sclerosis 
MUPP – multiple PDZ domain containing 
protein 
N 
NaCl – sodium chloride 
NCAD – neural cadherin 
NES – nuclear export signal 
NFAT – Nuclear factor of activated T-cells 
NISCH - Neonatal ichthyosis and sclerosing 
cholangitis 
NLS – nuclear localisation signal  
NSD – not statistically different/no significant 
difference 
NT – no treatment 
O 
OCT – optimal cutting temperature embedding 
medium 
OMIM – Online Mendelian Inheritance In Man 
P 
PAL – palmitoyl  
PAR – partitioning-defective 
PAGE – polyacrylamide gel electrophoresis 
PBS – phosphate-buffered saline 
PCNA – proliferating cell nuclear antigen 
PCR – polymerase chain reaction 
PDGFB - platelet-derived growth factor B 
PDGFRβ - platelet-derived growth factor 
receptor beta 
PDZ domain – from the 3 proteins: post 
synaptic density protein (PSD95), Drosophila 
disc large tumour suppressor (Dlg1), and 
zonula occludens-1 protein (ZO-1) 
PE – phycoerythrin 
PECAM – platelet endothelial cell adhesion 
molecule 
PET – positron emission tomography 
PFA – paraformaldehyde 
PI3K – phosphatidylinositol-3-kinase 
PKC – protein kinase C 
PLCγ – phospholipase C gamma 
PlGF – placenta growth factor 
pMLEC – primary mouse lung endothelial cells 
PMSF – phenylmethanesulfonylfluoride 
Pttg1ip – pituitary tumour-transforming 1 
interacting protein 
R 
RGD – Arginine-Glycine-Aspartate (amino 
acid motif) 
RIPA – radioimmunoprecipitation assay buffer 
RISC – RNA-induced silencing complex  
RNA – ribonucleic acid 
RNAi – RNA interference  
RNase – ribonuclease 
RTK – tyrosine kinase receptor 
RTKI – tyrosine kinase receptor inhibitor  
S 
Scr – scrambled 
SEM – standard error of the mean 
SH3 – Src homology 3 domain 
siRNA – small interfering RNA 
 
 
SMA – smooth muscle actin 
Sumo3 – small ubiquitin-like modifier 3 
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T 
TAM – tumour-associated macrophage 
TAMPs – tight junction associated MARVEL proteins 
TBE – Tris/Borate/EDTA 
TEMED – tetramethylethylenediamine 
TGFβ - transforming growth factor beta 
TM – transmembrane 
TJ – tight junction 
TRITC – tetramethyl rhodamine isothiocyanate 
TSP – thrombospondin 
TUNEL – terminal deoxynucleotidyl transferase dUTP nick end labelling 
U 
UV – ultraviolet 
V 
VE-Cadherin/VECAD – vascular endothelial cadherin 
VE-JAM – vascular endothelial junctional adhesion molecule (JAMB) 
VEGF – vascular endothelial growth factor 
VEGFR1/2/3 – vascular endothelial growth factor 1/2/3 
VN – vitronectin 
vSMC – vascular smooth muscle cell 
vWF – von Willebrand factor 
W 
WT – wild-type 
Z 
ZO1 – zonula occludens 1 
ZONAB –  ZO-1 associated nucleic acid binding protein 
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7.2 Hsa21 Gene list 
Colours mark synteny to Mmu16, Mmu17, Mmu10. Genes without synteny to Mmu16, Mmu17, or 
Mmu10 are black. ncRNAs (including microRNAs) are magenta.  Genes missing in Tc1 mice are 
highlighted in grey. Genes duplicated in Tc1 mice are highlighted in yellow. 
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(Hsa21 gene list continued) 
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7.3 Publications 
Two publications relating to my study are attached: 
 
Reynolds L. E. et al. Tumour angiogenesis is reduced in the Tc1 mouse model of 
Down’s syndrome. Nature (2010) 465, 813–817 
 
Supplementary information:  
http://www.nature.com/nature/journal/v465/n7299/abs/nature09106.html?lang=en#/su
pplementary-information 
 
Baker M. et al. Use of the mouse aortic ring assay to study angiogenesis. Nature 
Protocols (2012) 7, 89–104 
 
Supplementary information: 
http://www.nature.com/nprot/journal/v7/n1/abs/nprot.2011.435.html#/supplementary-
information 
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Tumour angiogenesis is reduced in the Tc1 mouse
model of Down’s syndrome
Louise E. Reynolds1, Alan R. Watson1*, Marianne Baker1*, Tania A. Jones3, Gabriela D’Amico1,
Stephen D. Robinson1, Carine Joffre2, Sarah Garrido-Urbani5, Juan Carlos Rodriguez-Manzaneque6,
Estefanı´a Martino-Echarri6, Michel Aurrand-Lions7, Denise Sheer3, Franca Dagna-Bricarelli8, Dean Nizetic4,
Christopher J. McCabe9, Andrew S. Turnell10, Stephanie Kermorgant2, Beat A. Imhof5, Ralf Adams11,
Elizabeth M. C. Fisher12, Victor L. J. Tybulewicz13, Ian R. Hart2 & Kairbaan M. Hodivala-Dilke1
Down’s syndrome (DS) is a genetic disorder caused by full or partial
trisomy of human chromosome 21 and presents with many clinical
phenotypes includinga reduced incidence of solid tumours1,2. Recent
work with the Ts65Dnmodel of DS, which has orthologues of about
50% of the genes on chromosome 21 (Hsa21), has indicated that
three copies of the ETS2 (ref. 3) or DS candidate region 1 (DSCR1)
genes4 (a previously known suppressor of angiogenesis5,6) is suf-
ficient to inhibit tumour growth. Here we use the Tc1 transchromo-
somicmousemodel ofDS7 to dissect the contribution of extra copies
of genes on Hsa21 to tumour angiogenesis. This mouse expresses
roughly 81% of Hsa21 genes but not the human DSCR1 region.
We transplanted B16F0 and Lewis lung carcinoma tumour cells into
Tc1mice and showed that growth of these tumourswas substantially
reduced compared with wild-type littermate controls. Furthermore,
tumour angiogenesis was significantly repressed in Tc1 mice. In
particular, in vitro and in vivo angiogenic responses to vascular
endothelial growth factor (VEGF) were inhibited. Examination of
the genes on the segment of Hsa21 in Tc1 mice identified putative
anti-angiogenic genes (ADAMTS18,9and ERG10) and novel endothe-
lial cell-specific genes11, never previously shown to be involved in
angiogenesis (JAM-B12 and PTTG1IP), that, when overexpressed,
are responsible for inhibiting angiogenic responses to VEGF. Three
copies of these genes within the stromal compartment reduced
tumour angiogenesis, explaining the reduced tumour growth
in DS. Furthermore, we expect that, in addition to the candidate
genes that we show to be involved in the repression of angiogenesis,
the Tc1 mouse model of DS will permit the identification of other
endothelium-specific anti-angiogenic targets relevant to a broad
spectrum of cancer patients.
DS, or trisomy 21, is responsible for developmental abnormalities,
learning disability, cardiovascular defects and dementia1. As well as
these phenotypes, which have been well documented in DS, three
independent studies have drawn attention to the fact that malignant
solid tumours are under-represented when compared with age-
matched and sex-matched individuals from the general popu-
lation1,2. This phenotype is probably due to ‘gene dosage’ effects; that
is, an extra copy of Hsa21 leads to higher levels of gene product
protecting DS individuals from solid tumour growth.
Orthology to Hsa21 is found on three mouse chromosomes:
Mmu16, Mmu17 and Mmu10, with 29 genes found on Hsa21 not
being represented in the mouse (Supplementary Fig. 1). Early trans-
genic mouse models, including the Ts65Dn model, which contains
orthologues of up to only 50% of the genes located on Hsa21, have
been used to study the reduced solid tumourmalignancies3. However,
it was not possible to examine the contribution of trisomy 21 speci-
fically to angiogenesis, a process essential for solid tumour growth, in
this system because all cells, including the tumour cells and stromal
cells, were potentially trisomic.We used the Tc1mousemodel of DS7,
which has 81% of Hsa21 genes but lacks the duplication of 29 genes
includingDSCR1, to test the effect of this additional segment of chro-
mosome 21 specifically on tumour neovascularization (Supplemen-
tary Fig. 1).
To determine whether Tc1 mice were protected from solid tumour
growth, we examined the growth of B16F0 and Lewis lung carcinoma
(LLC) tumour xenografts. Tumour growth of both B16F0 andLLCwas
significantly repressed in Tc1 mice in comparison with wild-type con-
trols (Fig. 1a). Additionally, LLC tumour growth kinetics were signifi-
cantly slower in Tc1 mice, especially at larger tumour sizes, which
require neovascularization rather than vessel co-option13 (Supplemen-
tary Fig. 2). To confirm that this phenotype was not the result of a
disproportionate increase of Mmu10, Mmu16 and Mmu17 relative to
the ploidy of the tumour cells, we examined the chromosomes in the
B16F0 and LLC cell lines.Mmu10,Mmu16 andMmu17were found to
be correct relative to the ploidy (Supplementary Fig. 3). These observa-
tions confirm that three copies of chromosome 21 genes suppress the
growth of tumours through reduced tumour neoangiogenesis.
To address specifically the contribution of tumour angiogenesis to
this phenotype, we examined the tumour vasculature. The additional
Hsa21 fragment in Tc1 mice induced a significant and substantial
decrease in tumour blood vessel density in both B16F0 and LLC
tumours in comparison with tumours grown in wild-type littermate
controls (Fig. 1b).Dextran-fluorescein isothiocyanate (FITC)-perfused
*These authors contributed equally to this work.
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blood vessel numbers were also decreased in Tc1 mouse tumours
(Fig. 1c). In contrast, examination of blood vessel density in un-
challenged skin and other organs fromwild-type control and Tc1mice
showed no difference between the genotypes (Fig. 1d and Supplemen-
tary Fig. 4), suggesting that pathological angiogenesis, but not normal
blood vessel density, is negatively affected by the Hsa21 fragment. In
addition, the growth of Tc1 endothelial cells was not affected by the
additional Hsa21 fragment14 (Supplementary Fig. 5). Furthermore, the
differences in tumour vascularity were not due to differences in
immune-cell infiltration between the genotypes (Supplementary
Fig. 6), and the contribution of Tc1 bone-marrow-derived cells to
tumour growth was not apparent (Supplementary Fig. 7). Taken
together, our data from Tc1 mice suggest that it is the presence of
an additional copy of a fragment of Hsa21, within blood vessels, that
inhibits solid tumour growth and represses tumour angiogenesis.
To assess whether the decreased tumour angiogenesis observed in
the Tc1 mice was due to reduced sensitivity to VEGF, we performed
in vivo growth-factor-induced angiogenesis assays. VEGF-mediated
neovascularization was reduced significantly in the Tc1mice in com-
parison with littermate controls (Fig. 2a). Treatment with PBS
resulted in similar baseline angiogenic responses in both genotypes
(data not shown). In addition to the lack of in vivo angiogenesis, Tc1
aortic rings were also unresponsive to stimulation with VEGF, in
contrast to VEGF-treated wild-type controls. Baseline responses to
PBS were not affected in the Tc1 aortic rings, indicating further that
an additional copy of the fragment of Hsa21 specifically suppresses
VEGF-induced neovascularization (Fig. 2b).
Vascular endothelial growth factor receptor 2 (VEGFR2) is amajor
pro-angiogenic growth factor receptor15. VEGF, by means of
VEGFR2, induces extracellular signal-regulated kinase (ERK)1/2
(p42/p44) phosphorylation and mediates endothelial cell activation
during angiogenesis, and inhibition of VEGFR2 or the ERK1/2 path-
way reduces VEGF-mediated angiogenic responses16. ERK1/2 phos-
phorylation was reduced specifically in response to VEGF, but not
basic fibroblast growth factor (bFGF), in Tc1 endothelial cells in
comparison with wild-type controls and in VEGF-stimulated prim-
ary cells isolated from individuals with DS (Fig. 2c, d, and Sup-
plementary Fig. 8). This specific response to VEGF focused our atten-
tion on VEGFR2.
Although other molecules, such as DYRK1A (dual-specificity
tyrosine-phosphorylation-regulated kinase 1A), have been reported
to beupstreamof ERK signalling17 andmay contribute to thedecreased
ERK phosphorylation in response to VEGF, we show that surface
levels, but not total levels, of VEGFR2 are substantially increased in
Tc1 endothelial cells (Supplementary Fig. 9a, b). After stimulationwith
VEGF, the surface levels of VEGFR2 remain consistently higher onTc1
endothelial cells than on control cells (Supplementary Fig. 9c). This
discrepancy between total VEGFR2 and surface VEGFR2 levels
indicates that Tc1 endothelial cells have lower cytoplasmic levels
of VEGFR2. Indeed, examination of endothelial cells in culture by
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Figure 1 | Tumour angiogenesis is restricted in Tc1mice. a, B16F0 and LLC
tumour size was reduced significantly in the Tc1 mice. Representative
tumour images are given. n5 20 per group. b, Blood vessel density was
reduced significantly in tumours from Tc1 mice. Representative staining for
endomucin in tumour sections is given. n5 5–10 per group. c, Perfusion of
tumour blood vessels in Tc1mice was reduced in comparison with wild-type
(WT) controls. Graph shows the mean number of dextran-FITC-perfused
blood vessels. Arrowheads, perfused vessels; arrows, non-perfused vessels.
d, Blood vessel density was similar in unchallenged skin ofWT andTc1mice.
n5 5 per group. Two asterisks, P, 0.05; asterisk, P, 0.01, n.s., not
statistically significant. Scale bars, 10mm (a) and 100mm (b). All values are
means and s.e.m.
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Figure 2 | VEGF-mediated angiogenic responses are inhibited in Tc1 mice.
a, VEGF-stimulated neovascularization into subcutaneously implanted
sponges, quantified by numbers of endomucin-positive blood vessels, was
decreased in Tc1 mice in comparison with wild-type (WT) mice. n5 20 per
group. b, VEGF-induced vessel sprouting ex vivo from Tc1 aortic rings was
inhibited. Representative images of aortic ring sprouts are given. n5 6–12
aortic rings per test. Asterisk, aortic ring; arrows, microvessel sprouts.
c, Phospho-ERK1 (pp44) was increased in WT but not in Tc1 primary
endothelial cells stimulated with VEGF. d, Phospho-ERK1 (pp44) was
increased in normal human cells stimulated with VEGF but not in DS cells.
Asterisk, P, 0.01; two asterisks, P, 0.05; n.s., not statistically significant.
Scale bars, 100mm (a) and 500mm (b). All values are means and s.e.m.
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immunofluorescence show that stimulation of wild-type cells with
VEGF induced an apparent internalization of phosphorylated
VEGFR2 that was not present in Tc1 endothelial cells (Supplemen-
tary Fig. 9c). The phosphorylated VEGFR2 in Tc1 endothelial cells
seemed to be restricted at the cell surface after stimulation with
VEGF. Although beyond the scope of the study, it is tempting to
speculate that defects in VEGFR2 subcellular localization are relevant
to the repressed angiogenesis in Tc1mice and provide a novel aspect to
the regulation of angiogenesis in DS18,19.
We identified several putative anti-tumorigenic, anti-angiogenic
and endothelial-cell-specific genes expressed on Hsa21 in the Tc1
mice likely to be responsible for the decreased angiogenic responses.
These included ETS2, encoding a transcription factor whose over-
expression reduces tumour growth in the Ts65Dn mouse model of
DS and in other models3,20 but is not yet linked with angiogenesis;
ADAMTS1, encoding a protease known to inhibit angiogenesis8,9,21;
and three endothelial-cell-specific Hsa21 genes (ERG, encoding a
transcription factor implicated in endothelial tube formation and
angiogenesis10; JAM-B, encoding a cell–cell adhesion molecule not
yet implicated in angiogenesis or tumorigenesis; and PTTG1IP,
which is overexpressed in cancers but is also not yet linked to angio-
genesis). All mouse transcripts were expressed in Tc1 and wild-type
endothelial cells and human transcripts only in the Tc1 endothelial
cells (Supplementary Fig. 10a, b). To test whether three copies of any
of these candidate genes negatively affected angiogenesis, we first
observed the effects of depleting individual human transcripts by
RNA-mediated interference (RNAi) on VEGF-mediated microvessel
sprouting in aortic ring assays (Fig. 3). Knockdown of the human
transcripts and protein in Tc1 endothelial cells was confirmed byRT–
PCR and western blot analysis, and no detectable effects on mouse
orthologues were observed (Fig. 3a and Supplementary Fig. 11).
Wild-type aortic rings stimulated with VEGF showed a significant
increase in microvessel sprouting that was not affected by treatment
with scrambled (Scr) short interfering RNA (siRNA) or the human-
specific siRNAs against ETS2, ERG, ADAMTS1, JAM-B or PTTG1IP
(Fig. 3b). This was expected, because these aortic rings lacked any
human genes and acted as a control. In contrast, Tc1 aortic rings
did not show enhanced microvessel sprouting in response to stimu-
lation with VEGF with or without Scr-siRNA transfection (Fig. 3c).
However, the use of human-specific siRNAs to deplete one of three
copies of ERG,ADAMTS1, JAM-B orPTTG1IP transcripts (effectively
recreating wild-type copy numbers for each gene) was sufficient to
restore VEGF-mediatedmicrovessel sprouting to VEGF-treated wild-
type levels. Depletion of one of three copies of ETS2 did not induce a
significant increase in microvessel sprouting in response to VEGF
(Fig. 3c), suggesting that vascular ETS2 is not involved in this res-
ponse. In contrast, data from ref. 3 suggest that ETS2 is involved in the
growth of spontaneous intestinal tumours in APCmin mice. Taken
together, these data suggest that the effect of ETS2 occurs in the
non-stromal tumour cell compartment. Indeed, ETS2 has been
reported to be responsible for different biological responses in differ-
ent cell types22–24. Our data provide an example of how the xenograft
model used in theTc1mice enables us to dissect the role of genes in the
tumour and in the stromal compartment.
To test the gene-dosage effect of the remaining candidate genes
further, we used mouse-specific siRNAs to deplete two of three tran-
script copies in Tc1 aortic rings. Using RT–PCR we showed that
mouse-specific siRNAs for the candidate genes Erg, Adamts1, Jam-b
and Pttg1ip effectively depleted mouse transcripts in Tc1 endothelial
cells (Fig. 4a). As in Fig. 3c, VEGF treatment of Tc1 aortic rings that
were either untransfectedor transfectedwith Scr-siRNAdidnot induce
an increase in microvessel sprouting over untreated control aortic
rings. In contrast, targeting the mouse Adamts1, Jam-b or Pttg1ip
transcripts by siRNA promoted VEGF-mediated microvessel sprout-
ing over and above Scr-siRNA-treated controls. Depleting two of three
copies of these transcripts (effectively reducing the copy number of
each gene from three to one) is sufficient to promote VEGF-mediated
microvessel sprouting (Fig. 4b). Taken together, our data show that for
Adamts1, Jam-b and Pttg1ip one or two copies of the transcript is
sufficient to restore normal levels of VEGF-mediated vessel sprouting,
suggesting that a gene dosage effect is mediating the repressed angio-
genic phenotype in the Tc1 mice. In contrast, depleting two of three
copies of the Erg gene did not affect VEGF-mediated vessel sprouting,
suggesting that two copies of this transcript are required for normal
angiogenic responses.
In addition, an antibody against mouse JAM-B was injected into
B16F0-tumour-burdenedTc1mice. Intraperitoneal administrationof
this antibody increased tumour size and blood vessel density signifi-
cantly in Tc1mice in comparison with control-IgG-injected Tc1 con-
trols (Fig. 4c). To provide direct evidence of a gene-dosage effect of
JAM-B on angiogenesis we compared angiogenesis in wild-type mice
(two copies of JAM-B) with that in JAM-B heterozygous mice (one
copy of JAM-B). JAM-B heterozygous mouse tissue showed roughly
half the levels of JAM-B (Supplementary Fig. 12). B16F0 tumour
size and blood vessel density were increased significantly in JAM-B
heterozygous mice in comparison with wild-type mice (Fig. 4d, e).
Furthermore, aortic rings from JAM-B heterozygous mice showed a
significant increase inVEGF-mediatedaortic vessel sprouting(Fig. 4f).
Finally, we compared VEGF-induced angiogenesis ex vivo by using
aortae isolated from wild-type and ADAMTS1 heterozygous mice.
Once again, our data showed a gene-dosage effect of ADAMTS1 on
angiogenesis and corroborate previous findings in which genetic
ablation of ADAMTS1 enhanced angiogenesis25 (Supplementary
Fig. 13). Taken together, these results confirm that one extra copy
of the candidate genes onHsa21 canprovide an anti-angiogenic effect.
Our work establishes that three copies of individual genes in the
stromal compartment can confer a repressed tumour angiogenic
phenotype in the Tc1 mouse model of DS, supporting the notion
of a ‘gene-dosage’ effect, for some genes, protecting DS individuals
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from solid tumour growth1,2. In particular, VEGF-mediated angio-
genic processes are inhibited by the addition of a fragment of Hsa21
in the Tc1 mice. Our data show that individual depletion of JAM-B,
ADAMTS1, ERG or PTTG1IP, but not ETS2, is sufficient to restore
normal angiogenic responses to VEGF. This implies that three copies
of JAM-B, ADAMTS1, ERG and PTTG1IP, and probably others that
we have not tested, need to be present for the overall inhibitory effect.
The transchromosomic system used in our study has a unique
advantage in allowing species-specific silencing of the third gene
copy, leading to a rapid genetic dissection and pinpointing of the
causative trisomic genes. Although beyond the scope of the present
study, our results imply that JAM-B, ADAMTS1, ERG and PTTG1IP,
but not ETS2, are upstream of a common signalling pathway in the
control of angiogenic responses.
Although we see a phenotype in Tc1 mice similar to that described
in ref. 4, the mechanisms of this regulation are likely to be different
because the DSCR1 region is triplicated in TS65Dn mice but
expressed at normal levels in Tc1 mice. Because of this, changes in
DSCR1-mediated signalling through calcineurin are unlikely to be
affected in Tc1 mice. Indeed, although the overexpression of DSCR1
has been shown to inhibit tumour angiogenesis, overexpression of
this gene is also thought to contribute to several pathological
defects26, suggesting that manipulation of DSCR1 downstream sig-
nalling may have limited anti-angiogenic therapeutic potential. In
contrast, our studies not only confirmed the function of known anti-
angiogenic genes on Hsa21 but also identified and tested novel endo-
thelium-specific genes that are anti-angiogenic when overexpressed.
Our data highlight the importance of ADAMTS1, JAM-B, PTTG1IP
and other, potentially novel, genes in controlling tumour angiogenesis.
Furthermore, we have identified JAM-B and PTTG1IP as new anti-
angiogenic mediators.
Our study reveals that repression of angiogenesis by the addition of
a fragment of Hsa21 in DS models can direct the discovery of new
anti-angiogenic targets, which have the potential of being exploited
pharmacologically for the development of effective gene therapy for
treating cancer.
METHODS SUMMARY
Mice. Tc(Hsa21)1TybEmcf (Tc1) mice were generated by crossing Tc1 females
with (129S83B6)F1 males
7.
In vivo tumour assays. In vivo tumour assays and tumour kinetic studies were
performed as described previously27,28.
The anti-JAM-Bantibody (clone JB4.2)wasdeveloped inB.A. Imhof’s laboratory
and will be described elsewhere. For JAM-B blocking experiments, 100mg of JB4.2
was injected intraperitoneally every3days into tumour-burdenedTc1 andwild-type
mice. On day 12, tumours were measured and processed for histological analysis.
Subcutaneous angiogenesis assay. Assays were performed as described previ-
ously29. On day 14 the sponges were harvested and fixed for immunostaining for
blood vessel examination.
Western blot analysis.Wild-type and Tc1 primary endothelial cells were lysed,
and 30–100mg of protein for each protein sample was loaded onto 8–12% gels
and western blot analysis was performed (VEGFR2/phospho-VEGFR2, ERK1/2
and phospho-ERK1/2 were from Cell Signaling Technology). Anti-ADAMTS1
antibody was a gift from L. Iruela-Arispe. Anti-PTTG1IP antibody was raised in
rabbits against the human PTTG1IP protein. Anti-JAM-B antibody was pro-
vided by B. A. Imhof.
Aortic ring assay. This assay was performed as described previously28. For RNAi
studies, aortic rings were transfected with various siRNAs (Dharmacon) before
being embedded in collagen.
Blood vessel quantification. Sections of size-matched tumours or sponges were
immunostained with rat anti-endomucin (Santa Cruz) antibody to identify
blood vessels. The number of blood vessels was counted as described previ-
ously28.
Statistical analysis. Statistical significance was calculated with Student’s t-test.
P, 0.05 was considered statistically significant.
Animal regulations. All animals were used in accordance with UKHomeOffice
regulations.
Full Methods and any associated references are available in the online version of
the paper at www.nature.com/nature.
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METHODS
Mice. Tc(Hsa21)1TybEmcf (Tc1) mice were generated by crossing Tc1 females
with (129S83B6)F1 males
7. Experiments were performed with male JAM-B
heterozygous, Tc1 and wild-type littermate mice aged 2–4months.
In vivo tumour assays. B16F0 melanoma cells (106) or 53 105 LLC cells were
injected subcutaneously into the scruff of test and control mice and were mea-
sured and processed for histological analysis after 12 or 10 days of growth,
respectively, as described previously27. For the LLC tumour kinetic experiment,
53 105 LLC cells were injected subcutaneously into the flank of Tc1 and wild-
type littermate control mice; tumour volume, v, was calculated by palpation
(with the formula v5 0.5(l3w2), where l is tumour length and w is tumour
width) every 2 days up to day 16.
The anti-JAM-Bantibody (clone JB4.2)wasdeveloped inB.A. Imhof’s laboratory
and will be described elsewhere. For JAM-B blocking experiments, 100mg of JB4.2
was injected intraperitoneally every 3days into tumour-burdenedTc1andwild-type
mice. On day 12, tumours were measured and processed for histological analysis.
Subcutaneous angiogenesis assay. Assays were performed as described previ-
ously29. Spongeswere implanted into the flanks of age-matched and sex-matched
Tc1 and wild-type littermate control mice and on the following day the sponges
were injected directly with either VEGF (10 ng final concentration) or PBS as a
control, every 3 days up to 14 days. On day 14 the sponges were harvested and
fixed for immunostaining for blood vessel examination.
Western blot analysis.Wild-type and Tc1 primary endothelial cells were plated
into 6-cm or 10-cm dishes and grown in MLEC (mouse lung endothelial cell)
medium to 70% confluence. The medium was removed and the dishes were
washed twicewith PBS followed by lysis with RIPA buffer or 13modified sample
buffer (3% SDS, 60mM sucrose, 65mM Tris-HCl pH6.8). For phosphorylation
studies, the cellswere incubated for 4 h in serum-freeOptimem, afterwhichhalf of
the dishes were treated for 5min with 30 ngml21 VEGF or 30ngml21 bFGF at
37 uC. The remainder were left untreated. The cell lysates were sonicated briefly
and centrifuged, and the supernatant was collected for western blot analysis.
Protein (30–100mg) for each protein sample was loaded onto 8–12% gels and
western blot analysis was performed. Membranes were incubated with primary
antibody at 4 uC (VEGFR2/phospho-VEGFR2, ERK1/2 and phospho-ERK1/2 all
from Cell Signaling Technology). Anti-ADAMTS1 antibody was a gift from
L. Iruela-Arispe. Anti-PTTG1IP antibodywas raised in rabbits against the human
PTTG1IPprotein.Anti-JAM-BantibodywasprovidedbyB.A. Imhof. Incubation
for 1 h with the relevant secondary horseradish peroxidase-conjugated antibody
was followed by chemiluminescence detection of bands.
Aortic ring assay. This assay was performed as described previously27,28. In brief,
aortae were isolated from Tc1 and wild-type littermate controls, sliced into rings
and serum-starved overnight in Optimem. Aortic rings were embedded in a
collagen matrix and cultured in the presence of VEGF (30 ngml21), bFGF
(30 ngml21) or PBS as a negative control or 10% FCS as a positive control. For
RNAi studies, aortic rings were transfected with various siRNAs (Dharmacon)
before being embedded in collagen. Angiogenic sproutswere counted up to 7 days
after embedding. To confirm gene knockdown, whole aortic rings were trans-
fected with RNAi for 48 h. RNA was extracted from the aortae with the Qiagen
RNeasy mini kit and reverse transcribed; the resulting complementary DNA was
used for RT–PCR analysis.
Blood vessel quantification. Frozen tumour sections or paraffin-fixed sponge
sections were immunostained with rat anti-endomucin (Santa Cruz) primary
antibody to identify blood vessels. The number of blood vessels was counted in a
double-blindmanner across entire midline sections of size-matched tumours or
sponges27,28. Blood vessel density was calculated as the number of blood vessels
per unit area of section.
Statistical analysis. Statistical significance was calculated with Student’s t-test.
P, 0.05 was considered statistically significant.
Animal regulations. All animals were used in accordance with UKHomeOffice
regulations.
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IntroDuctIon
Angiogenesis, the growth of new blood vessels from pre-existing 
ones, is a highly complex process involving a range of cell types and 
signaling pathways. Angiogenic processes involve the stimulation of 
endothelial cells by several different pro-angiogenic factors such as 
vascular endothelial growth factor (VEGF), basic fibroblast growth 
factor (bFGF) and others1–4. These induce changes in a multitude 
of downstream signaling pathways involved in the control of neo- 
vessel sprouting and branching. However, many of these pathways 
are poorly understood. As with many essential physiological pro-
cesses, angiogenesis is normally tightly regulated but is disrupted in 
many pathological conditions, including cancer, diabetes, arthritis 
and ischemic heart disease5.
In vivo analysis of angiogenesis currently involves models includ-
ing the following: tumor angiogenesis, both in injectable and spon-
taneous tumor models6–10; growth factor–stimulated angiogenesis 
assays using subcutaneously implanted sponges, Matrigel plugs, 
the chick embryo chorioallantoic membrane assay or DIVAA (the 
directed in vivo angiogenesis assay from amsbio)11–17; retinoangio-
genic assays8,12,13,17–19; and ischemia models such as retinopathy of 
prematurity and hind limb ischemia. More recently, the use of 
zebrafish to analyze the molecular basis of developmental and 
tumor angiogenesis has also been explored20–22.
The obvious advantage of examining angiogenesis in vivo is 
that the process involves several cell types and a complex balance 
of pro- and antiangiogenic factors that work together to regulate 
blood vessel formation. Therefore, to understand the full regula-
tion of neovascularization, in vivo analysis is required. However, 
the major disadvantages of such models are that in vivo experi-
ments are relatively expensive and the involvement of inflamma-
tion and other cell types (i.e., not blood vessel cells) in angiogenic 
processes in vivo can make it difficult to discriminate between 
responses of blood vessel cells themselves and the paracrine effects 
of other tissues.
In tissue culture, the isolation and growth factor stimulation of 
endothelial cells has provided the basis for many in vitro assays for 
the analysis of angiogenic processes. These include: pure endothelial 
tube formation assays23; fibroblast and endothelial cell coculture 
tube formation assays, either in two dimensions or on beads24,25; 
and the aortic ring assay4,6–8,12,13,26–30.
The limitations of the cell-based assays are varied. Development 
of cords and networks of cells often occurs but without sprouting 
lumenized blood vessels per se. In addition, they do not involve 
the incorporation of supporting cells such as pericytes, which are 
known to have a pivotal role in the stability of newly formed blood 
vessels. These are clear disadvantages of studying angiogenesis using 
such systems, although these assays are cheap and do not require the 
use of model organisms. In contrast, the aortic ring assay provides 
a more physiologically relevant in vitro model for angiogenesis, 
developing lumenized blood vessels with surrounding supporting 
cells in a timescale similar to that observed in vivo.
Development of the aortic ring assay
Nicosia and Ottinetti4 were the first to devise the rat aortic ring 
assay in 1990 to assess angiogenesis in an ex vivo model that bridged 
the gap between existing in vitro and in vivo technologies, and it 
was expanded on in 2008 (ref. 27). The rat assay has been used 
in many laboratories, and it has also been adapted to porcine 
tissue31–35. However, transgenic mouse technologies are now far 
more readily available and cost-efficient than those based on rats; 
therefore, mouse-based aortic ring assays are a marked advance-
ment over the original rat-based model.
As a result, to further the original rat aortic ring method and 
translation of the assay to mice36,37, we present a step-by-step 
 protocol for mouse aortic ring assays that we have tested and refined 
over several years to provide a useful and versatile ex vivo assay for 
those interested in studying sprouting angiogenic responses.
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Here we provide a protocol for quantitative three-dimensional ex vivo mouse aortic ring angiogenesis assays, in which developing 
microvessels undergo many key features of angiogenesis over a timescale similar to that observed in vivo. the aortic ring 
assay allows analysis of cellular proliferation, migration, tube formation, microvessel branching, perivascular recruitment and 
remodeling—all without the need for cellular dissociation—thus providing a more complete picture of angiogenic processes 
compared with traditional cell-based assays. our protocol can be applied to aortic rings from embryonic stage e18 through to 
adulthood and can incorporate genetic manipulation, treatment with growth factors, drugs or sirna. this robust assay allows 
assessment of the salient steps in angiogenesis and quantification of the developing microvessels, and it can be used to identify 
new modulators of angiogenesis. the assay takes 6–14 d to complete, depending on the age of the mice, treatments applied and 
whether immunostaining is performed.
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Advantages of the aortic ring assay
The aortic ring assay is a more physiologically relevant assay 
with clear advantages over other in vitro methods: it is relatively 
inexpensive and quick to perform, with many rings available from 
few animals; supporting cells are included in the formation of 
microvessels; the model generally excludes inflammatory compo-
nents (although the involvement of macrophages has been exam-
ined38); and tubule structures are clearly visible, develop over a time 
course similar to that in vivo and are lumenized4.
In particular, our method can be expanded easily to the analysis 
of hundreds of rings per experiment, overcoming the issue of the 
time-consuming and difficult-to-scale-up preparation of agarose 
rings to house collagen gels for each aortic ring36. This also means 
that several conditions may be tested at once: for example, knock-
down of genes of interest or drug concentrations. We also routinely 
perform high-quality imaging of aortic ring cultures at both low 
and high magnification, and this combined with the standardiza-
tion of all the aortic ring protocols allows for the collection of a 
wide range of data.
Applications of the aortic ring assay
A particular strength of the assay is the ease with which it adapts to 
different applications, such as testing the effects of growth factors 
and small-molecule drugs; genetic manipulation (including tran-
sient, inducible and constitutive knockout/overexpression, together 
with available transgenic mouse technology); and combinations 
of the above.
Limitations of the aortic ring assay
Notable limitations of the assay include the requirement for fresh 
mouse tissue; the lack of involvement of nonaortic tissues; the lack 
of flow; and the regression of vessels over time, giving a limited 
window for analysis.
Overview of the procedure
The general protocol for mouse aortic ring culture involves 
dissection of the aorta, serum starvation, embedding and feed-
ing of the aortic rings, and imaging and quantifying microvessel 
sprouts (Fig. 1).
Thoracic aortae are first dissected from mice (Fig. 2 and 
Supplementary Video 1) and then cleaned and cut into rings. They 
are then serum-starved overnight to equilibrate their growth factor 
responses, effectively creating a uniform baseline state. During 
serum starvation, the rings can be transfected with siRNAs6 or 
transduced with viral expression constructs to manipulate gene 
expression and test the effects on sprouting angiogenesis39,40. 
Although serum starvation is not an absolute requirement for 
sprouting, we have found that it increases the difference between 
stimulated and nonstimulated growth of microvessels. Notably, it 
Dissection of aortic rings
Serum starvation
Embedding
Feeding
Matrix:
(A) Type l collagen
(B) Fibrin
(C) Matrigel
Imaging and quantification
Live/fixed
Phase contrast
Epifluorescence
          (A,B) Immunofluorescence
          (C) Proliferation assay
Confocal
3D reconstruction
Growth factors: VEGF/bFGF
Drugs
etc.
(A) siRNA
(B) shRNA (lentiviral transduction)
Adult / newborn / embryonic
Sprout number
Sprout length
Pericyte coverage
Vessel area
etc.
Day –1
Steps 1–12
Day –1 to 0
Steps 12,13
Day 0
Step 14
Days 0, 3, 5, 7...
Step 14
Days 5–9
(approx.)
Steps 15–18
Figure 1 | Flow diagram of the general procedure. The time course is 
indicated on the left with main steps highlighted in solid boxes and options 
for modification/intermediate steps in a dotted outline.
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Figure 2 | Dissection of mouse aorta from the thoracic cavity. (a) After  
the opening of the chest cavity by cutting around the rib cage and  
through the diaphragm, the heart and lungs have been removed and the 
esophagus cut away. The aorta runs along the spine (white arrowheads) 
from the anterior end (A) to the posterior end (P), and the stomach (S)  
and liver (L) are visible. (b–d) Grasping the anterior end of the aorta 
(white arrowhead) gently with forceps, the artery is lifted slightly and 
closed scissors run between it and the spine to detach the fatty layer using 
blunt dissection, moving gently toward the posterior end (P) until the 
aorta is mostly detached. (e) The aorta is cut once at the posterior end (P). 
(f) The aorta is cut again at the anterior end (white arrowhead). Also see 
supplementary Video 1.
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is an essential step whenever siRNA transfections are performed. 
Therefore, starvation is performed in all cases for consistency.
The next day, rings are embedded in one of three possible matrices 
(see Experimental design): collagen, fibrin or Matrigel (Fig. 3 and 
ref. 39). Once embedded, the rings are fed with growth medium 
every 2–3 d. This can be supplemented with various growth factors 
as stated above. Alternatively, small-molecule drugs can be added 
to the medium to test their effects7.
Endothelial microvessel sprouts grow out from the rings in 
phases: exponential growth and then regression. Sprouts can be 
counted during the exponential growth phase to obtain angiogenic 
response data (Fig. 4). Before the regression phase, rings can be 
fixed for immunofluorescence staining to examine the sprout struc-
ture in detail and perform further quantification (Figs. 5–7).
Experimental design
Experimental animals. This protocol is applicable to mice of 
 various ages, from embryonic stage 18 (E18) embryos to adults, 
and it can be used to test the effects of exogenous agents on angio-
genesis (for example, drugs7,41,42 and growth factors12) and/or genetic 
 ablation, either globally or cell type specifically (for example, using a 
Cre-lox system7,41–44; see ANTICIPATED RESULTS and Figs. 3–7).
An adult mouse aorta can provide 20–30 aortic rings. Rings from 
at least three separate aortae should be used per condition. As many 
variables are involved, ring size in particular, it is best to carry out 
experiments with n ≥ 20 rings per condition to attain reproducible 
results. Because of the inherent variability of animal experiments, it 
has proven necessary to repeat each experiment at least three times. 
Previous experience has shown that use of the specified number of 
animals/aortic rings will give unequivocal results, which avoids the 
need for additional experiments. Differences between data sets are 
analyzed using the Student’s t test.
The sex of the mice does not appear to substantially influence 
aortic ring sprouting, but this may be subject to change depending 
on the conditions. Genetic background significantly affects aortic 
ring sprouting27,45. Adult C57BL/6 mice of 8–12 weeks of age are 
most appropriate for the assay. C57/129Sv mixed-background 
mice can also be used successfully; however, the FVB background 
is not recommended, as we and others have shown that sprouting 
is minimal and is not amenable to the generation of statistically 
meaningful results45. Aortic rings from embryos begin to sprout 
Figure 3 | Optimization of the mouse ex vivo 
aortic ring assay. Millipore type 1 rat-tail 
collagen-embedded wild-type aortic rings.  
(a) Rings fed with Opti-MEM  +  2.5% (vol/vol) 
FBS or DMEM  +  2.5% (vol/vol) FBS, with or 
without penicillin-streptomycin (P/S), and 
supplemented with PBS ( − ) or VEGF ( + ). 
Significant increases in microvessel sprouting  
are observed in Opti-MEM–fed rings when  
VEGF-treated rings are compared with PBS-treated 
controls both with and without P/S, with some 
inhibition of VEGF-induced microvessel  
sprouting in the presence of P/S. FBS-
supplemented medium (2%, vol/vol) was also 
tested with very poor (little to no sprouting) results (not shown). (b) Growth factor–stimulated microvessel sprouting in three different matrices: collagen, 
fibrin and Matrigel. Collagen-embedded rings were fed with P/S-free medium. PBS control bars in white; growth factor–stimulated results in gray; Matrigel 10%  
(vol/vol) FBS positive control in dark gray. No sprouting was observed in bFGF-treated rings embedded in collagen. Aortae were isolated from wild-type 
C57BL/6 mice (8–12 weeks); n  =  6–104 rings per treatment. *P  <  0.01, **P  <  0.001. Errror bars represent the mean number of microvessel sprouts ± s.e.m.
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Figure 4 | Collecting aortic ring data. (a,b) Phase-contrast images of aortic 
rings embedded in type I collagen and Matrigel, respectively, showing 
microvessel outgrowth (black arrows). Scale bar, 200 µm. (c) Time course 
of microvessel sprouting from aortic rings embedded in collagen and 
stimulated with VEGF or PBS as a control. Counts were carried out using 
a phase-contrast microscope from days 5 to 9 after embedding (day 0). 
Peak microvessel numbers were observed on day 6 in this experiment, and 
by day 9 the number of sprouts had become more variable. Bars represent 
the mean number of microvessel sprouts ± s.e.m. (d) A monochrome 
epifluorescence image at ×5 magnification of a wild-type, VEGF-treated 
aortic ring embedded in collagen and stained with BS1 lectin-FITC 6 d after 
embedding. Scale bar, 200 µm. (e) The skeletonized representation of the 
aortic ring shown in d identifies how the microvessels can be numbered 
systematically and counted. Aortae were isolated from wild-type C57BL/6 
mice aged 8–12 weeks. 
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earlier and sprouts grow faster and more extensively. The assay will 
not provide meaningful results if the mice are too old (more than 
18 weeks of age).
Transfection methods. For transient gene silencing, siRNA 
constructs can be delivered to aortic ring tissue using the 
Oligofectamine transfection reagent as per the manufacturers’ 
instructions, to quickly and easily assess the effects of temporary 
gene knockdown on angiogenic processes6,39. As the Opti-MEM 
medium is crucial for this protocol, we always use this reagent 
 (supplemented with 2.5% (vol/vol) FBS unless using the fibrin 
matrix) to maintain consistency. Notably, we have found that it 
supports VEGF-stimulated microvessel growth in the presence or 
absence of penicillin-streptomycin markedly better than DMEM  + 
2.5% (vol/vol) FBS (Fig. 3a).
We have also used lentiviral transduction of aortic rings to 
knockdown genes for the duration of the experiment using small 
hairpin RNA39,40. In addition, this protocol can be adapted for gene 
overexpression by inserting an expression clone in place of the 
small hairpin RNA sequence. Other groups have also optimized 
gene transduction using different viral vectors46–48.
RNA and/or protein extraction can be performed before 
 embedding in order to quantify RNA-mediated interference (RNAi) 
efficiency or to analyze endogenous RNA/protein levels in aortic 
tissue (Fig. 8 and Box 1).
Choice of matrix. We have optimized aortic ring microvessel 
outgrowth supported by three different extracellular matrices: 
type I collagen, fibrin and Matrigel (Fig. 3b). Matrix choice can 
be influenced by the type of growth factor-induced angiogenic 
response being studied; for example, VEGF-induced sprouting is 
best observed in a collagen matrix, whereas bFGF-induced sprout-
ing, in our experience, is not viable in collagen and instead a fibrin 
matrix is used12,45. However, others have applied the collagen-based 
assay to bFGF studies49. The original method was devised using auto-
logous rat-tail collagen; however, for the mouse assay, commercially 
available collagen can be used to avoid time-consuming in-house 
collagen purification from mouse serum36.
Collagen-embedded rings respond well to VEGF, producing thick 
sprouts, with associated supporting cells, which are clearly different 
from fibroblast outgrowth. Having tested type I rat-tail collagen 
provided by SERVA Electrophoresis (Collagen R, as used by Bruyère 
et al.50 in the mouse lymphatic ring assay), BD Biosciences and 
Millipore, we found that the Millipore brand supported microvessel 
sprouting most reliably (Fig. 3a).
Alternatively, aortic rings can be embedded in a fibrin matrix to 
observe bFGF-induced sprouting12,45. In our experience, neither 
collagen nor Matrigel is suitable for use with this growth factor, as 
fibroblast outgrowth is too extensive.
Matrigel, a mixture of extracellular matrix components 
 (predominantly laminins), could be considered to mimic in vivo 
conditions more closely than pure matrices. However, higher-quality 
a Collagen+ VEGF
c Collagen
+ PBS
BS1 lectin
α-SMA
DAPI
b Fibrin+ bFGF
d Fibrin
+ PBS
Figure 5 | Immunofluorescence staining of aortic rings. Confocal images 
of growth factor–induced microvessel sprouts in collagen and fibrin. BS1 
lectin-FITC (green) stains endothelial sprouts (white arrows); α-SMA-Cy3 
(red) indicates supporting cells. DAPI-stained nuclei (blue). (a) VEGF-treated 
ring embedded in collagen. (b) bFGF-treated ring in fibrin. (c,d) PBS-treated 
control aortic rings in collagen and fibrin, respectively. All animals were 
wild-type C57BL/6 mice aged 8–12 weeks. Scale bar, 200 µm. Panel d of 
this figure was originally published under the Creative Commons Attribution 
License in ref. 12.
a
BS1 lectin
α-SMA
DAPI
BS1 lectin
NG2
DAPI
b
c d
Figure 6 | Microvessel sprout imaging: visualizing supporting cell  
coverage. (a–d) VEGF-treated aortic rings grown in type I collagen were  
stained for endothelial cells using BS1 lectin (green) and antibodies  
to α-SMA in red (a) or NG2 (b–d). (a) Epifluorescence microscopy: ×40 
image of a microvessel with high supporting cell coverage. (b) Confocal 
microscopy using a Zeiss LSM 510 laser-scanning microscope. The tips of  
two microvessel sprouts were imaged with a plan Apochromat ×63/1.4  
oil objective lens. Images were acquired with sequential scanning of the 
three different channels (blue, red and green) at a resolution of 1,024 ×  
1,024 and every 0.5 µm in the z plane. Images were analyzed using 
the image processing software Imaris 7.2 (Bitplane), which renders the 
optical sections into 3D images (c: unprocessed 3D reconstruction; d: 3D 
reconstruction with background subtracted). Scale bars, 20 µm.
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images are routinely obtained in our hands from immunostained 
rings embedded in collagen or fibrin, which are cheaper reagents, 
and in these cases supporting cell association with endothelial cells 
is also clear. The morphology of microvessel sprouting in Matrigel 
is markedly different, with very thin, spindle-like networks growing 
from the rings, which is distinct from the robust tubules that are 
observed in collagen and fibrin (Fig. 4a).
Imaging and quantification. We routinely use phase-contrast 
microscopy for a crude view of microvessel outgrowth that is suf-
ficient to identify and count microvessels during the experiment, 
but which does not definitively distinguish endothelial sprouts 
from other cell types (Fig. 4a,b). Microvessel sprouts are struc-
tures of connected cells that are attached, at their base, to the aortic 
ring. The outgrowths of single cells, many of which are likely to 
be fibroblasts, are not considered to be microvessel sprouts. This 
method is used to produce a time course of growth from days 5 to 9 
(when 8- to 12-week-old mice are used, embryonic rings will begin 
sprouting earlier) as shown in Figure 4c.
Immunofluorescence staining is required for a more informa-
tive view of microvessel sprouting, including the identification of 
supporting cells, which can be analyzed further (Figs. 4d and 5). 
Epifluorescence microscopes are sufficient for collecting images 
for automatic quantification and for an overview of the extent of 
microvessel sprouting in various conditions. For greater detail, 
high-power images of microvessels can be obtained from immu-
nostained aortic ring cultures using confocal microscopy. Examples 
of such images are presented in Figure 5.
Pericyte or supporting cell coverage can be quantified 
in immunostained cultures by measuring sprout length 
and counting the number of associated pericytes per unit 
length using immunofluorescence staining for endothelial- 
specific and pericyte markers such as BS1 lectin and α-smooth 
muscle actin (or NG2 chondroitin sulfate proteoglycan), 
respectively. Further structural analysis may be performed with 
confocal microscopy and 3D image reconstruction using Imaris 
software (Fig. 6).
To analyze cell proliferation in the aortic ring assay, we also 
tested the Invitrogen Click-iT EdU Alexa Fluor 488 imaging kit. 
Immunostaining for endothelial and/or supporting cells, com-
bined with high-power microscopy, allows the identification of 
proliferating cells (both endothelial and pericytes), as shown 
in Figure 7.
EdU Alexa Fluor 488a b
c d
e f
BS1 lectin-TRITC + EdU
DAPI + EdU Merge
50 µM
50 µM 10 µM
Z-stack
Imaris 3D reconstruction
Figure 7 | Cellular proliferation in aortic rings. Confocal imaging of 
a VEGF-treated aortic ring microvessel grown in type I collagen with 
proliferating cells detected using the Invitrogen Click-iT EdU Alexa 
Fluor 488 kit; endothelial cells stained with BS1 lectin-TRITC and 
counterstained with DAPI as a nuclear marker. (a) EdU-positive nuclei.  
(b) BS1 lectin-TRITC-positive endothelial cells merged with EdU.  
(c) EdU merged with DAPI-stained nuclei. (d) Three-channel merge.  
(e) Z-stack of the whole microvessel sprout with the proliferating cell 
nucleus (white arrowheads) surrounded by TRITC staining showing that 
it is an endothelial cell within the microvessel and not a supporting cell 
as seen around the microvessel tip in d. (f) 3D reconstruction of the 
microvessel sprout in Imaris (Fig. 6) showing the proliferating endothelial 
cell. Arrows show proliferating supporting cell nuclei. Arrowheads show 
proliferating endothelial cell nuclei.
Figure 8 | RNAi in aortic rings. (a) Example 
control data for aortic rings embedded in  
collagen for 6 d. PBS treatment is shown in white 
and VEGF stimulation in gray. No significant 
differences in sprouting are observed when 
Oligofectamine transfection reagent alone 
(transfection control, TC) or nonsilencing 
(scrambled, Scr) siRNA-transfected rings  
are compared with nontreated (NT) rings. 
Significant increases in microvessel sprouting 
upon VEGF stimulation occurred in all three 
conditions. Knockdown of Flk1 (VEGFR2) 
blocked VEGF-induced sprouting. (b) Reverse 
transcription–PCR quantification of Rac1 
knockdown in aortic tissue. (c) Quantification of Rac1 knockdown in aortic tissue at the protein level. See also ref. 40. *P  <  0.01, **P  <  0.001. Error bars 
represent mean band intensity ± s.e.m. All animals were wild-type C57BL/6 mice aged 8–12 weeks; n  =  6–23 rings per condition, n  =  3–5 independent 
experiments. Panels b and c of this figure were originally published under the Creative Commons Attribution License in D’Amico et al.40.
M
ea
n 
nu
m
be
r o
f s
pr
ou
ts
 p
er
 ri
ng 30
1.00
0.75
0.50
0.25
0
1.00
0.75
0.50
0.25
0
siRNA:
siRNA: siRNA:
*
*
**
**
* **
R
el
at
iv
e 
m
R
N
A
le
ve
ls
R
el
at
iv
e 
pr
ot
ei
n
le
ve
ls
25
20
15
10
5
0
TC TCNT NTScr Scr
Scr
Scr Scr
Flk1
Actin Hsc-70
VEGF Rac1 siRNA: Scr Rac1
Rac1
Rac1 Rac1
cba
Rac1
PBS
©
20
11
 N
at
ur
e 
A
m
er
ic
a,
 
In
c.
 
 
A
ll 
rig
ht
s 
re
se
rv
ed
.
protocol
94 | VOL.7 NO.1 | 2012 | nature protocols
Controls. Variables must be considered and controlled within and 
between experiments as much as possible to improve the reliability 
and reproducibility of the results.
Age of animals and ring width. Ring width and the age of animals 
used should be kept as consistent as possible within and between 
experiments to limit variability due to these factors. Littermate 
controls should be used where available.
Medium supplement controls. A basal medium (Opti-MEM sup-
plemented with 2.5% (vol/vol) FBS) is used for all aortic rings to 
maintain explant viability and prevent the aortic ring tissue from 
dying. For growth factor–induced angiogenesis studies, the rel-
evant volume of PBS can be added to the basal medium in place 
of the growth factor as a control (see Steps 14A(vii), 14B(xi) and 
14C(vii)). If the number of aortic rings is limited, the number of 
PBS controls can be reduced (to 3–12 rings, for example) as these 
consistently sprout minimally (Figs. 8a and 3b). Growth medi-
um supplemented with 10% (vol/vol) FBS induces microvessel 
sprouting in Matrigel (whereas it does not in collagen) and there-
fore it may be used as a positive control in this matrix (Fig. 3b).
•
•
VEGF response-blocking controls. These can be used to confirm 
that the observed effects are VEGF dependent. For example, 
treatment with anti-VEGF receptor 2 (Flk1) monoclonal anti-
body DC101 inhibits VEGF-induced microvessel sprouting by 
preventing VEGF from binding to the receptor and simulating 
microvessel outgrowth7.
Drug treatment controls. Standard vehicle-alone treatments 
should be included for comparison.
RNAi controls. In RNAi experiments, the standard controls (un-
treated, transfection reagent-only and scrambled/nontargeting 
siRNA) should be used to confirm that any effects on microvessel 
sprouting are due to gene knockdown (Fig. 8a). Rings transfected 
with siRNAs targeting VEGFR2 (Flk1) do not respond to VEGF 
stimulation (Fig. 8a). Confirmation of knockdown efficacy can 
be measured at both the mRNA and protein level. For example, 
we have published previously that aortic tissue transfected with 
siRNA specifically targeted against Rac1 (encoding RAS-related 
C3 botulinum substrate 1) causes ~75% loss of Rac1 mRNA and 
Rac1 protein (Fig. 8b,c)40. 
•
•
•
 Box 1 | RNA and protein extraction ● tIMInG 45 min for three mice
This protocol can be used to check knockdown in aortic rings stored in starvation medium after transfection or transduction  
(Step 13A or 13B), or to check endogenous protein/mRNA levels after extraction and cleaning of the aortae (Step 12).
1.  At the desired time point, e.g., 24–72 h after transfection or transduction, pool ≥5 rings for RNA extraction or ≥10 rings for protein 
extraction (each pool undergoing the same treatment) in a 1.5-ml tube.
2. Aspirate the starvation medium.
3. Wash aortae with 1 ml of ice-cold PBS.
4. Use a fine-tipped pipette tip to remove as much of the wash as possible.
5. To extract protein, follow option A. To extract RNA, follow option B. To extract both protein and RNA simultaneously, follow option C.
(a) protein extraction
 (i) Add 50 µl of lysis buffer or the desired protein extraction buffer to the tube and crush the aortae with a 1.5-ml tube pestle.
 (ii) Spin the tubes in a microcentrifuge at ≥10,000g for 5 min to pellet insoluble fibrous debris.
 (iii) Move the supernatant to a fresh tube for storage or for immediate quantification and analysis.
  pause poInt Lysates may be stored at  − 20 °C before use.
(B) rna extraction
 (i)  We use the RNeasy mini kit for RNA purification. Add 250 µl of lysis buffer (provided with the kit) to the tube and crush the 
aortae with a 1.5-ml tube pestle.
 (ii) Follow the protocol provided by the manufacturers.
  pause poInt Store lysates at  − 20 °C (short term; less than 1 month) or at  − 80 °C for long-term storage before and/or after 
quantification and analysis.
(c) simultaneous rna and protein purification
 (i)  We use the Nucleospin RNA/protein kit to purify protein and RNA. Add 350 µl of lysis buffer (provided with the kit) to the tube 
and crush the aortae with a 1.5-ml tube pestle.
 (ii) Follow the protocol provided by the manufacturers.
  pause poInt Store lysates appropriately for quantification and analysis as described in option B.
 ?  trouBlesHootInG
MaterIals
REAGENTS
Mice (e.g., adult C57BL/6 mice of 8–12 weeks of age) ! cautIon Adhere to 
all relevant ethics guidelines for animal care and experimentation.
PBS (10× Dulbecco’s phosphate-buffered saline; Gibco, cat. no. 14200-067)
Dulbecco’s phosphate-buffered saline (10×)  +  CaCl
2
  +  MgCl
2
  
(Gibco, cat. no. 14080-089)
Opti-MEM  +  GlutaMAX-I (Gibco, cat. no. 51985-026)  
 crItIcal Substitution with other media may negatively affect 
 microvessel sprouting.
•
•
•
•
FBS (EU-approved heat-inactivated fetal bovine serum (PAA Laboratories, 
cat. no. A15-104)
Dulbecco’s modified Eagle’s medium, high glucose  +  l-glutamine  +  pyroxi-
dine hydroxide  +  110 mg per liter sodium pyruvate without sodium bicarbo-
nate (DMEM (10×), Gibco, cat. no. 12800-017). Store at 4 °C up to 4 months
Ethanol, analytical reagent grade, absolute (Fisher Scientific, cat. no. 
E/0650DF/17) ! cautIon It is a flammable liquid.
Penicillin-streptomycin (100×; 10,000-U ml − 1 penicillin, 10,000-µg ml − 1 
streptomycin; Gibco, cat. no. 15140-122)
•
•
•
•
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NaOH, 40 g mol − 1 (Sigma-Aldrich, cat. no. S8045) ! cautIon It is corrosive.
Collagen type I, rat tail, approximately 3.65 mg ml − 1 (Millipore,  
cat. no. 08-115)  crItIcal Other sources were found to support  
microvessel sprouting less reliably.
Growth factor–reduced Matrigel (BD Biosciences, cat. no. 354230)
Fibrinogen from bovine plasma (Sigma, cat. no. F8630)
Thrombin from bovine plasma (Sigma, cat. no. T7513)
Aprotinin from bovine lung (Sigma, cat. no. A1153)
VEGF (Peprotech, cat. no. 450-32. Also Genentech, by request). Alternatively,  
VEGF may be produced in-house according to the protocol of Krilleke et al.51
bFGF (Peprotech, cat. no. 450-33)
Formaldehyde solution (37–41%; Fisher Scientific, cat. no. F/1501/PB15)  
! cautIon It is toxic; use in an extraction hood.
Oligofectamine reagent (Invitrogen, cat. no. 12252-011)
Triton X-100 (Sigma Ultra, cat. no. T9284)
Protein block, serum free (DAKO, cat. no. X0909)
BS1 lectin-FITC/-TRITC (1 mg ml − 1; Sigma, cat. no. L9381/L5264)
Monoclonal anti-actin α-smooth muscle Cy3 (α-SMA; Sigma,  
cat. no. C6198)
MnCl
2
 (Interfocus, cat. no. 9114685) ! cautIon It is harmful; avoid contact 
with skin and eyes.
ProLong Gold antifade reagent with DAPI (Invitrogen, cat. no. P36931)
RNeasy mini kit (Qiagen, cat. no. 74104)
NucleoSpin RNA/protein (Fisher/Macherey-Nagel, cat. no. NZ74093350)
Click-iT EdU Alexa Fluor 488 imaging kKit (Invitrogen, cat. no. C10337)
Ham’s F-12  +  GlutaMAX (Gibco, cat. no. 31765)
DMEM  +  GlutaMAX  +  4.5-g per liter D-glucose (Gibco, cat. no. 21013)
Heparin from sodium salt, Grade 1-A, from porcine intestinal mucosa 
(Invitrogen, cat. no. H3149)
Distilled water
EQUIPMENT
Sterile dissection instruments: forceps (Dumont), scissors (Vannas), 
disposable scalpels (Swann-Morton)  crItIcal Keep dissection 
instruments in 70% (vol/vol) ethanol during the procedure to maintain 
sterility.
Laminar flow tissue culture hood (SCANLAF MARS Biosafety cabinet, Class 2)
Culture dishes (10 cm; Falcon, cat. no. 353003)
Syringe (1 ml; BD Plastipak, cat. no. REF 300013)
Needles (27-G × ¾ in., no. 20, 0.4 mm × 19 mm; BD Microlance 3,  
cat. no. REF 302200)
Filters (0.22 µm; Millipore, cat. no. SLGP033RS)
Plates (24 well; Costar, cat. no. 3526)
Plates (96 well; Costar, cat. no. 3599)
Microscope slides (Fisherbrand, cat. no. 451000) Twinfrost, ground
Coverslips (22 mm × 32 mm; VWR International, cat. no. 831-0134)
Humidified, water-jacketed incubator (Binder) at 37 °C and 5% CO
2
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
Dissecting microscope (Zeiss, Stemi SV6)
Laminar flow workstation (BassAire)
Light box (Whatman)
ViraPower lentiviral expression system (Invitrogen)
Beckman SW55Ti rotor
Falcon tube (15 ml)
Petri dish
α-NG2 (Millipore, cat. no. AB5320)
Imaris 7.2 (Bitplane)
Laser scanning microscope (Carl Zeiss)
REAGENT SETUP
PBS, 1× Dilute 10× PBS ( +  CaCl
2
  +  MgCl
2
) in distilled water, filter sterilize 
and then store indefinitely at room temperature (22–24 °C).
PBLEC Dilute 10× PBS  +  CaCl
2
  +  MgCl
2
 in distilled water, add 0.1 ml of 
1 M MnCl
2
 solution (prepared in water) per liter 1× PBS  +  CaCl
2
  +  MgCl
2
, 
add 1% (vol/vol) Tween-20 and store at room temperature.
NaOH (5 N) solution Dissolve 200 g per liter in distilled water and store at 
room temperature for up to 6 months.
Ethanol (70%, vol/vol) Dilute absolute ethanol in distilled water and store 
indefinitely at room temperature.
Formalin (4%, vol/vol)  Dilute ~40% formaldehyde solution in distilled 
water and store at room temperature indefinitely.
Lentivirus for transduction Generate lentiviral particles using the  
ViraPower lentiviral expression system (see manufacturers’ instructions). 
Collect viral supernatants at 72 h and pass through a 0.45-µm filter.  
Centrifuge the supernatant for 1.5 h at 25,000g in a Beckman SW55Ti rotor. 
Viral pellets can be stored indefinitely at  − 80 °C.
Proliferation medium For the proliferation assay, mix Gibco Ham’s F-12 
and DMEM in equal volumes and add 1% (vol/vol) FBS. Dissolve 1 mg ml − 1 
of heparin in an aliquot of the medium to attain a final concentration of  
1 mg ml − 1. Add this to the total volume and filter to sterilize. Add penicillin-
streptomycin to 1× (e.g., 1:100 dilution of a 100× stock) and store at 4 °C for 
up to 3 months.
EQUIPMENT SETUP
Housing and husbandry of experimental animals Mice are housed  
in pathogen-free, regulated-humidity conditions and kept in a 12-h  
light cycle with sterilized chow and water provided. The ‘Three Rs’  
(replacement, reduction, refinement) have been observed in the design  
and execution of all experiments.  crItIcal All experiments were  
conducted in compliance with Home Office/Local Ethical Committee  
guidelines. The laboratory Animal License was approved by the local  
ethical review committee and permission was granted according to the  
UK Animal [Scientific Procedures] Act of 1986. We have complied with all 
the governmental and institutional guidelines for the care and use of  
animals within our research program.
•
•
•
•
•
•
•
•
•
•
proceDure
Dissection and preparation of mouse thoracic aortic rings (day 1) ● tIMInG 45 min for three mice, plus overnight 
serum starvation
1| Kill mice by cervical dislocation.
 crItIcal step This step must be performed by licensed, qualified individuals.
 pause poInt The carcass can be stored at 4 °C for up to 5 h until dissection.
2| Surface-sterilize the mouse with 70% (vol/vol) ethanol.
3| Lay mice back-down on a dissecting board in a laminar flow tissue culture hood to maintain sterility, fixing the legs to 
the board with pins if desired. Note that for embryos the use of a dissection microscope is necessary.
4| Open the ventral skin with a single cut; thereafter, use dissection scissors and blunt dissection to peel back  
the skin.
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5| Use fresh sterile scissors to open the thoracic cavity, either below the diaphragm or by cutting through the sternum,  
and cut around the rib cage.
6| Remove the heart and lungs to expose the aorta, visible as a fat-covered blood vessel tracking down along the spine  
(Fig. 2a and supplementary Video 1). A 15-ml Falcon tube can be placed beneath the back of adult mice to bend the spine, 
exposing the thoracic cavity and aorta for easier dissection.
7| Gently grasping the anterior end of the aorta, use a closed pair of sharp forceps or closed small scissors to detach the 
aorta from the spinal column by blunt dissection, running the instrument between the aorta and the spine all the way down 
toward the posterior end before the artery branches into the iliacs in the abdomen (Fig. 2b–d).
8| When the aorta has been separated from the spine, cut it once near the abdominal branch (Fig. 2e) and once at the 
anterior end (Fig. 2f).
9| Transfer dissected aortae to a Petri dish containing Opti-MEM.
 pause poInt Aortae can be stored in a Petri dish or multiwell plate in Opti-MEM for up to 4 h at 4 °C.
10| Under a dissection microscope, remove all extraneous fat, tissue and branching vessels with forceps and a scalpel.
11| For aortae from adult mice only, flush out blood from the lumen: hold the aorta with forceps, insert a 27-G needle fixed 
to a 1-ml syringe filled with Opti-MEM into an end of the blood vessel and pass 1 ml of Opti-MEM gently through it.
 crItIcal step This should not be performed on embryonic aortae, as they are more fragile (easily damaged) and their red 
blood cell content is minimal.
 crItIcal step Failure to flush out adult aortae can lead to impaired sprouting.
12| Cut the aortae into rings ~0.5 mm in width with a scalpel and transfer to at least 5 ml of Opti-MEM in a 10-cm dish. 
If transfection or transduction is required, proceed with Step 13A or 13B, respectively. Otherwise, serum-starve rings by 
incubating them overnight at 37 °C and 5% CO2 in Opti-MEM. If required, protein and RNA levels can be checked after serum 
starvation (with or without transfection or transduction) as described in Box 1.
 crItIcal step A total of 20–25 rings can be obtained, on average, from an ~20-mm length of adult aorta, but fewer can 
be obtained from E18 embryos or newborn mice (approximately 5–10 rings). Consider the diameter of the vessel; cut thinner 
rings from smaller aortae (e.g., from younger mice), keeping ring width as consistent as possible within the experiment.
 crItIcal step If you are performing Step 13A or 13B, do not include penicillin-streptomycin in the medium, as it will 
interfere with the transfection.
? trouBlesHootInG
transfection or transduction (optional)
13| Perform optional transfection with siRNA (option A) or transduction with lentiviral vectors (option B) under sterile 
conditions.
 (a) transfection with sirna (day 1) ● tIMInG 1 h for three mice, plus overnight serum starvation
 (i)  In a sterile tissue culture hood, aliquot 800 µl of Opti-MEM per well of a 24-well plate and transfer 8–24 aortic rings 
to each well as required.
 (ii)  For each well, dilute 2.5 µl of 40 µM siRNA stock in 182.5 µl of OPTI-MEM in a 1.5- or 2-ml tube (as necessary) and 
let it stand for 5 min at room temperature (solution A).
 (iii) Dilute 3 µl of Oligofectamine reagent in 12 µl of Opti-MEM in a separate 1.5-ml tube (solution B).
 (iv) Add 15 µl of solution B to 185 µl of solution A and let it stand for 20 min at room temperature.
 (v) Add the 200-µl A  +  B mix to each well to achieve a final volume of 1 ml.
 (vi)  Serum-starve rings by incubating them overnight at 37 °C and 5% CO2 in the Opti-MEM mixture created in  
Step 13A(v).
 (vii) If required, check the protein and RNA levels as described in Box 1.
(B) lentiviral transduction (day 1) ● tIMInG 30 min for three mice, plus overnight serum starvation
 (i) Thaw and resuspend viral pellets (see REAGENT SETUP) in 1 ml of Opti-MEM.
 (ii) Directly infect aortic rings at 8–24 rings per well of a 24-well plate by adding 1 ml of supernatant to each well.
 (iii) Serum-starve rings by incubating overnight at 37 °C and 5% CO2 in Opti-MEM.
 (iv) If required, check protein and RNA levels as described in Box 1.
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embedding (day 0) ● tIMInG 1 h 30 min–2 h for aortic rings from three mice, plus feeding time
14| Embed one aortic ring per well of a 96-well (supplementary Video 2) or 24-well plate, depending on the embedding 
matrix used; option A (collagen type I), option B (fibrin) or option C (Matrigel). The collagen matrix is used to support VEGF 
(but not bFGF)-stimulated microvessel sprouting. Microvessels are large and easily distinguishable from fibroblast outgrowth; 
unless there is a specific requirement for a different matrix, collagen is recommended. A fibrin matrix can be used if  
bFGF-induced microvessel sprouting is to be studied. Matrigel supports thin microvessel sprouting.
 crItIcal step Ensure that only one ring is embedded per well; multiple rings in a single well should not be counted,  
as sprouts interfere with each other.
(a) embedding in type I collagen
 (i)  On ice, add a one-tenth volume of sterile 10× DMEM to sterile distilled water. 
 crItIcal step Prepare embedding matrix on ice (Steps 14A(i–iii)); failure to keep the mixture on ice will cause 
premature polymerization.
 (ii) Add the collagen to a final concentration of 1 mg ml − 1.
 (iii)  Adjust the pH with a few drops of 5-N NaOH: ~20 µl per 10 ml or enough to turn the mixture pink so that the phenol 
red indicates a slightly basic pH (supplementary Video 2).
 (iv)  Transfer 50 µl of collagen matrix to each well of a 96-well plate, a few wells at a time, so that the matrix does not 
polymerize before aortic rings are added. The 96-well plate format is essential for efficient aortic ring sprouting in 
collagen; aortic rings embedded in collagen in larger wells produce less growth factor and thereby support microvessel 
growth to a lesser extent27. 
 crItIcal step Transfer of the mixture to too many wells at once will cause polymerization before rings are added 
and failure of the rings to embed properly. 
? trouBlesHootInG
 (v)  Transfer the rings from the starvation plate to the collagen carefully with forceps, placing rings so that the luminal 
axis is perpendicular to the bottom of the well; ensure that the rings are completely submerged in the liquid collagen. 
Alternatively, the rings can be placed with the luminal axis parallel to the bottom of the well; in either case,  
intra- and interexperimental consistency is most important. 
? trouBlesHootInG
 (vi)  Leave the plate undisturbed for 10–15 min at room temperature and then incubate it at 37 °C/5% CO2 for 1 h. 
? trouBlesHootInG
 (vii)  Carefully feed embedded rings with 150 µl of Opti-MEM culture medium supplemented with 2.5% (vol/vol) FBS and 
VEGF to attain a final concentration of 30 ng ml − 1. Include penicillin-streptomycin in the medium unless the rings 
have been transfected or transduced (Step 13).
 (viii)  Change the growth medium first on day 3 or day 4 and then approximately every other day until the experiment ends; 
remove 130 µl of old medium and replace with 150 µl of fresh medium.
(B) embedding in fibrin
 (i)  Add coverslips to wells before starting the embedding procedure if immunofluorescence staining is planned at the end 
of the experiment.
 (ii) Dilute 60 mg of fibrinogen in 20 ml of Opti-MEM to yield a final concentration of 3 mg ml − 1.
 (iii) Incubate at 37 °C for 1 h to dissolve; filter (0.22 µm) to sterilize and remove unpolymerized fibrinogen.
 (iv)  Prepare 500-µl aliquots of the fibrinogen solution and keep them on ice; catalysis of polymerization to fibrin is rapid 
after the addition of thrombin. 
 crItIcal step The solution must be aliquotted and kept on ice to prevent premature polymerization when 
thrombin is added.
 (v)  Add 0.5 U of thrombin to each aliquot (1 U ml − 1) to begin the polymerization of fibrinogen into fibrin strands  
immediately before using the aliquot.
 (vi)  Mix well by pipetting up and down. 
 crItIcal step Failure to mix adequately will cause uneven polymerization.
 (vii)  Place aortic rings into wells of a 24-well plate, one ring per well, up to 10 wells at a time, to prevent rings from  
drying out.
 (viii) Cover each ring with 30 µl of polymerizing fibrinogen solution.
 (ix) Incubate at room temperature for 10 min.
 (x)  Confirm that the fibrin clot has solidified; it should be uniformly opaque. 
 crItIcal step The addition of medium before the clot has set will irreversibly damage the gel. 
? trouBlesHootInG
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 (xi)  Carefully feed embedded rings with 1 ml of Opti-MEM culture medium supplemented with bFGF to a final concentration 
of 30 ng ml − 1 and 10 µg ml − 1 of aprotinin. Include penicillin-streptomycin in the medium unless the rings have been 
transfected or transduced (Step 13). 
 crItIcal step Aprotinin prevents degradation of the fibrin matrix by proteases. 
? trouBlesHootInG
 (xii)  Change growth medium first on day 3 or day 4 and then approximately every other day until the experiment ends;  
fully aspirate the growth medium and replace it with 1 ml of fresh medium.
(c) embedding in Matrigel
 (i)  Thaw growth factor–reduced Matrigel stock on ice. 
 crItIcal step Failure to thaw Matrigel on ice can cause inconsistent effects on the 3D structure of laminin, the 
main component of the matrix, and it can reduce aortic ring sprouting rate. Keep thawed Matrigel at 4 °C throughout 
the procedure to prevent polymerization.
 (ii)  Add 40–50 µl of Matrigel to 12 wells of a 24-well plate at a time.
 (iii) Incubate plates at 37 °C for 10–15 min to allow the matrix to polymerize.
 (iv) Place one aortic ring on top of the solid matrix layer per well.
 (v) Add another 40–50 µl of Matrigel to cover each ring.
 (vi)  Return the plate to the incubator at 37 °C for another 10–15 min to allow polymerization of the second matrix layer 
and repeat Step 14C(ii–vi) as necessary for further sets of up to 12 wells.
 (vii)  Carefully feed embedded rings with 1 ml of Opti-MEM culture medium supplemented with 2.5% (vol/vol) FBS and 
VEGF to a final concentration of 30 ng ml − 1. Include penicillin-streptomycin in the medium unless the rings have been 
transfected or transduced (Step 13).
 (viii)  Change growth medium first on day 3 or day 4 and then approximately every other day until the experiment ends;  
fully aspirate the growth medium and replace it with 1 ml of fresh medium.
staining and imaging ● tIMInG 3–4 h for aortae from three mice
15| Quantify microvessel growth during the experiment (nonfixed, live rings) by live phase-contrast microscopy: starting from 
a specific point on the ring (for example, the 12 o’clock position), count each microvessel emerging from the main ring as a 
sprout and then individual branches arising from it as separate vessels, working around the ring consistently either clockwise 
or anticlockwise (as described by Aplin et al.27; Fig. 4d,e). Count microvessel loops (where cells emerge from the ring but 
loop back to contact it rather than growing out into the gel) either once or twice, with consistency across experiments being 
essential. Manually adjust the focus while moving around the ring to ensure that vessels growing out in different planes are 
counted. The data collected may be plotted as mean microvessel numbers per ring, with the s.e.m. as the error margins. In 
addition to this counting method, specific epitopes can be fluorescently labeled (at the end of the experiment, after fixing the 
rings) to definitively identify and image various cell types, which is not possible with live imaging alone (see option A for the 
96-well format or option B for the 24-well format). Alternatively, a proliferation assay may be carried out (option C).
? trouBlesHootInG
(a) Basic immunofluorescence protocol for 96-well plates ● tIMInG 3 h for aortae from three mice
 (i) Remove the culture medium and wash the whole plate with PBS  +  CaCl2  +  MgCl2.
 (ii) Fix with 50–100 µl of 4% (vol/vol) formalin per well for 30 min at room temperature.
 (iii) Remove the fixative.
 (iv)  Permeabilize with PBS  +  CaCl2  +  MgCl2  +  0.25% (vol/vol) Triton X-100; carry out two 15-min incubations at room 
temperature.
 (v) Block using 1 drop of DAKO buffer per well for 30 min at 37 °C.
 (vi)  Prepare primary antibodies in PBLEC: 0.1 mg ml − 1 of BS1 lectin-FITC to stain endothelial cells and 1/1,000 anti–actin 
α-smooth muscle Cy3 for supporting cells. If different primary antibodies are used, e.g., 5 µg ml − 1 of α-NG2 (Fig. 6b–d), 
BS1 lectin-FITC and anti-actin should be omitted at this stage and included with the secondary incubation in  
Step 15A(ix).
 (vii) Incubate overnight with 50 µl of antibody solution per well at 4 °C.
 (viii) Wash three times in PBS  +  0.1% (vol/vol) Triton X-100 for 15 min.
 (ix)  If unconjugated primary antibody was used in Step 15A(vi), add 50 µl of secondary antibodies if required and incubate 
for 2–3 h at room temperature. Thereafter, remove the antibody solution and wash three times in PBS +  0.1% (vol/vol) 
Triton X-100. Otherwise, proceed directly to Step 15A(x).
 (x) Wash once with distilled water.
(B) Basic immunofluorescence protocol for 24-well plates (fibrin gels prepared on coverslips) ● tIMInG 3 h for  
aortae from three mice
 (i) Aspirate the culture medium and wash each well with 1 ml of PBS  +  CaCl2  +  MgCl2.
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 (ii) Fix with 1 ml of 4% (vol/vol) formalin per well for 30 min at room temperature.
 (iii) Aspirate the fixative.
 (iv)  Permeabilize with 0.5 ml of PBS  +  CaCl2  +  MgCl2  +  0.25% (vol/vol) Triton X-100; carry out two 15-min incubations at 
room temperature.
 (v) Block with 1 ml of 5% (vol/vol) BSA in PBLEC for 30 min at 37 °C.
 (vi) Prepare primary antibodies in PBLEC as in Step 15 A(vi).
 (vii) Incubate overnight with 500 µl of antibody solution per well at 4 °C.
 (viii) Wash three times in PBS  +  0.1% (vol/vol) Triton X-100 for 15 min.
 (ix) Incubate with 500 µl of secondary antibodies as in Step 15A(ix).
 (x) Wash the plate once in distilled water.
(c) Invitrogen clickIt edu alexa 488 proliferation assay (96-well plate) ● tIMInG 4 h for aortae from three mice
 (i)  Follow the manufacturer’s instructions, changing the specified volumes according to the following protocol. Perform  
labeling at the end of the assay before fixation, for example, at day 9. Prepare 2× proliferation medium: 20 µl of  
10-mM EdU stock per 10-ml medium (1:1 Ham’s F-12/DMEM, 1% (vol/vol) FBS, 1 mg ml − 1 heparin, penicillin- 
streptomycin).
 (ii) Remove growth medium, leaving 100 µl per well.
 (iii) Add 100 µl of 2× proliferation medium.
 (iv) Return the plate to the incubator for 2–3 h to allow incorporation of EdU into the DNA.
 (v)  Wash the plate in PBLEC. 
 crItIcal step The EdU staining protocol gives a high background impairing quantification and imaging, which can 
be reduced with repeated, longer washes. To achieve thorough washing, plates can be immersed in wash solution and 
somewhat forcefully inverted to remove the solution without dislodging collagen gels.
 (vi)  Fix with 4% (vol/vol) formalin per well for 20 min at room temperature and follow the manufacturer’s staining  
protocol (quantities can be reduced to 40 µl per well for 96-well plates).
 (vii) Permeabilize for 25–30 min with PBLEC  +  0.5% (vol/vol) Triton X-100.
 (viii) EdU detection: follow the manufacturer’s protocol, reducing quantities to 40 µl per well.
 (ix)  Precede optional additional staining with a 1-h DAKO blocking step as in Step 15A(v) or proceed directly to  
Step 15C(x).
 (x)  Counterstain endothelial sprouts (as in Step 15A(vi–x)) with BS1 lectin conjugated to the relevant fluorochrome  
overnight at 4 °C. For visualization of endothelial cells in this method, tetramethyl rhodamine isothiocyanate (TRITC)-
conjugated BS1 lectin can be used as opposed to the FITC-conjugated lectin used in Step 15A, which is chosen to 
allow co-staining with supporting cell markers fluorescing red. Alternatively, primary antibody specific for supporting 
cells, e.g., anti-NG2, can be added at this stage and BS1 lectin labeling performed in conjunction with the secondary  
antibody incubation step following washing to remove the primary antibody, as in Step 15A(vi–x). A secondary  
antibody that fluoresces in the far-red end of the spectrum would allow for four-color confocal imaging with the use of 
DAPI-containing mounting medium; this method can be used to detect EdU-positive and -negative nuclei, endothelial 
cells and supporting cells.
 (xi) Wash the plate in distilled water.
16| After immunofluorescence staining of gels from 96-well plates (Step 15A or C) or 24-well plates (option B), mount the 
gels on microscope slides. Gels mounted on slides are amenable to both epifluorescence and confocal microscopy. Alterna-
tively, aortic rings can be imaged directly in the culture plate if appropriate microscopy technology is available.
(a) Mounting collagen gels from 96-well plates
 (i) Refill each well of the plate with water.
 (ii)  Detach the gel from the walls of each well by gently tapping all the way around its edge with a pointed probe or  
needle. Perform this step on a light box, if available, to aid visibility.
 (iii) Carefully detach the gel from the bottom of the well using closed, thin forceps to lift it from the base.
 (iv) Slowly remove the gel with forceps by taking hold of the edge of the gel and dragging it up the side of the well.
 ? trouBlesHootInG
 (v) Arrange up to six gels per microscope slide.
 (vi) Add ProLong Gold antifade mounting medium to the gels on the slide.
 (vii) Carefully place a coverslip over the gels, avoiding the formation of air bubbles.
 (viii) Allow the coverslip to set overnight at room temperature.
(B) Mounting coverslips from 24-well plates
 (i) Add ProLong Gold antifade mounting medium to the slide.
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 (ii) Remove the coverslip from the well and invert it to mount on the slide.
 (iii) Allow it to set overnight at room temperature.
17| When the mounting medium has solidified, seal around coverslips with nail polish to minimize the risk of slides drying 
out; gels will contract over time. Image as soon as possible.
 pause poInt Store slides dry at 4 °C; moisture can cause coverslips to detach.
Quantification ● tIMInG Variable
18| Quantify immunostained rings manually and/or automatically: for example, total microvessel numbers (as described in 
Step 15 for nonimmunostained rings; Fig. 4); length (for example, using the free software ImageJ, simply by drawing radial 
lines around the ring to the lengths of sprouting microvessels and saving data to calculate average values per treatment); 
branch points; supporting cell coverage; area covered by microvessel sprouts (automatic quantification as detailed in Box 2;  
supplementary Fig. 1); endothelial and/or nonendothelial cell proliferation (only in the case of Step 15C, proliferation 
assay). For images of whole rings and their radiating microvessels, Blatt et al.52 have also devised an automated counting 
algorithm.
? trouBlesHootInG
Troubleshooting advice is provided in table 1.
 Box 2 | Automated microvessel area quantification ● tIMInG 1 min for  
10 images
In addition to manual quantification of parameters such as microvessel number and average length, the total area covered by BS1  
lectin-stained cells as well as total and average staining intensity can be quantified automatically. This procedure has been automated 
in the computer program TRI2 (http://www.assembla.com/spaces/ATD_TRI/wiki). Software executable is free to download and requires 
an access key provided by P.R. Barber for use. Source code for this processing will also be available under the LGPL Open Source  
License so that a number of files can be loaded and processed. The results are saved in a comma separated value (.csv) text file  
alongside the segmented images.
1.  Use an epifluorescence microscope to obtain images of whole aortic rings and their microvessel sprouts at ×5 magnification  
(or a scale of ~2 µm per pixel so that the ring itself is 500 pixels in diameter) in JPEG, bitmap or TIFF format.
2. Load images into TRI2 version 2.5 or later.
3. Use the menu option Macros → Multiple Image Aortic Ring Assay Processing.
4.  Choose a directory into which the output files will be saved. When processing has finished (approximately 20–30 s per image),  
a file called Data.csv will contain the results, and binary (pure black-and-white) images of the segmented vessels will be saved  
as .bmp files (~5 s per image).
This built-in macro performs the following functions:
• Menu option Processing → Aortic Ring Assay.
• Select the resulting binary image.
• Use menu Mask → Get Mask From Image Data.
• Select the original image and use Mask → Paste Mask.
• Choose menu Processing → Histogram → Histogram (or Histogram from the toolbar).
• In the Histogram window, set minimum to 1 and maximum to 255, and ensure that the Apply Mask is checked (ticked).
• Read off the Mask Area in pixels as the area occupied by the vessels and the Total, Average and StDev intensities  
(supplementary Fig. 1).
The algorithm functions as follows:
• Gaussian blur with 14 × 14-pixel kernel and sigma  =  2.
• Subtract from the original (suppresses the main ring).
• Threshold at grayscale value 8, store as result 1 (binary vessels  +  ring outline).
• Perform three binary dilations (5 × 5), followed by three erosions (5 × 5; microvessel region).
• Perform a fill holes operation, subtract the result from the last step and fill holes again (main ring region).
• Perform 10 binary erosions (5 × 5), followed by 13 dilations (5 × 5; remove any microvessel detail remaining to leave the area of the 
main ring).
• Perform a binary open on result 1 (remove small unwanted particles) and subtract the result from the last step (remove ring).
The result is a binary (pure black-and-white) image showing the area occupied by the vessels that is then used as a mask on the  
original image data.
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taBle 1 | Troubleshooting table.
step problem possible reason possible solution
12 Rings are stuck together 
after starvation
Rings are still partially connected Ensure that rings are properly separated when cutting 
before transfer to the starvation plate (Step 11)
14A(iv) Collagen mixture polymerizes 
before experiment setup is 
completed
Mixture became too warm Keep the mixture on ice at all times
The mixture has been standing for 
too long
Prepare only up to 10 ml of collagen mixture at a time
14A(v) Rings float out of the matrix Gel has polymerized unevenly Ensure that collagen mixture is well mixed before add-
ing it to the 96-well plate  
Do not keep the plate on ice during embedding in an 
attempt to prevent matrix polymerization
Collagen matrix has  
polymerized unevenly or  
not set at all
Mixture was not well mixed Ensure that collagen mixture is well mixed before  
transferring it to wells
Mixture was prepared incorrectly Prepare a new batch (up to 10 ml)
14A(vi) Matrix does not polymerize 
properly
Mixture has been diluted excessively 
by ring starvation medium
Remove excess medium from forceps before  
embedding rings by touching them on sterile plastic
14B(x) Fibrin matrix polymerizes 
unevenly with visible strands
Fibrin/thrombin is not evenly  
distributed
Ensure fibrinogen/thrombin is mixed well before adding 
it to the plate
14B(xi) Fibrin clot is damaged upon 
feeding
Clot has not solidified completely 
before the addition of growth 
medium
Ensure that the clot has fully polymerized before 
attempting to feed the wells
The force of adding or changing 
growth medium has lifted or broken 
the clot
Add new medium slowly and carefully to the side of the 
well to prevent the fragile clot from lifting and being 
damaged
15 Bacterial/fungal  
contamination
Nonsterile conditions and/or 
inadequate sterile technique
Ensure that dissection instruments are sterile and avoid 
transfer of fur from the outside of the mouse to the 
inner cavity (Steps 2–5)  
If RNAi is not being performed, anti-microbials  
(penicillin-streptomycin) may be used in all medium, 
including during overnight starvation, to minimize the 
risk of contamination  
Use sterile growth medium throughout the procedure
Rings do not sprout at all or 
as much as anticipated
Aortic tissue has been damaged Avoid overstretching the tissue, as this damages the 
endothelial layer and can inhibit microvessel sprouting 
(Steps 7–12)  
Do not immerse aortic tissue in ethanol at any time 
Keep aortic tissue submerged in Opti-MEM to prevent 
drying 
Take care not to damage the inner surface of the  
aorta when syringing to flush blood out of the lumen 
(Step 11)
Rings are too small Do not cut rings too thinly, as this increases the risk of 
rings dying or of reducing the sprout numbers (Step 12)
Growth factors have been diluted 
excessively
Do not change growth medium too frequently; aortic 
tissue produces growth factors that help stimulate 
and maintain microvessel sprouting (Steps 14A(viii), 
14B(xii), 14C(viii))
(continued)
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● tIMInG
The entire method takes between 6 and 14 d to complete, depending on the age of the mice (younger aortae begin to sprout 
earlier), the optional steps taken and the duration of the experiment. Approximate timings are noted below, which apply  
to those new to the technique. The method will inevitably require more time when the investigators are inexperienced  
with respect to mouse dissection and, more specifically, to cleaning of the aortae. Therefore, we recommend that early  
experiments be small in scale (3–9 mice; 30- to 90-min dissection, plus the same again for cleaning and cutting aortae)  
as too many at once increases the risk of contamination and unreliable results. The time required will decrease as experience 
is gained, and larger-scale experiments can then be performed. Addition of the RNAi step will add 1–2 h to the first day  
of the procedure, allowing for sorting of aortic rings into the appropriate wells, preparation of reagents and the  
transfection protocol.
Steps 1–12, Dissection and preparation of aortic rings: 45 min for three mice, plus overnight serum starvation
Step 13, Transfection/transduction: 30 min–1 h for three mice, plus overnight serum starvation
Step 14, Embedding: 1.5–2 h for aortic rings from three mice
Step 14, Feeding: 30 min for aortic rings from three mice (over 5–11 d)
Steps 15–17, Immunofluorescence staining: 3 h (or 4 h with proliferation assay) with overnight incubation
Step 18, Quantification: variable
Box 1, RNA and protein extraction: 45 min for three mice
Box 2, Automated microvessel area quantification: 1 min for 10 images
antIcIpateD results
The extent and time course of microvessel sprouting depend primarily on treatments applied and the particular protocol steps 
undertaken, as well as on the age of the mice, their genetic background and the embedding matrix used.
Microvessels go through an exponential phase of sprouting and growth and then a second phase when they begin to  
recede, at which point differences may no longer be visible. Counting microvessel numbers too soon after embedding also 
may not reveal condition-specific differences, as the number of sprouts is low at early stages.
Statistically significant results are likely to be obtained on days 6–9 for rings from adult C57BL/6 or C57/129Sv mixed-
background mice (the FVB background frequently shows a suboptimum response and is not used in our laboratory in this 
assay45). An example time course of microvessel sprouting in adult wild-type aortic rings embedded in collagen and  
supplemented with VEGF or PBS is shown in Figure 4c. Peak sprouting is seen on day 6 (it may also occur on day 7 if the 
mice are older) with an increase in variability by day 9 when microvessel regression is occurring. This peak occurs earlier in 
rings taken from embryos and newborns (days 4–6).
Examples of mean microvessel number in the three different matrices—collagen, fibrin and Matrigel—are shown in  
Figure 3b. Growth factor stimulation over PBS-only treatment is apparent in all three of the matrix conditions. Typically, 
0–5 short and thin sprouts can be expected from PBS control rings from C57BL/6 background mice in any matrix, which is 
increased four- to fivefold upon VEGF treatment in collagen but commonly less (two- to threefold) in Matrigel. FBS treatment 
taBle 1 | Troubleshooting table (continued).
step problem possible reason possible solution
16A(iv) Collagen gels consistently 
break up during attempts to 
remove them from the plate
Too many breaks created in the gel 
Attempted to remove gels too quickly
When detaching the collagen gel (Step 16A(ii– iv)), 
do not run the probe/needle around the edge in one 
movement, as this increases likelihood of breakage  
Take greater care while removing gel from the plate and 
arranging it on the slide
Microvessels appear very 
distorted compared with 
phase-contrast views before 
immunostaining and  
mounting
Movement of the gel to the slide has 
broken microvessels 
Gel is broken 
Gel is not mounted flat
Take greater care while removing gel from the plate  
and arranging it on the slide (mounting on slides  
generally allows for higher magnification and better 
quality imaging, but risks damaging microvessels if 
gels are broken or not mounted flat)
Box 1 Gene knockdown/
overexpression failed
Transfection inhibited by anti- 
microbials
Penicillin-streptomycin must not be added to the  
starvation medium when transfection is performed,  
as it interferes with the reaction (Steps 12 and 13)
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(10%, vol/vol) is also shown as it can be used as a positive control in Matrigel, increasing sprout numbers over and above 
VEGF treatment, to levels comparable to VEGF-treated rings in collagen.
Microvessel sprouts in Matrigel display markedly different morphology from those in collagen, with very thin endothelial 
networks growing out from the ring as opposed to the thicker, more obvious blood vessel-like structures in collagen  
(Fig. 4a,b). Supporting cell association is not clear in this matrix.
Visualization of microvessels with a high level of detail is best achieved with immunostaining and confocal (or high- 
quality epifluorescence) imaging. Examples of aortic rings fixed at day 6 are shown in Figure 5; these images illustrate  
overall microvessel morphology, but higher magnification images can be studied for greater details at the cellular level.  
If supporting cells have been labeled, for example, with anti-α-SMA or anti-NG2 antibodies, the extent of coverage can be 
examined by epifluorescence microscopy at high power (Fig. 6a). 3D reconstruction of high-power confocal images can also 
be performed using Imaris software for further detail (Fig. 6b–d).
Images of the aortic ring proliferation assay, adapted from cell-based applications, are shown in Figure 7. This addition to 
the assay can be used to identify proliferating cells in the aortic ring explants. Combined with epitope-specific co-staining, 
both proliferating endothelial and nonendothelial supporting cells can be identified. Commonly, the most widespread prolif-
erating cells are the fibroblasts growing out in the lower planes of the culture (closest to the base of the well; not shown). 
Proliferating endothelial cells are more likely to be observed at the base of the sprout, where it emerges from the ring, than 
further down the length toward the tip. Proliferating supporting cells have often been found along the microvessel length 
and around the tip.
Data from aortic ring controls are shown in Figure 8a; VEGF stimulation consistently increases sprouting approximately 
four- to fivefold over PBS treatment (depending on factors such as age of the mice, treatments applied and matrix used, as 
previously discussed), and this response can be abrogated by targeting VEGFR2 (also known as Flk1 and Kdr), which prevents 
the rings from responding to VEGF stimulation—sprout number and length are markedly decreased (not shown). This treat-
ment can be used as a control to confirm that growth factor stimulation and the RNAi protocol are working in principle.  
At times, a slight inhibitory or stimulatory effect of the siRNA transfection reagent is observed, but this is usually non- 
statistically significant.
RNAi studies may show increased sprouting when the targeted genes are negative regulators of angiogenesis (for example, 
Jam-B6, also known as Jam2), decreased sprouting in the case of positive regulators (for example, VEGFR2/Flk1; Fig. 8a) or 
no effect when the genes are not involved in angiogenesis or not required for microvessel sprouting in this ex vivo system 
(for example, Rac1 as presented in D’Amico et al.40). siRNA transfection of aortic tissue can efficiently decrease expression 
of the target gene, significantly reducing both mRNA abundance and protein levels, making transient gene knockdown in 
the aortic ring assay a useful tool for the assessment of the role of new genes in sprouting angiogenesis ex vivo (Fig. 8b,c).
Note: Supplementary information is available via the HTML version of this article.
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